age,sex,hospdead,dzgroup,edu,income,charges,race,adls,sfdm2,adlsc
62.84998,male,0.0,Lung Cancer,11.0,$11-$25k,9715.0,other,7.0,<2 mo. follow-up,7.0
60.33899,female,1.0,Cirrhosis,12.0,$11-$25k,34496.0,white,1.0,<2 mo. follow-up,1.0
52.74698,female,0.0,Cirrhosis,12.0,under $11k,41094.0,white,0.0,<2 mo. follow-up,0.0
42.38498,female,0.0,Lung Cancer,11.0,under $11k,3075.0,white,0.0,no(M2 and SIP pres),0.0
79.88495,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,50127.0,white,2.0,no(M2 and SIP pres),2.0
93.01599,male,1.0,Coma,14.0,under $11k,6884.0,white,1.0,<2 mo. follow-up,1.0
62.37097,male,0.0,CHF,14.0,$25-$50k,30460.0,white,1.0,no(M2 and SIP pres),1.0
86.83899,male,0.0,CHF,12.0,under $11k,30460.0,white,0.0,<2 mo. follow-up,0.0
85.65594,male,0.0,Lung Cancer,12.0,under $11k,25024.0,black,7.0,<2 mo. follow-up,7.0
42.25897,female,0.0,Colon Cancer,11.0,$25-$50k,9914.0,hispanic,1.0,<2 mo. follow-up,0.4947999
47.94498,male,0.0,CHF,12.0,under $11k,15558.0,white,1.0,no(M2 and SIP pres),1.0
59.20099,male,1.0,Lung Cancer,14.0,under $11k,29388.0,white,1.0,<2 mo. follow-up,1.0
29.002,female,0.0,Cirrhosis,16.0,$11-$25k,4353.0,white,0.0,no(M2 and SIP pres),0.0
68.14197,male,0.0,CHF,12.0,$11-$25k,19783.0,white,0.0,no(M2 and SIP pres),0.0
43.53998,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,706577.0,white,1.0,SIP>=30,2.7641602
58.823,female,0.0,Lung Cancer,12.0,>$50k,10758.0,white,0.0,<2 mo. follow-up,0.0
45.418,male,0.0,Lung Cancer,12.0,under $11k,8400.0,white,1.0,<2 mo. follow-up,3.3515625
63.66299,female,1.0,ARF/MOSF w/Sepsis,22.0,$25-$50k,283303.0,white,0.0,<2 mo. follow-up,0.0
31.84399,male,1.0,Cirrhosis,16.0,under $11k,27985.0,white,7.0,<2 mo. follow-up,7.0
55.13797,male,0.0,CHF,8.0,$11-$25k,18191.0,hispanic,1.0,no(M2 and SIP pres),2.5110989
68.25494,male,0.0,Lung Cancer,13.0,>$50k,10755.0,white,0.0,no(M2 and SIP pres),0.0
48.70398,male,0.0,Lung Cancer,16.0,under $11k,55384.0,other,1.0,<2 mo. follow-up,3.2636719
49.61298,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,542266.0,white,5.0,adl>=4 (>=5 if sur),5.0
50.724,female,0.0,Lung Cancer,12.0,$25-$50k,4913.0,asian,1.0,no(M2 and SIP pres),2.065918
29.36099,female,0.0,Colon Cancer,17.0,$25-$50k,7792.0,white,1.0,no(M2 and SIP pres),1.8149414
53.84,male,0.0,COPD,12.0,under $11k,9871.0,white,4.0,no(M2 and SIP pres),4.0
82.41498,female,1.0,Lung Cancer,12.0,under $11k,7212.0,white,1.0,<2 mo. follow-up,3.7041016
27.32399,male,1.0,MOSF w/Malig,19.0,under $11k,160060.0,asian,2.0,<2 mo. follow-up,2.0
30.10799,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,57611.0,asian,1.0,<2 mo. follow-up,2.8461914
50.37097,male,0.0,Cirrhosis,16.0,$11-$25k,465380.0,white,1.0,SIP>=30,1.0
74.48297,male,0.0,CHF,16.0,>$50k,18134.0,white,1.0,<2 mo. follow-up,1.0
55.73199,male,0.0,Cirrhosis,8.0,under $11k,52092.0,hispanic,6.0,SIP>=30,6.0
77.21295,female,0.0,COPD,0.0,under $11k,9078.0,hispanic,7.0,<2 mo. follow-up,7.0
61.02399,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,109627.0,white,1.0,<2 mo. follow-up,2.8251953
56.48999,female,0.0,CHF,12.0,under $11k,38548.0,hispanic,1.0,<2 mo. follow-up,3.0981445
57.53299,female,0.0,Cirrhosis,14.0,under $11k,156556.0,hispanic,1.0,no(M2 and SIP pres),3.1318359
68.98596,female,0.0,COPD,10.0,under $11k,5763.0,white,0.0,SIP>=30,0.0
41.97897,male,0.0,CHF,14.0,$11-$25k,5552.0,white,0.0,no(M2 and SIP pres),0.0
19.79199,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,167971.0,black,0.0,adl>=4 (>=5 if sur),0.0
57.50897,female,0.0,CHF,14.0,under $11k,6403.0,black,6.0,SIP>=30,6.0
73.40698,male,0.0,Colon Cancer,12.0,under $11k,22934.0,white,1.0,<2 mo. follow-up,2.4677734
68.31799,male,0.0,Colon Cancer,21.0,>$50k,9205.0,white,0.0,no(M2 and SIP pres),0.0
75.79498,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,271250.0,white,1.0,<2 mo. follow-up,2.6855469
45.71899,male,0.0,CHF,12.0,under $11k,115112.0,white,0.0,no(M2 and SIP pres),0.0
75.48798,male,0.0,CHF,16.0,under $11k,120920.0,hispanic,0.0,<2 mo. follow-up,0.0
74.995,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,348931.0,white,1.0,<2 mo. follow-up,2.4423828
56.19397,male,1.0,ARF/MOSF w/Sepsis,6.0,under $11k,230733.0,other,3.0,<2 mo. follow-up,3.0
44.849,female,0.0,MOSF w/Malig,10.0,$11-$25k,25176.0,hispanic,0.0,no(M2 and SIP pres),0.0
51.09698,female,0.0,CHF,11.0,under $11k,30877.0,black,1.0,<2 mo. follow-up,1.8389997
36.30899,male,0.0,CHF,16.0,under $11k,23476.0,white,0.0,<2 mo. follow-up,0.0
76.25696,male,0.0,CHF,12.0,under $11k,14926.0,white,2.0,<2 mo. follow-up,2.0
51.30499,male,0.0,CHF,12.0,under $11k,52187.0,black,0.0,no(M2 and SIP pres),0.0
74.54297,female,0.0,COPD,12.0,under $11k,9631.0,white,0.0,no(M2 and SIP pres),0.0
54.30798,male,0.0,Lung Cancer,17.0,$25-$50k,29939.0,white,0.0,no(M2 and SIP pres),0.0
77.57697,female,0.0,CHF,12.0,under $11k,3124.0,other,1.0,<2 mo. follow-up,2.3085938
84.95795,male,0.0,CHF,14.0,>$50k,30942.0,white,1.0,no(M2 and SIP pres),0.4947999
41.52197,male,1.0,MOSF w/Malig,18.0,>$50k,320843.0,white,0.0,<2 mo. follow-up,0.0
39.685,female,0.0,ARF/MOSF w/Sepsis,22.0,$25-$50k,220639.0,white,0.0,no(M2 and SIP pres),0.0
72.55896,female,1.0,COPD,12.0,under $11k,4894.0,white,1.0,<2 mo. follow-up,3.9550781
60.10098,male,0.0,Cirrhosis,12.0,under $11k,63466.0,white,1.0,<2 mo. follow-up,2.3813477
70.81195,male,0.0,CHF,12.0,under $11k,6254.0,black,1.0,<2 mo. follow-up,2.5957031
30.76199,male,0.0,CHF,10.0,under $11k,8437.0,hispanic,1.0,no(M2 and SIP pres),0.4947999
64.23798,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,321716.0,white,0.0,<2 mo. follow-up,0.0
51.70999,male,0.0,CHF,12.0,under $11k,31222.0,asian,0.0,no(M2 and SIP pres),0.0
64.64294,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,180786.0,white,0.0,no(M2 and SIP pres),0.0
69.41498,male,0.0,Lung Cancer,16.0,$25-$50k,8706.0,white,2.0,adl>=4 (>=5 if sur),2.0
57.19098,male,0.0,CHF,12.0,$11-$25k,28476.0,white,1.0,<2 mo. follow-up,0.4947999
37.73297,male,0.0,CHF,12.0,$25-$50k,26278.0,white,7.0,<2 mo. follow-up,7.0
44.05499,female,0.0,Colon Cancer,16.0,>$50k,18563.0,white,0.0,no(M2 and SIP pres),0.0
72.15594,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,187014.0,white,1.0,adl>=4 (>=5 if sur),2.7045898
45.56598,male,1.0,MOSF w/Malig,18.0,$25-$50k,181701.0,white,0.0,<2 mo. follow-up,0.0
41.95999,male,0.0,Lung Cancer,16.0,>$50k,4173.0,white,1.0,no(M2 and SIP pres),2.1796875
59.31,male,0.0,ARF/MOSF w/Sepsis,15.0,>$50k,538692.0,white,2.0,adl>=4 (>=5 if sur),2.0
45.61499,female,1.0,Cirrhosis,16.0,>$50k,302353.0,white,1.0,<2 mo. follow-up,3.5454102
65.98499,female,0.0,Colon Cancer,12.0,under $11k,18980.0,hispanic,1.0,no(M2 and SIP pres),1.1668997
95.79199,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,74764.0,white,1.0,<2 mo. follow-up,5.9414062
76.59094,male,0.0,Colon Cancer,17.0,$11-$25k,7137.0,white,2.0,<2 mo. follow-up,2.0
68.10095,male,0.0,CHF,12.0,$11-$25k,9586.0,white,1.0,no(M2 and SIP pres),1.9719238
78.85297,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,39420.0,white,1.0,<2 mo. follow-up,4.9472656
37.87,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,397017.0,white,1.0,<2 mo. follow-up,2.5400391
74.90997,female,0.0,COPD,16.0,under $11k,8166.0,white,0.0,<2 mo. follow-up,0.0
31.702,female,0.0,Cirrhosis,14.0,under $11k,231119.0,black,1.0,SIP>=30,1.0
54.93997,female,0.0,CHF,14.0,$11-$25k,27561.0,white,0.0,<2 mo. follow-up,0.0
43.30197,male,1.0,Cirrhosis,14.0,under $11k,283145.0,hispanic,2.0,<2 mo. follow-up,2.0
54.92999,female,0.0,Lung Cancer,12.0,$25-$50k,15392.0,asian,0.0,<2 mo. follow-up,0.0
70.21497,male,0.0,Colon Cancer,12.0,$11-$25k,8442.0,white,0.0,no(M2 and SIP pres),0.0
67.09399,female,0.0,Cirrhosis,3.0,under $11k,71992.0,black,1.0,<2 mo. follow-up,1.0
65.05096,male,0.0,Cirrhosis,14.0,$25-$50k,14944.0,white,2.0,<2 mo. follow-up,2.0
69.34698,male,1.0,MOSF w/Malig,18.0,under $11k,433684.0,asian,4.0,<2 mo. follow-up,4.0
64.98798,female,0.0,Lung Cancer,12.0,under $11k,8137.0,white,1.0,<2 mo. follow-up,2.1987305
80.62097,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,104163.0,white,1.0,<2 mo. follow-up,3.3618164
72.172,male,1.0,Lung Cancer,12.0,under $11k,62158.0,white,0.0,<2 mo. follow-up,0.0
53.06198,male,0.0,COPD,12.0,under $11k,6734.0,white,1.0,<2 mo. follow-up,2.6191406
52.50699,female,1.0,CHF,12.0,$11-$25k,20735.0,white,7.0,<2 mo. follow-up,7.0
74.97095,male,0.0,Colon Cancer,12.0,under $11k,43009.0,white,1.0,<2 mo. follow-up,1.9162598
53.34998,male,0.0,ARF/MOSF w/Sepsis,17.0,>$50k,483991.0,asian,6.0,<2 mo. follow-up,6.0
89.58795,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,19238.0,white,1.0,<2 mo. follow-up,5.5683594
56.62399,male,0.0,Colon Cancer,12.0,>$50k,27408.0,white,0.0,no(M2 and SIP pres),0.0
75.04199,male,0.0,Colon Cancer,16.0,under $11k,8723.0,hispanic,1.0,SIP>=30,2.2495117
75.76196,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,74162.0,white,1.0,<2 mo. follow-up,0.4947999
32.99899,female,1.0,Cirrhosis,19.0,$25-$50k,88720.0,other,0.0,<2 mo. follow-up,0.0
72.39697,female,0.0,CHF,10.0,under $11k,11588.0,black,1.0,<2 mo. follow-up,1.0
66.5,male,0.0,CHF,10.0,under $11k,29870.0,white,0.0,no(M2 and SIP pres),0.0
72.78296,male,0.0,CHF,13.0,under $11k,45798.0,white,1.0,no(M2 and SIP pres),1.8389997
61.56897,female,0.0,CHF,8.0,under $11k,22040.0,white,1.0,no(M2 and SIP pres),1.0
52.43298,female,0.0,Colon Cancer,16.0,$11-$25k,12161.0,black,2.0,<2 mo. follow-up,2.0
66.93195,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,88469.0,black,2.0,<2 mo. follow-up,2.0
84.76697,female,0.0,COPD,16.0,under $11k,19608.0,white,7.0,adl>=4 (>=5 if sur),7.0
80.172,male,0.0,CHF,8.0,$11-$25k,6148.0,white,1.0,no(M2 and SIP pres),0.4947999
79.96997,male,0.0,CHF,14.0,$11-$25k,17554.0,other,1.0,<2 mo. follow-up,0.4947999
66.45599,male,0.0,CHF,16.0,under $11k,25668.0,white,0.0,<2 mo. follow-up,0.0
58.116,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,33960.0,white,1.0,<2 mo. follow-up,2.7563477
67.49097,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,172597.0,white,1.0,<2 mo. follow-up,2.7509766
52.09,male,0.0,Cirrhosis,8.0,$11-$25k,13414.0,white,1.0,<2 mo. follow-up,1.0
66.59296,male,0.0,CHF,8.0,$11-$25k,5872.0,black,0.0,<2 mo. follow-up,0.0
56.13998,male,0.0,Cirrhosis,12.0,under $11k,6083.0,white,1.0,<2 mo. follow-up,2.0625
63.76199,male,0.0,Colon Cancer,12.0,under $11k,7737.0,white,1.0,<2 mo. follow-up,2.7080078
39.73199,male,0.0,CHF,12.0,under $11k,16616.0,black,4.0,no(M2 and SIP pres),4.0
60.40198,male,0.0,CHF,16.0,>$50k,9381.0,white,0.0,<2 mo. follow-up,0.0
57.771,male,0.0,Colon Cancer,12.0,under $11k,25187.0,other,1.0,<2 mo. follow-up,2.0932617
48.07397,male,0.0,CHF,12.0,under $11k,5570.0,other,1.0,<2 mo. follow-up,2.3574219
76.68396,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,229314.0,black,3.0,<2 mo. follow-up,3.0
78.35699,male,0.0,CHF,12.0,under $11k,4629.0,black,1.0,no(M2 and SIP pres),1.0
85.29999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,20365.0,white,1.0,<2 mo. follow-up,2.9472656
62.47498,male,0.0,CHF,11.0,$11-$25k,68367.0,white,0.0,no(M2 and SIP pres),0.0
76.41296,female,0.0,CHF,6.0,under $11k,4386.0,black,1.0,adl>=4 (>=5 if sur),2.3959961
45.11398,male,1.0,Lung Cancer,12.0,under $11k,13100.0,black,1.0,<2 mo. follow-up,3.7583008
68.12598,female,0.0,Cirrhosis,12.0,under $11k,6992.0,black,1.0,<2 mo. follow-up,2.2592773
82.17694,female,0.0,Lung Cancer,15.0,$25-$50k,15942.0,white,1.0,no(M2 and SIP pres),0.4947999
41.87,male,0.0,Cirrhosis,12.0,>$50k,68108.0,white,0.0,no(M2 and SIP pres),0.0
76.20795,female,0.0,Cirrhosis,11.0,under $11k,3644.0,black,6.0,<2 mo. follow-up,6.0
60.04398,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,506141.0,white,2.0,<2 mo. follow-up,2.0
77.13898,male,1.0,ARF/MOSF w/Sepsis,20.0,$11-$25k,159553.0,white,4.0,<2 mo. follow-up,4.0
72.96399,female,0.0,ARF/MOSF w/Sepsis,13.0,$11-$25k,42243.0,white,3.0,adl>=4 (>=5 if sur),3.0
59.40598,male,0.0,CHF,12.0,>$50k,19852.0,white,0.0,adl>=4 (>=5 if sur),0.0
72.83795,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,740010.0,white,1.0,Coma or Intub,2.8237305
50.23099,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,44480.0,white,1.0,<2 mo. follow-up,3.4614258
71.56195,female,0.0,Colon Cancer,12.0,$25-$50k,15051.0,white,1.0,<2 mo. follow-up,1.1668997
71.90399,male,0.0,Colon Cancer,10.0,under $11k,24612.0,hispanic,0.0,no(M2 and SIP pres),0.0
44.62997,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,40418.0,white,1.0,<2 mo. follow-up,2.3632812
51.98398,female,0.0,Colon Cancer,17.0,>$50k,29303.0,white,1.0,no(M2 and SIP pres),1.0
53.82599,male,0.0,CHF,12.0,$25-$50k,24587.0,hispanic,1.0,<2 mo. follow-up,2.6064453
50.431,male,1.0,MOSF w/Malig,12.0,under $11k,70463.0,white,1.0,<2 mo. follow-up,3.1044922
31.69099,male,0.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,274531.0,hispanic,0.0,no(M2 and SIP pres),0.0
65.30896,female,0.0,COPD,12.0,under $11k,84901.0,white,1.0,SIP>=30,3.0009766
81.54095,male,0.0,CHF,12.0,$25-$50k,20850.0,white,6.0,<2 mo. follow-up,6.0
66.39795,male,0.0,CHF,16.0,under $11k,17247.0,white,0.0,no(M2 and SIP pres),0.0
50.20099,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,218924.0,white,1.0,<2 mo. follow-up,2.5366211
88.29797,male,0.0,CHF,8.0,under $11k,63639.0,white,2.0,<2 mo. follow-up,2.0
58.41498,female,0.0,Colon Cancer,14.0,$25-$50k,58940.0,white,1.0,<2 mo. follow-up,2.5058594
56.34998,female,0.0,Lung Cancer,12.0,under $11k,26731.0,white,1.0,<2 mo. follow-up,3.6875
71.69897,female,0.0,Colon Cancer,19.0,under $11k,5319.0,white,1.0,no(M2 and SIP pres),0.4947999
32.13998,male,1.0,MOSF w/Malig,12.0,under $11k,256835.0,other,1.0,<2 mo. follow-up,2.2148438
48.10999,female,0.0,Cirrhosis,2.0,$11-$25k,56562.0,hispanic,0.0,<2 mo. follow-up,0.0
76.383,male,0.0,Colon Cancer,12.0,under $11k,24788.0,other,1.0,<2 mo. follow-up,2.262207
57.81,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,125797.0,white,0.0,<2 mo. follow-up,0.0
66.76794,female,0.0,Colon Cancer,12.0,under $11k,15358.0,white,1.0,no(M2 and SIP pres),0.4947999
46.45898,male,0.0,Colon Cancer,16.0,>$50k,21906.0,white,0.0,no(M2 and SIP pres),0.0
64.34796,female,0.0,Colon Cancer,12.0,$11-$25k,77328.0,white,1.0,no(M2 and SIP pres),1.0
75.23596,female,0.0,Colon Cancer,12.0,$11-$25k,26189.0,asian,0.0,no(M2 and SIP pres),0.0
74.60394,male,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,58853.0,white,1.0,<2 mo. follow-up,4.6474609
36.45999,female,0.0,Coma,12.0,under $11k,201322.0,white,1.0,<2 mo. follow-up,2.3637695
63.77298,male,1.0,ARF/MOSF w/Sepsis,16.0,>$50k,89043.0,white,1.0,<2 mo. follow-up,4.4150391
65.70599,male,0.0,Colon Cancer,18.0,$25-$50k,8729.0,hispanic,0.0,no(M2 and SIP pres),0.0
20.83199,male,1.0,MOSF w/Malig,12.0,under $11k,392950.0,white,1.0,<2 mo. follow-up,1.1416016
52.668,female,1.0,Coma,12.0,under $11k,104602.0,white,1.0,<2 mo. follow-up,2.5009766
75.36798,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,125256.0,white,1.0,<2 mo. follow-up,2.9306641
53.86697,male,0.0,CHF,18.0,under $11k,20923.0,white,1.0,no(M2 and SIP pres),0.4947999
44.35898,male,0.0,CHF,12.0,$11-$25k,12042.0,white,1.0,no(M2 and SIP pres),2.4326172
53.62097,female,0.0,Cirrhosis,12.0,under $11k,279530.0,white,1.0,<2 mo. follow-up,2.4321289
84.90295,female,0.0,Colon Cancer,15.0,$11-$25k,9291.0,white,1.0,no(M2 and SIP pres),0.4947999
70.83899,male,0.0,CHF,12.0,under $11k,10955.0,white,1.0,<2 mo. follow-up,4.1845703
70.06195,male,0.0,CHF,12.0,under $11k,15687.0,hispanic,1.0,SIP>=30,1.0
37.71899,male,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,268805.0,white,1.0,<2 mo. follow-up,1.0
65.45697,female,1.0,Lung Cancer,13.0,$11-$25k,41397.0,black,5.0,<2 mo. follow-up,5.0
29.88399,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,223581.0,white,2.0,<2 mo. follow-up,2.0
87.521,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,469824.0,white,1.0,<2 mo. follow-up,3.3193359
18.146,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,641888.0,hispanic,0.0,Coma or Intub,0.0
42.92398,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,277421.0,white,1.0,<2 mo. follow-up,3.0610352
37.396,female,1.0,Cirrhosis,13.0,$11-$25k,166927.0,black,1.0,<2 mo. follow-up,2.8491211
63.46899,male,0.0,Colon Cancer,12.0,under $11k,29732.0,white,1.0,<2 mo. follow-up,2.1762695
53.57999,female,0.0,COPD,12.0,under $11k,5132.0,white,1.0,<2 mo. follow-up,2.3583984
70.07495,male,0.0,CHF,11.0,$11-$25k,33290.0,black,1.0,<2 mo. follow-up,1.0
47.633,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,138674.0,asian,1.0,<2 mo. follow-up,1.6940918
51.54797,male,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,170244.0,white,2.0,no(M2 and SIP pres),2.0
90.83899,female,0.0,CHF,12.0,under $11k,14065.0,white,1.0,<2 mo. follow-up,3.8759766
35.625,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,23421.0,black,1.0,<2 mo. follow-up,2.0986328
63.85999,female,1.0,Coma,12.0,under $11k,47424.0,white,1.0,<2 mo. follow-up,2.5307617
67.04199,male,0.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,100735.0,white,0.0,adl>=4 (>=5 if sur),0.0
61.16098,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,970982.0,white,1.0,adl>=4 (>=5 if sur),2.8037109
77.13098,male,0.0,Lung Cancer,12.0,under $11k,29403.0,white,1.0,<2 mo. follow-up,2.9814453
19.14,male,0.0,CHF,12.0,$25-$50k,216359.0,white,0.0,no(M2 and SIP pres),0.0
64.18097,male,0.0,Colon Cancer,14.0,$11-$25k,26311.0,white,0.0,no(M2 and SIP pres),0.0
53.30298,female,0.0,Colon Cancer,12.0,under $11k,17823.0,white,1.0,no(M2 and SIP pres),1.8389997
55.28799,female,0.0,CHF,13.0,under $11k,19419.0,white,1.0,no(M2 and SIP pres),3.1230469
53.14697,male,0.0,CHF,14.0,under $11k,16552.0,asian,0.0,no(M2 and SIP pres),0.0
32.44098,male,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,1273347.0,white,7.0,Coma or Intub,7.0
58.95999,female,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,207902.0,white,0.0,adl>=4 (>=5 if sur),0.0
27.411,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,122322.0,white,1.0,<2 mo. follow-up,1.0
77.09497,male,0.0,CHF,16.0,>$50k,23862.0,white,0.0,<2 mo. follow-up,0.0
63.69299,female,0.0,CHF,11.0,$11-$25k,46112.0,white,3.0,SIP>=30,3.0
62.185,female,0.0,Lung Cancer,12.0,under $11k,35575.0,black,1.0,<2 mo. follow-up,2.390625
53.52197,female,0.0,COPD,12.0,$11-$25k,20893.0,white,1.0,no(M2 and SIP pres),4.2832031
23.39999,female,1.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,943804.0,hispanic,0.0,Coma or Intub,0.0
65.60999,female,0.0,CHF,12.0,under $11k,25467.0,white,2.0,SIP>=30,2.0
70.28094,male,1.0,Cirrhosis,12.0,under $11k,28159.0,white,1.0,<2 mo. follow-up,1.1668997
60.71997,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,63858.0,white,1.0,<2 mo. follow-up,2.6665039
77.00494,female,0.0,CHF,12.0,under $11k,15565.0,white,1.0,<2 mo. follow-up,3.0146484
42.05298,male,0.0,CHF,12.0,$11-$25k,24897.0,hispanic,0.0,no(M2 and SIP pres),0.0
60.75,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,254366.0,asian,1.0,<2 mo. follow-up,2.5249023
71.28796,male,1.0,CHF,15.0,under $11k,4854.0,white,0.0,<2 mo. follow-up,0.0
22.66899,female,0.0,CHF,15.0,under $11k,18751.0,hispanic,1.0,adl>=4 (>=5 if sur),3.1831989
59.12399,female,0.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,43164.0,white,7.0,<2 mo. follow-up,7.0
63.896,male,0.0,Cirrhosis,12.0,>$50k,227392.0,hispanic,5.0,SIP>=30,5.0
87.43097,male,1.0,CHF,12.0,under $11k,89889.0,white,1.0,<2 mo. follow-up,3.5537109
78.89899,male,0.0,COPD,12.0,under $11k,40247.0,white,0.0,<2 mo. follow-up,0.0
83.64099,male,0.0,CHF,10.0,under $11k,25653.0,white,1.0,<2 mo. follow-up,1.0
47.737,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,592486.0,black,1.0,Coma or Intub,1.0
78.84998,female,0.0,CHF,8.0,under $11k,9914.0,black,6.0,SIP>=30,6.0
51.18399,male,0.0,CHF,6.0,under $11k,22621.0,black,1.0,no(M2 and SIP pres),1.1668997
61.45398,male,0.0,Colon Cancer,30.0,>$50k,60175.0,white,1.0,no(M2 and SIP pres),2.0556641
55.20297,male,0.0,CHF,15.0,under $11k,3035.0,other,1.0,no(M2 and SIP pres),0.4947999
74.06396,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,44728.0,white,1.0,<2 mo. follow-up,2.402832
90.90796,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,69364.0,white,5.0,<2 mo. follow-up,5.0
38.94897,male,1.0,Cirrhosis,9.0,$11-$25k,133918.0,hispanic,3.0,<2 mo. follow-up,3.0
65.14697,female,0.0,Lung Cancer,12.0,under $11k,5223.0,white,1.0,<2 mo. follow-up,2.4189453
51.62799,female,0.0,CHF,13.0,$25-$50k,23146.0,white,0.0,no(M2 and SIP pres),0.0
56.20499,male,0.0,Lung Cancer,12.0,under $11k,42041.0,white,1.0,no(M2 and SIP pres),2.7797852
65.88599,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,19662.0,white,1.0,<2 mo. follow-up,2.237793
69.19598,male,0.0,CHF,14.0,$11-$25k,24859.0,asian,0.0,no(M2 and SIP pres),0.0
77.74695,male,0.0,Lung Cancer,12.0,under $11k,16325.0,other,0.0,no(M2 and SIP pres),0.0
80.09595,male,0.0,CHF,12.0,$11-$25k,5293.0,white,6.0,SIP>=30,6.0
71.54596,male,0.0,Lung Cancer,20.0,>$50k,23304.0,white,0.0,no(M2 and SIP pres),0.0
60.61899,male,0.0,CHF,14.0,under $11k,49079.0,white,1.0,no(M2 and SIP pres),1.0
58.478,male,0.0,CHF,12.0,under $11k,3580.0,white,1.0,<2 mo. follow-up,2.6030273
52.67899,male,0.0,CHF,16.0,under $11k,17110.0,asian,1.0,no(M2 and SIP pres),0.4947999
70.48596,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,149983.0,white,1.0,<2 mo. follow-up,3.6967773
50.58197,male,0.0,Cirrhosis,10.0,$25-$50k,9113.0,hispanic,1.0,Coma or Intub,3.1831989
25.487,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,126732.0,white,1.0,<2 mo. follow-up,2.3955078
88.69495,male,1.0,Coma,12.0,>$50k,24242.0,white,0.0,<2 mo. follow-up,0.0
68.01898,male,0.0,MOSF w/Malig,12.0,under $11k,659433.0,white,1.0,<2 mo. follow-up,3.2172852
81.77698,female,0.0,Cirrhosis,7.0,under $11k,5405.0,black,0.0,SIP>=30,0.0
71.86298,male,0.0,CHF,12.0,under $11k,3869.0,white,1.0,<2 mo. follow-up,2.2963867
72.19696,female,0.0,CHF,12.0,under $11k,9991.0,black,1.0,<2 mo. follow-up,3.4404297
53.40997,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,102911.0,white,1.0,no(M2 and SIP pres),2.5112305
34.35699,male,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,110596.0,hispanic,5.0,<2 mo. follow-up,5.0
56.66498,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,206651.0,white,1.0,<2 mo. follow-up,2.3227539
53.67798,female,0.0,Cirrhosis,13.0,under $11k,14583.0,white,0.0,<2 mo. follow-up,0.0
55.32898,male,0.0,Lung Cancer,12.0,$25-$50k,11985.0,asian,1.0,no(M2 and SIP pres),0.4947999
54.056,male,1.0,Coma,18.0,$25-$50k,46156.0,white,1.0,<2 mo. follow-up,1.0
70.80396,male,1.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,222230.0,hispanic,1.0,<2 mo. follow-up,3.2109375
86.57098,female,1.0,Coma,12.0,under $11k,10662.0,white,1.0,<2 mo. follow-up,3.831543
52.44897,male,0.0,Lung Cancer,12.0,under $11k,10469.0,white,0.0,<2 mo. follow-up,0.0
50.97897,male,0.0,COPD,14.0,under $11k,27015.0,white,1.0,no(M2 and SIP pres),1.0
77.75995,male,1.0,CHF,14.0,under $11k,34038.0,white,0.0,<2 mo. follow-up,0.0
54.18198,male,1.0,MOSF w/Malig,17.0,>$50k,40620.0,white,1.0,<2 mo. follow-up,1.0
34.17398,female,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,39002.0,white,3.0,<2 mo. follow-up,3.0
80.52295,male,0.0,CHF,12.0,under $11k,5853.0,white,1.0,<2 mo. follow-up,2.6611328
50.53,male,0.0,CHF,13.0,under $11k,18574.0,white,1.0,<2 mo. follow-up,2.0595703
56.82397,female,0.0,COPD,12.0,under $11k,49730.0,black,1.0,adl>=4 (>=5 if sur),3.105957
45.892,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,330735.0,black,1.0,<2 mo. follow-up,2.6865234
69.71698,female,1.0,Coma,12.0,under $11k,21696.0,white,1.0,<2 mo. follow-up,2.9838867
65.89996,male,0.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,143419.0,white,1.0,<2 mo. follow-up,1.1668997
38.491,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,111543.0,white,1.0,<2 mo. follow-up,2.4545898
65.53595,male,0.0,MOSF w/Malig,27.0,>$50k,61126.0,black,1.0,no(M2 and SIP pres),2.1010742
59.146,male,0.0,Lung Cancer,11.0,under $11k,17737.0,white,3.0,<2 mo. follow-up,3.0
53.922,female,0.0,Colon Cancer,16.0,$25-$50k,46135.0,white,1.0,<2 mo. follow-up,2.050293
40.63199,male,0.0,CHF,1.0,$11-$25k,29551.0,hispanic,0.0,no(M2 and SIP pres),0.0
65.67596,male,0.0,Lung Cancer,12.0,under $11k,57969.0,white,1.0,<2 mo. follow-up,0.4947999
53.10098,male,1.0,CHF,12.0,under $11k,15394.0,white,1.0,<2 mo. follow-up,2.8071289
43.28299,female,1.0,MOSF w/Malig,12.0,under $11k,100051.0,white,1.0,<2 mo. follow-up,3.5332031
35.14297,male,0.0,Lung Cancer,14.0,>$50k,7880.0,white,1.0,no(M2 and SIP pres),0.4947999
51.49899,female,0.0,Cirrhosis,12.0,under $11k,5765.0,white,3.0,<2 mo. follow-up,3.0
76.44897,male,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,92307.0,white,6.0,<2 mo. follow-up,6.0
81.24597,female,1.0,Coma,12.0,under $11k,15473.0,white,1.0,<2 mo. follow-up,5.2402344
19.60599,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,413774.0,white,1.0,<2 mo. follow-up,2.1264648
63.431,male,0.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,409250.0,white,2.0,no(M2 and SIP pres),2.0
52.37198,male,0.0,COPD,12.0,under $11k,6622.0,black,1.0,no(M2 and SIP pres),1.1668997
38.883,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,34680.0,hispanic,6.0,adl>=4 (>=5 if sur),6.0
77.67596,male,1.0,MOSF w/Malig,12.0,under $11k,26620.0,white,1.0,<2 mo. follow-up,3.7626953
75.96698,female,0.0,Lung Cancer,12.0,under $11k,12424.0,white,0.0,<2 mo. follow-up,0.0
42.38699,female,1.0,MOSF w/Malig,12.0,under $11k,221026.0,white,1.0,<2 mo. follow-up,2.3369141
47.24698,female,0.0,Lung Cancer,16.0,under $11k,29076.0,asian,1.0,<2 mo. follow-up,2.9604492
69.66699,male,1.0,Cirrhosis,12.0,under $11k,122908.0,white,1.0,<2 mo. follow-up,2.5512695
57.58197,male,0.0,CHF,10.0,under $11k,26110.0,white,1.0,no(M2 and SIP pres),0.4947999
50.64798,male,0.0,CHF,12.0,under $11k,23376.0,black,0.0,no(M2 and SIP pres),0.0
60.07898,male,0.0,Colon Cancer,12.0,>$50k,22300.0,white,0.0,no(M2 and SIP pres),0.0
67.47998,male,0.0,Colon Cancer,12.0,under $11k,11506.0,white,1.0,<2 mo. follow-up,2.2626953
62.875,male,0.0,Colon Cancer,14.0,>$50k,23575.0,white,1.0,no(M2 and SIP pres),1.8389997
74.10797,male,1.0,COPD,12.0,$11-$25k,73695.0,white,7.0,<2 mo. follow-up,7.0
66.73199,male,0.0,Colon Cancer,16.0,$25-$50k,30052.0,white,1.0,no(M2 and SIP pres),1.1668997
71.39996,female,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,163714.0,white,1.0,<2 mo. follow-up,3.855299
60.85699,female,0.0,Lung Cancer,12.0,under $11k,22052.0,white,1.0,<2 mo. follow-up,2.5507812
47.37598,female,1.0,MOSF w/Malig,12.0,$11-$25k,266998.0,white,0.0,<2 mo. follow-up,0.0
71.15094,female,1.0,CHF,10.0,$11-$25k,27021.0,black,1.0,<2 mo. follow-up,1.0
64.24597,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,32157.0,hispanic,1.0,<2 mo. follow-up,1.0
21.63699,female,0.0,Colon Cancer,16.0,>$50k,17730.0,white,0.0,no(M2 and SIP pres),0.0
60.58899,male,1.0,Lung Cancer,12.0,>$50k,17989.0,white,0.0,<2 mo. follow-up,0.0
55.20599,female,0.0,COPD,12.0,under $11k,28330.0,black,6.0,adl>=4 (>=5 if sur),6.0
66.54596,male,1.0,ARF/MOSF w/Sepsis,15.0,>$50k,348628.0,white,1.0,<2 mo. follow-up,2.9897461
66.66895,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,922581.0,asian,1.0,Coma or Intub,2.265625
73.36597,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,536925.0,white,1.0,<2 mo. follow-up,3.1137695
37.59299,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,29615.0,white,1.0,<2 mo. follow-up,2.9033203
61.34399,female,0.0,Colon Cancer,11.0,under $11k,30431.0,hispanic,1.0,no(M2 and SIP pres),1.1668997
65.92499,male,0.0,Colon Cancer,16.0,>$50k,6228.0,asian,0.0,no(M2 and SIP pres),0.0
47.33197,female,0.0,COPD,12.0,under $11k,35296.0,white,1.0,<2 mo. follow-up,4.0380859
32.18298,female,0.0,CHF,12.0,under $11k,12924.0,white,1.0,<2 mo. follow-up,2.8623047
48.04398,male,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,786088.0,white,3.0,<2 mo. follow-up,3.0
71.66296,female,1.0,Coma,12.0,under $11k,21598.0,white,1.0,<2 mo. follow-up,2.2768555
64.45197,male,0.0,CHF,12.0,under $11k,30265.0,white,2.0,<2 mo. follow-up,2.0
24.515,female,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,83772.0,hispanic,4.0,no(M2 and SIP pres),4.0
74.034,female,1.0,Colon Cancer,12.0,under $11k,6429.0,white,1.0,<2 mo. follow-up,3.3735352
72.03296,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,61750.0,white,1.0,<2 mo. follow-up,3.8081055
68.60797,male,0.0,CHF,12.0,under $11k,8303.0,white,1.0,<2 mo. follow-up,2.9321289
59.40598,male,0.0,CHF,14.0,$11-$25k,157585.0,asian,1.0,no(M2 and SIP pres),1.0
20.312,male,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,99728.0,white,3.0,<2 mo. follow-up,3.0
80.19397,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,29857.0,white,1.0,<2 mo. follow-up,2.9487305
42.06699,male,1.0,MOSF w/Malig,18.0,$11-$25k,137943.0,white,1.0,<2 mo. follow-up,2.2294922
23.81699,male,0.0,MOSF w/Malig,13.0,$25-$50k,245347.0,black,2.0,adl>=4 (>=5 if sur),2.0
65.97095,male,0.0,CHF,12.0,under $11k,16273.0,white,1.0,<2 mo. follow-up,2.4047852
67.00098,male,0.0,CHF,12.0,under $11k,15242.0,white,1.0,<2 mo. follow-up,2.1396484
58.09698,male,0.0,ARF/MOSF w/Sepsis,15.0,$25-$50k,150445.0,hispanic,1.0,no(M2 and SIP pres),2.3178711
34.99799,female,0.0,Coma,18.0,>$50k,8265.0,white,1.0,adl>=4 (>=5 if sur),1.0
65.96295,male,0.0,ARF/MOSF w/Sepsis,4.0,under $11k,181645.0,hispanic,1.0,no(M2 and SIP pres),2.097168
43.85999,female,0.0,Cirrhosis,12.0,$11-$25k,186293.0,hispanic,3.0,<2 mo. follow-up,3.0
29.769,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,181539.0,asian,1.0,<2 mo. follow-up,2.1264648
52.71997,female,1.0,Cirrhosis,20.0,$11-$25k,45273.0,white,1.0,<2 mo. follow-up,3.0878906
26.24799,male,1.0,MOSF w/Malig,12.0,under $11k,260829.0,white,1.0,<2 mo. follow-up,3.0917969
66.75397,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,306038.0,white,1.0,<2 mo. follow-up,2.4399414
53.125,male,0.0,Lung Cancer,8.0,$11-$25k,13872.0,white,1.0,<2 mo. follow-up,0.4947999
70.74097,male,0.0,ARF/MOSF w/Sepsis,17.0,>$50k,72222.0,white,1.0,no(M2 and SIP pres),2.4282227
54.67798,male,0.0,CHF,14.0,under $11k,38322.0,white,1.0,<2 mo. follow-up,2.5110989
81.45398,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,92518.0,white,1.0,<2 mo. follow-up,2.4912109
58.27499,female,0.0,COPD,12.0,under $11k,161257.0,black,6.0,<2 mo. follow-up,6.0
36.96899,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,85027.0,other,1.0,<2 mo. follow-up,2.4121094
44.47897,male,0.0,Cirrhosis,16.0,$25-$50k,12696.0,white,0.0,no(M2 and SIP pres),0.0
79.98096,male,0.0,Colon Cancer,16.0,>$50k,42514.0,white,0.0,<2 mo. follow-up,0.0
82.245,female,1.0,Coma,12.0,under $11k,73656.0,white,1.0,<2 mo. follow-up,2.355957
38.49698,male,0.0,ARF/MOSF w/Sepsis,17.0,>$50k,463001.0,white,0.0,no(M2 and SIP pres),0.0
59.37598,male,0.0,MOSF w/Malig,12.0,under $11k,64372.0,black,0.0,<2 mo. follow-up,0.0
58.44998,male,0.0,CHF,20.0,under $11k,30148.0,white,1.0,<2 mo. follow-up,0.4947999
83.30194,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,49455.0,white,1.0,<2 mo. follow-up,3.5644531
43.995,female,0.0,Cirrhosis,12.0,$11-$25k,260514.0,white,1.0,no(M2 and SIP pres),1.0
50.09698,male,0.0,MOSF w/Malig,12.0,under $11k,29840.0,other,1.0,<2 mo. follow-up,1.0
80.18896,male,1.0,ARF/MOSF w/Sepsis,19.0,>$50k,257589.0,white,2.0,<2 mo. follow-up,2.0
40.20499,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,151181.0,white,1.0,<2 mo. follow-up,3.0107422
57.01797,female,0.0,CHF,12.0,under $11k,12504.0,white,1.0,<2 mo. follow-up,2.4633789
38.90799,female,0.0,ARF/MOSF w/Sepsis,13.0,under $11k,48336.0,white,3.0,<2 mo. follow-up,3.0
75.54297,male,0.0,Colon Cancer,14.0,$25-$50k,18233.0,white,0.0,no(M2 and SIP pres),0.0
34.80899,female,1.0,MOSF w/Malig,12.0,under $11k,71315.0,white,1.0,<2 mo. follow-up,3.0834961
73.72998,male,0.0,Colon Cancer,12.0,under $11k,41836.0,white,1.0,<2 mo. follow-up,2.1674805
42.543,male,1.0,MOSF w/Malig,12.0,under $11k,217970.0,white,1.0,<2 mo. follow-up,2.6279297
68.70099,male,0.0,Lung Cancer,12.0,under $11k,8570.0,white,1.0,<2 mo. follow-up,2.2436523
73.56299,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,192983.0,white,1.0,<2 mo. follow-up,2.9082031
69.10297,female,0.0,Colon Cancer,12.0,under $11k,39080.0,white,1.0,<2 mo. follow-up,2.4438477
67.41095,male,1.0,Coma,12.0,under $11k,19247.0,white,1.0,<2 mo. follow-up,2.9233398
79.72095,male,1.0,CHF,18.0,>$50k,23327.0,asian,4.0,<2 mo. follow-up,4.0
48.35898,male,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,60676.0,hispanic,0.0,<2 mo. follow-up,0.0
60.67398,male,1.0,CHF,12.0,>$50k,481475.0,white,3.0,adl>=4 (>=5 if sur),3.0
58.31897,female,0.0,Cirrhosis,12.0,under $11k,5877.0,hispanic,1.0,<2 mo. follow-up,3.1245117
59.88498,male,0.0,CHF,14.0,$25-$50k,25441.0,white,1.0,no(M2 and SIP pres),0.4947999
64.02698,male,0.0,CHF,12.0,under $11k,11926.0,white,1.0,<2 mo. follow-up,1.6655273
34.461,female,1.0,MOSF w/Malig,12.0,under $11k,193371.0,white,1.0,<2 mo. follow-up,1.9511719
47.33499,female,0.0,Colon Cancer,12.0,under $11k,53037.0,white,1.0,<2 mo. follow-up,2.6083984
47.77798,female,0.0,Cirrhosis,12.0,under $11k,14867.0,other,1.0,<2 mo. follow-up,2.1303711
49.28998,male,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,73143.0,white,1.0,<2 mo. follow-up,2.1860352
51.573,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,121630.0,white,1.0,<2 mo. follow-up,3.3798828
73.90295,male,0.0,CHF,16.0,under $11k,6676.0,white,1.0,<2 mo. follow-up,2.2524414
71.28497,male,0.0,Lung Cancer,12.0,under $11k,16142.0,white,1.0,<2 mo. follow-up,2.5341797
55.29898,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,85170.0,white,1.0,<2 mo. follow-up,2.8974609
52.68997,male,0.0,MOSF w/Malig,12.0,under $11k,50315.0,white,1.0,<2 mo. follow-up,3.7290039
81.38794,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,207883.0,white,1.0,<2 mo. follow-up,3.1708984
49.29999,male,0.0,Cirrhosis,12.0,under $11k,241565.0,white,1.0,<2 mo. follow-up,3.9243164
64.69299,male,0.0,Colon Cancer,12.0,$25-$50k,24410.0,white,1.0,<2 mo. follow-up,0.4947999
61.67798,male,0.0,Colon Cancer,12.0,>$50k,18565.0,white,1.0,no(M2 and SIP pres),2.5693359
64.25195,male,0.0,CHF,6.0,under $11k,7339.0,white,1.0,no(M2 and SIP pres),2.1958008
56.95798,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,80188.0,other,1.0,<2 mo. follow-up,2.5454102
29.71399,male,1.0,MOSF w/Malig,12.0,under $11k,55429.0,other,1.0,<2 mo. follow-up,2.3691406
35.56998,female,0.0,MOSF w/Malig,19.0,>$50k,141926.0,black,6.0,<2 mo. follow-up,6.0
38.42297,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,36468.0,black,1.0,<2 mo. follow-up,3.4711914
62.53497,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,188728.0,white,1.0,<2 mo. follow-up,2.7363281
76.49597,male,1.0,Lung Cancer,12.0,under $11k,7422.0,white,1.0,<2 mo. follow-up,3.1860352
83.16199,male,1.0,Coma,12.0,under $11k,13767.0,white,1.0,<2 mo. follow-up,3.2773438
57.52798,male,0.0,Coma,12.0,under $11k,82244.0,white,1.0,<2 mo. follow-up,2.3989258
73.66498,male,0.0,Colon Cancer,12.0,under $11k,9640.0,white,3.0,<2 mo. follow-up,3.0
46.51099,male,0.0,Cirrhosis,15.0,$25-$50k,603388.0,black,6.0,adl>=4 (>=5 if sur),6.0
78.91895,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,219537.0,white,1.0,<2 mo. follow-up,3.2841797
68.91394,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,30869.0,white,1.0,<2 mo. follow-up,2.762207
42.29199,female,1.0,MOSF w/Malig,12.0,under $11k,161776.0,white,1.0,<2 mo. follow-up,2.1401367
46.57898,male,0.0,CHF,22.0,under $11k,17254.0,black,1.0,<2 mo. follow-up,0.4947999
54.03998,male,0.0,CHF,16.0,>$50k,135849.0,white,1.0,<2 mo. follow-up,1.0
45.10599,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,35204.0,white,1.0,<2 mo. follow-up,2.7602539
87.46295,female,0.0,CHF,12.0,>$50k,12163.0,white,1.0,no(M2 and SIP pres),3.7792969
79.24695,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,174898.0,black,0.0,<2 mo. follow-up,0.0
39.73999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,352017.0,other,1.0,<2 mo. follow-up,3.2241211
78.17395,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,372459.0,asian,1.0,<2 mo. follow-up,2.9794922
79.13196,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,36811.0,white,1.0,<2 mo. follow-up,4.6357422
70.63898,male,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,104045.0,white,1.0,<2 mo. follow-up,0.4947999
41.26498,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,597427.0,white,1.0,no(M2 and SIP pres),3.331543
38.35699,female,0.0,Colon Cancer,12.0,under $11k,5573.0,white,1.0,<2 mo. follow-up,2.0043945
59.92099,male,0.0,Lung Cancer,12.0,under $11k,19491.0,black,1.0,<2 mo. follow-up,3.5507812
58.11899,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,40421.0,white,1.0,<2 mo. follow-up,2.1513672
35.25,female,0.0,MOSF w/Malig,12.0,under $11k,271731.0,white,1.0,<2 mo. follow-up,2.2861328
66.18994,female,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,53786.0,white,1.0,no(M2 and SIP pres),1.1668997
41.02698,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,237244.0,white,1.0,<2 mo. follow-up,3.1860352
54.93198,male,0.0,Cirrhosis,12.0,under $11k,25024.0,white,1.0,no(M2 and SIP pres),2.9755859
78.58997,male,1.0,Colon Cancer,12.0,under $11k,5871.0,black,1.0,<2 mo. follow-up,3.1899414
82.21497,male,0.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,135785.0,white,1.0,adl>=4 (>=5 if sur),1.0
40.34198,male,1.0,MOSF w/Malig,16.0,>$50k,370093.0,white,0.0,<2 mo. follow-up,0.0
60.84097,male,1.0,CHF,16.0,under $11k,173498.0,white,1.0,<2 mo. follow-up,2.7094727
67.82996,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,242746.0,white,1.0,<2 mo. follow-up,2.4858398
65.41296,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,86956.0,black,1.0,<2 mo. follow-up,2.5546875
74.297,male,0.0,CHF,18.0,>$50k,19565.0,white,1.0,no(M2 and SIP pres),0.4947999
61.78799,female,0.0,Lung Cancer,12.0,under $11k,4226.0,black,1.0,no(M2 and SIP pres),2.5039062
45.43198,male,1.0,MOSF w/Malig,16.0,$11-$25k,110902.0,hispanic,1.0,<2 mo. follow-up,2.4604492
62.45297,male,0.0,CHF,16.0,>$50k,269517.0,white,1.0,no(M2 and SIP pres),0.4947999
70.28094,male,0.0,Colon Cancer,12.0,under $11k,25535.0,white,1.0,<2 mo. follow-up,2.3105469
52.28497,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,303548.0,white,0.0,no(M2 and SIP pres),0.0
57.76599,male,0.0,CHF,12.0,under $11k,30477.0,black,1.0,<2 mo. follow-up,3.3032227
54.74298,male,1.0,MOSF w/Malig,12.0,under $11k,79089.0,white,1.0,<2 mo. follow-up,3.3017578
54.78198,male,0.0,Lung Cancer,12.0,under $11k,7383.0,black,1.0,<2 mo. follow-up,0.4947999
46.69998,female,1.0,MOSF w/Malig,12.0,under $11k,105684.0,other,1.0,<2 mo. follow-up,1.8427734
36.59097,male,1.0,MOSF w/Malig,12.0,under $11k,80565.0,white,1.0,<2 mo. follow-up,2.6972656
83.39496,male,0.0,CHF,13.0,$11-$25k,3968.0,black,0.0,no(M2 and SIP pres),0.0
41.29797,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,182264.0,black,1.0,<2 mo. follow-up,1.0
90.13794,male,0.0,MOSF w/Malig,24.0,under $11k,124700.0,white,1.0,<2 mo. follow-up,5.7294922
20.09599,female,0.0,CHF,12.0,$11-$25k,51152.0,black,2.0,no(M2 and SIP pres),2.0
38.92999,male,0.0,Cirrhosis,14.0,$25-$50k,4117.0,white,1.0,no(M2 and SIP pres),0.4947999
39.81897,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,79944.0,white,1.0,<2 mo. follow-up,3.0444336
53.09497,female,1.0,Cirrhosis,12.0,under $11k,47800.0,white,1.0,<2 mo. follow-up,3.5976562
53.38498,female,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,81459.0,white,1.0,no(M2 and SIP pres),2.7265625
79.81396,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,98268.0,white,1.0,adl>=4 (>=5 if sur),3.371582
68.45996,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,26493.0,black,1.0,adl>=4 (>=5 if sur),3.9082031
52.52597,female,0.0,CHF,16.0,$11-$25k,20605.0,black,3.0,adl>=4 (>=5 if sur),3.0
62.50198,male,0.0,CHF,4.0,$11-$25k,8761.0,hispanic,1.0,<2 mo. follow-up,2.5043945
57.02899,male,0.0,Cirrhosis,17.0,$11-$25k,145874.0,white,0.0,<2 mo. follow-up,0.0
61.448,male,0.0,CHF,3.0,under $11k,13444.0,black,0.0,no(M2 and SIP pres),0.0
87.76697,female,0.0,COPD,16.0,under $11k,109552.0,white,1.0,<2 mo. follow-up,4.4589844
65.71399,male,1.0,Coma,12.0,under $11k,45707.0,white,1.0,<2 mo. follow-up,2.753418
46.97098,female,0.0,COPD,9.0,under $11k,5975.0,hispanic,1.0,<2 mo. follow-up,1.8389997
62.10797,male,0.0,CHF,7.0,under $11k,22091.0,white,5.0,SIP>=30,5.0
81.99896,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,117689.0,white,1.0,<2 mo. follow-up,3.9467773
62.53,female,0.0,Colon Cancer,12.0,under $11k,16862.0,white,0.0,no(M2 and SIP pres),0.0
54.52197,female,0.0,CHF,13.0,>$50k,414803.0,white,1.0,no(M2 and SIP pres),0.4947999
49.87,male,1.0,MOSF w/Malig,12.0,under $11k,59913.0,white,1.0,<2 mo. follow-up,2.2265625
61.69199,female,0.0,Colon Cancer,12.0,$11-$25k,75618.0,white,1.0,no(M2 and SIP pres),4.5273972
39.14899,female,0.0,CHF,12.0,$25-$50k,147711.0,black,4.0,<2 mo. follow-up,4.0
50.45599,female,1.0,MOSF w/Malig,12.0,under $11k,202111.0,white,1.0,<2 mo. follow-up,2.5595703
50.57599,female,0.0,Cirrhosis,10.0,under $11k,303934.0,white,2.0,no(M2 and SIP pres),2.0
68.80798,female,0.0,CHF,14.0,under $11k,7354.0,black,1.0,SIP>=30,3.1831989
46.07797,male,0.0,Cirrhosis,18.0,>$50k,353422.0,white,0.0,no(M2 and SIP pres),0.0
79.16498,female,0.0,CHF,12.0,under $11k,3974.0,white,1.0,<2 mo. follow-up,2.2495117
81.758,female,0.0,CHF,8.0,under $11k,22800.0,white,6.0,<2 mo. follow-up,6.0
76.98798,female,0.0,COPD,16.0,under $11k,113045.0,white,5.0,<2 mo. follow-up,5.0
81.66498,female,1.0,ARF/MOSF w/Sepsis,17.0,$11-$25k,31827.0,white,1.0,<2 mo. follow-up,3.6464844
54.26999,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,44608.0,white,0.0,no(M2 and SIP pres),0.0
22.825,male,1.0,MOSF w/Malig,12.0,under $11k,254601.0,white,1.0,<2 mo. follow-up,2.9663086
58.43698,female,0.0,Colon Cancer,20.0,>$50k,14670.0,white,1.0,<2 mo. follow-up,1.8389997
58.28598,male,0.0,Colon Cancer,14.0,>$50k,24073.0,white,0.0,no(M2 and SIP pres),0.0
84.29297,female,0.0,CHF,12.0,under $11k,5110.0,white,1.0,<2 mo. follow-up,3.0571289
47.01999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,56169.0,white,1.0,<2 mo. follow-up,3.171875
42.28897,female,0.0,Cirrhosis,15.0,$11-$25k,6057.0,white,1.0,no(M2 and SIP pres),1.1668997
86.37097,male,0.0,CHF,12.0,under $11k,14836.0,white,1.0,<2 mo. follow-up,4.03125
72.23499,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,23972.0,white,6.0,adl>=4 (>=5 if sur),6.0
85.35199,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,239683.0,white,1.0,<2 mo. follow-up,1.0
49.13898,female,0.0,Lung Cancer,12.0,under $11k,17775.0,black,5.0,adl>=4 (>=5 if sur),5.0
79.04395,female,1.0,COPD,12.0,under $11k,36520.0,white,1.0,<2 mo. follow-up,4.4482422
41.61798,male,1.0,MOSF w/Malig,12.0,under $11k,161755.0,white,1.0,<2 mo. follow-up,2.9682617
25.49199,female,1.0,MOSF w/Malig,12.0,under $11k,359124.0,white,1.0,<2 mo. follow-up,2.6630859
50.754,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,448431.0,white,1.0,<2 mo. follow-up,3.8657227
53.09198,female,0.0,Cirrhosis,12.0,>$50k,13434.0,white,0.0,no(M2 and SIP pres),0.0
75.80798,male,0.0,Lung Cancer,3.0,>$50k,73798.0,white,4.0,<2 mo. follow-up,4.0
75.99695,male,1.0,ARF/MOSF w/Sepsis,13.0,$11-$25k,99364.0,white,0.0,<2 mo. follow-up,0.0
54.491,male,0.0,Cirrhosis,12.0,under $11k,9974.0,white,1.0,<2 mo. follow-up,3.3310547
27.51799,female,1.0,MOSF w/Malig,12.0,under $11k,132130.0,hispanic,0.0,<2 mo. follow-up,0.0
59.62198,male,0.0,Lung Cancer,12.0,>$50k,11765.0,white,0.0,no(M2 and SIP pres),0.0
78.12695,female,1.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,107073.0,white,7.0,<2 mo. follow-up,7.0
30.023,male,0.0,ARF/MOSF w/Sepsis,15.0,$25-$50k,108131.0,white,1.0,no(M2 and SIP pres),2.0869141
52.70099,female,0.0,Lung Cancer,14.0,$25-$50k,6521.0,white,1.0,no(M2 and SIP pres),1.1668997
52.767,male,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,45767.0,black,5.0,<2 mo. follow-up,5.0
50.38199,female,0.0,CHF,11.0,under $11k,25748.0,black,5.0,adl>=4 (>=5 if sur),5.0
37.336,female,1.0,MOSF w/Malig,12.0,under $11k,168270.0,other,1.0,<2 mo. follow-up,2.4541016
65.57697,male,0.0,CHF,16.0,under $11k,42780.0,white,0.0,<2 mo. follow-up,0.0
42.29398,male,1.0,Cirrhosis,12.0,under $11k,49389.0,white,1.0,<2 mo. follow-up,3.9550781
55.31799,female,0.0,Cirrhosis,12.0,$11-$25k,16717.0,white,1.0,<2 mo. follow-up,1.8389997
51.89899,female,1.0,MOSF w/Malig,12.0,under $11k,85777.0,white,1.0,<2 mo. follow-up,3.7719727
48.98599,male,1.0,Cirrhosis,12.0,under $11k,131400.0,white,1.0,<2 mo. follow-up,3.5107422
76.33398,male,0.0,CHF,7.0,under $11k,24988.0,white,0.0,no(M2 and SIP pres),0.0
24.493,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,149776.0,white,0.0,SIP>=30,0.0
70.46698,female,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,57539.0,other,1.0,<2 mo. follow-up,3.690918
58.31897,male,0.0,MOSF w/Malig,23.0,under $11k,542326.0,white,1.0,adl>=4 (>=5 if sur),2.6416016
80.25494,female,1.0,Coma,12.0,under $11k,14297.0,white,1.0,<2 mo. follow-up,3.5532227
67.58398,male,0.0,Lung Cancer,12.0,$11-$25k,10819.0,black,1.0,no(M2 and SIP pres),2.7944336
40.96399,male,1.0,Cirrhosis,16.0,$11-$25k,93417.0,hispanic,1.0,<2 mo. follow-up,3.1333008
26.683,female,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,109747.0,other,0.0,<2 mo. follow-up,0.0
61.85397,female,1.0,MOSF w/Malig,11.0,under $11k,173968.0,white,1.0,<2 mo. follow-up,3.4663086
77.53595,male,1.0,Coma,12.0,under $11k,20078.0,white,1.0,<2 mo. follow-up,2.9956055
70.03998,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,444556.0,white,4.0,<2 mo. follow-up,4.0
66.00098,male,0.0,CHF,12.0,$25-$50k,31463.0,white,0.0,no(M2 and SIP pres),0.0
59.995,female,0.0,COPD,8.0,under $11k,41479.0,hispanic,1.0,no(M2 and SIP pres),1.0
49.91599,male,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,220490.0,black,1.0,<2 mo. follow-up,3.3061523
51.56699,female,0.0,Cirrhosis,12.0,under $11k,1435423.0,other,1.0,<2 mo. follow-up,2.4399414
55.13998,female,0.0,COPD,12.0,under $11k,7322.0,white,5.0,adl>=4 (>=5 if sur),5.0
30.69099,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,138003.0,white,1.0,<2 mo. follow-up,2.5795898
47.34799,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,23807.0,white,1.0,<2 mo. follow-up,3.4794922
60.23297,male,0.0,Lung Cancer,12.0,under $11k,16410.0,other,1.0,<2 mo. follow-up,3.3388672
37.08099,male,0.0,Cirrhosis,12.0,under $11k,7547.0,white,1.0,<2 mo. follow-up,3.2421875
63.25,male,0.0,Lung Cancer,13.0,$25-$50k,15400.0,asian,1.0,no(M2 and SIP pres),1.8708496
51.87698,male,0.0,Lung Cancer,16.0,>$50k,22975.0,white,0.0,no(M2 and SIP pres),0.0
69.50299,male,0.0,CHF,12.0,under $11k,45162.0,white,1.0,<2 mo. follow-up,0.4947999
84.43799,male,0.0,CHF,12.0,under $11k,25793.0,white,1.0,<2 mo. follow-up,3.6225586
46.60397,male,0.0,Lung Cancer,16.0,>$50k,17707.0,white,2.0,no(M2 and SIP pres),2.0
60.07397,female,1.0,Lung Cancer,12.0,under $11k,6149.0,white,1.0,<2 mo. follow-up,3.4169922
62.27197,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,150556.0,white,0.0,<2 mo. follow-up,0.0
48.353,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,565876.0,white,1.0,<2 mo. follow-up,2.8876953
78.33795,male,1.0,Coma,12.0,under $11k,31356.0,white,1.0,<2 mo. follow-up,3.2514648
58.14099,female,0.0,CHF,12.0,under $11k,4642.0,white,1.0,<2 mo. follow-up,2.5004883
60.87299,female,0.0,CHF,12.0,under $11k,29509.0,black,1.0,no(M2 and SIP pres),3.6489258
51.62198,male,1.0,MOSF w/Malig,10.0,under $11k,85043.0,black,1.0,<2 mo. follow-up,2.7714844
48.62399,female,0.0,MOSF w/Malig,16.0,$11-$25k,95852.0,white,6.0,<2 mo. follow-up,6.0
29.63699,male,0.0,Coma,12.0,under $11k,168489.0,hispanic,0.0,<2 mo. follow-up,0.0
54.146,male,0.0,Colon Cancer,16.0,>$50k,44109.0,white,1.0,<2 mo. follow-up,2.1723633
68.16998,female,0.0,Cirrhosis,12.0,under $11k,38996.0,white,1.0,<2 mo. follow-up,3.621582
47.73398,male,0.0,CHF,15.0,under $11k,30953.0,black,1.0,no(M2 and SIP pres),4.5273972
91.84399,female,1.0,Coma,12.0,under $11k,11415.0,white,1.0,<2 mo. follow-up,4.0322266
59.39798,male,0.0,Colon Cancer,16.0,$25-$50k,8512.0,white,1.0,no(M2 and SIP pres),1.1668997
49.59598,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,102876.0,white,1.0,<2 mo. follow-up,2.527832
51.086,female,0.0,ARF/MOSF w/Sepsis,10.0,$25-$50k,480519.0,hispanic,1.0,adl>=4 (>=5 if sur),1.0
46.22598,male,0.0,CHF,12.0,under $11k,349052.0,hispanic,0.0,no(M2 and SIP pres),0.0
76.77197,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,92775.0,white,1.0,<2 mo. follow-up,2.2773438
50.59497,male,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,93265.0,hispanic,1.0,<2 mo. follow-up,4.1542969
60.56897,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,75752.0,white,1.0,<2 mo. follow-up,3.6948242
43.21399,female,1.0,MOSF w/Malig,12.0,under $11k,43810.0,white,1.0,<2 mo. follow-up,2.7348633
82.63098,male,0.0,CHF,16.0,under $11k,7920.0,white,2.0,<2 mo. follow-up,2.0
80.23798,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,43960.0,white,2.0,adl>=4 (>=5 if sur),2.0
26.023,male,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,166772.0,hispanic,1.0,<2 mo. follow-up,1.0
22.72699,female,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,23778.0,black,0.0,<2 mo. follow-up,0.0
52.67599,male,0.0,Lung Cancer,17.0,>$50k,22661.0,white,0.0,no(M2 and SIP pres),0.0
64.11798,female,0.0,Lung Cancer,12.0,under $11k,12023.0,black,1.0,<2 mo. follow-up,2.8193359
36.211,female,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,374053.0,black,1.0,<2 mo. follow-up,3.503418
29.588,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,563075.0,black,1.0,adl>=4 (>=5 if sur),3.7104492
63.95599,male,1.0,CHF,9.0,>$50k,68631.0,hispanic,1.0,<2 mo. follow-up,3.855299
70.90997,male,1.0,CHF,18.0,under $11k,13400.0,white,1.0,<2 mo. follow-up,0.4947999
66.63098,female,0.0,Cirrhosis,10.0,>$50k,14175.0,white,1.0,no(M2 and SIP pres),3.2807617
77.17499,female,0.0,Cirrhosis,12.0,under $11k,14976.0,white,1.0,<2 mo. follow-up,3.434082
60.54498,male,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,283844.0,hispanic,1.0,<2 mo. follow-up,2.7592773
76.56696,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,308455.0,white,1.0,<2 mo. follow-up,3.4482422
76.63495,male,0.0,CHF,11.0,$11-$25k,63938.0,white,1.0,<2 mo. follow-up,1.0
51.20099,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,41580.0,asian,1.0,<2 mo. follow-up,2.6914062
20.24399,male,0.0,CHF,12.0,under $11k,11528.0,hispanic,1.0,no(M2 and SIP pres),2.8491211
69.47296,female,0.0,Cirrhosis,12.0,>$50k,151788.0,white,0.0,no(M2 and SIP pres),0.0
76.76099,female,1.0,Lung Cancer,12.0,under $11k,18406.0,white,1.0,<2 mo. follow-up,3.887207
24.56699,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,392270.0,hispanic,0.0,adl>=4 (>=5 if sur),0.0
53.62097,female,0.0,Colon Cancer,12.0,under $11k,28094.0,white,1.0,<2 mo. follow-up,2.5981445
78.88794,male,1.0,MOSF w/Malig,13.0,>$50k,88377.0,white,2.0,<2 mo. follow-up,2.0
68.40497,female,0.0,Lung Cancer,12.0,under $11k,32994.0,white,1.0,<2 mo. follow-up,0.4947999
74.94299,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,345855.0,black,1.0,<2 mo. follow-up,3.6743164
72.98798,female,1.0,Coma,12.0,under $11k,16404.0,asian,1.0,<2 mo. follow-up,3.2197266
50.28897,female,0.0,Colon Cancer,12.0,under $11k,6673.0,white,1.0,<2 mo. follow-up,1.871582
87.48297,female,0.0,CHF,12.0,under $11k,4969.0,white,1.0,<2 mo. follow-up,2.8491211
25.95799,male,1.0,ARF/MOSF w/Sepsis,12.0,>$50k,73645.0,white,1.0,<2 mo. follow-up,2.4125977
78.88794,female,0.0,ARF/MOSF w/Sepsis,7.0,under $11k,198860.0,white,1.0,no(M2 and SIP pres),2.5380859
52.30099,male,0.0,Colon Cancer,12.0,under $11k,4510.0,white,1.0,<2 mo. follow-up,1.5620117
49.08698,male,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,176752.0,white,1.0,<2 mo. follow-up,3.0224609
54.48599,female,0.0,Colon Cancer,15.0,under $11k,37609.0,white,1.0,no(M2 and SIP pres),0.4947999
32.70599,female,1.0,ARF/MOSF w/Sepsis,21.0,under $11k,1233213.0,white,3.0,<2 mo. follow-up,3.0
40.46799,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,289233.0,white,1.0,no(M2 and SIP pres),1.0
76.47095,male,1.0,ARF/MOSF w/Sepsis,12.0,>$50k,203430.0,asian,1.0,<2 mo. follow-up,3.0458984
64.20496,female,1.0,Cirrhosis,12.0,>$50k,103876.0,hispanic,1.0,<2 mo. follow-up,1.0
56.07397,female,0.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,131009.0,white,4.0,SIP>=30,4.0
73.01794,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,57560.0,hispanic,1.0,no(M2 and SIP pres),1.0
75.50195,female,0.0,Colon Cancer,12.0,$11-$25k,14005.0,white,0.0,no(M2 and SIP pres),0.0
66.77594,female,0.0,Colon Cancer,12.0,under $11k,46753.0,white,1.0,<2 mo. follow-up,2.3530273
52.30698,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,54390.0,black,0.0,no(M2 and SIP pres),0.0
50.17099,female,0.0,Lung Cancer,12.0,>$50k,13399.0,white,1.0,<2 mo. follow-up,0.4947999
47.18997,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,160900.0,other,1.0,<2 mo. follow-up,2.7456055
55.25497,female,1.0,Lung Cancer,12.0,under $11k,13593.0,black,1.0,<2 mo. follow-up,4.0058594
59.36798,male,0.0,CHF,12.0,>$50k,15494.0,white,5.0,<2 mo. follow-up,5.0
63.22498,male,0.0,Colon Cancer,12.0,under $11k,34247.0,white,1.0,<2 mo. follow-up,2.1767578
54.69699,male,1.0,MOSF w/Malig,18.0,>$50k,168940.0,white,1.0,<2 mo. follow-up,2.4682617
75.66095,male,0.0,CHF,12.0,under $11k,16067.0,white,1.0,no(M2 and SIP pres),2.421875
65.09198,female,0.0,Colon Cancer,12.0,>$50k,56695.0,white,0.0,adl>=4 (>=5 if sur),0.0
60.55298,male,0.0,Lung Cancer,12.0,under $11k,5619.0,white,1.0,<2 mo. follow-up,1.7854004
30.015,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,871855.0,white,0.0,adl>=4 (>=5 if sur),0.0
35.92899,male,1.0,Colon Cancer,12.0,under $11k,39582.0,white,1.0,<2 mo. follow-up,2.546875
54.84998,female,0.0,Lung Cancer,16.0,$11-$25k,3278.0,black,1.0,SIP>=30,1.0
90.32196,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,106419.0,white,7.0,<2 mo. follow-up,7.0
84.33899,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,271224.0,white,1.0,<2 mo. follow-up,3.4804688
57.23999,male,0.0,Cirrhosis,19.0,>$50k,410745.0,white,1.0,no(M2 and SIP pres),3.9970703
38.80399,female,0.0,CHF,14.0,$25-$50k,133255.0,white,1.0,no(M2 and SIP pres),0.4947999
72.46497,female,0.0,Lung Cancer,12.0,under $11k,5552.0,black,1.0,<2 mo. follow-up,2.6166992
92.60199,female,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,50810.0,white,2.0,<2 mo. follow-up,2.0
59.69299,female,1.0,MOSF w/Malig,12.0,under $11k,71936.0,white,1.0,<2 mo. follow-up,3.4375
52.767,male,0.0,Cirrhosis,12.0,>$50k,43499.0,white,1.0,no(M2 and SIP pres),0.4947999
54.97098,female,0.0,COPD,8.0,>$50k,4936.0,black,1.0,no(M2 and SIP pres),0.4947999
62.35699,male,0.0,Coma,12.0,under $11k,58097.0,white,1.0,<2 mo. follow-up,2.0390625
82.01196,female,0.0,COPD,11.0,$11-$25k,45384.0,white,2.0,<2 mo. follow-up,2.0
53.46997,female,0.0,CHF,9.0,under $11k,23440.0,white,3.0,no(M2 and SIP pres),3.0
21.092,male,1.0,Coma,12.0,>$50k,91295.0,white,1.0,<2 mo. follow-up,2.5375977
19.866,female,0.0,CHF,11.0,under $11k,120028.0,black,0.0,no(M2 and SIP pres),0.0
52.10999,female,0.0,ARF/MOSF w/Sepsis,21.0,under $11k,546390.0,white,3.0,adl>=4 (>=5 if sur),3.0
69.66498,male,0.0,Lung Cancer,6.0,under $11k,9574.0,black,1.0,no(M2 and SIP pres),0.4947999
66.409,female,0.0,CHF,14.0,>$50k,43722.0,white,4.0,no(M2 and SIP pres),4.0
39.84698,female,0.0,MOSF w/Malig,12.0,under $11k,47588.0,white,1.0,no(M2 and SIP pres),3.7070312
66.14099,male,1.0,COPD,16.0,>$50k,21075.0,white,1.0,<2 mo. follow-up,4.0595703
53.24597,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,231587.0,white,5.0,<2 mo. follow-up,5.0
69.94098,male,0.0,CHF,18.0,>$50k,5631.0,white,0.0,no(M2 and SIP pres),0.0
20.69299,male,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,125185.0,white,0.0,no(M2 and SIP pres),0.0
48.78598,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,96189.0,white,1.0,<2 mo. follow-up,3.5883789
35.047,male,1.0,MOSF w/Malig,12.0,under $11k,155711.0,other,1.0,<2 mo. follow-up,2.3032227
72.01398,male,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,173394.0,white,0.0,adl>=4 (>=5 if sur),0.0
42.823,female,1.0,MOSF w/Malig,15.0,under $11k,393995.0,white,1.0,Coma or Intub,1.0
63.84097,female,0.0,Colon Cancer,14.0,$25-$50k,13525.0,white,1.0,<2 mo. follow-up,2.6625977
62.59497,female,0.0,Cirrhosis,12.0,$11-$25k,30117.0,white,1.0,adl>=4 (>=5 if sur),1.0
70.823,female,0.0,CHF,14.0,under $11k,51017.0,white,1.0,<2 mo. follow-up,0.4947999
60.758,female,0.0,Colon Cancer,10.0,$25-$50k,24158.0,white,1.0,<2 mo. follow-up,2.5664062
76.03296,male,0.0,Colon Cancer,17.0,$25-$50k,14594.0,white,0.0,no(M2 and SIP pres),0.0
62.42599,male,0.0,Lung Cancer,12.0,under $11k,9366.0,white,0.0,no(M2 and SIP pres),0.0
58.58197,male,0.0,Cirrhosis,8.0,$11-$25k,44079.0,black,1.0,no(M2 and SIP pres),3.112793
38.155,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,143906.0,white,1.0,no(M2 and SIP pres),1.0
79.97797,female,1.0,ARF/MOSF w/Sepsis,15.0,under $11k,214894.0,white,0.0,<2 mo. follow-up,0.0
72.71497,female,0.0,CHF,14.0,$11-$25k,76132.0,black,0.0,adl>=4 (>=5 if sur),0.0
65.53894,female,0.0,Lung Cancer,14.0,$25-$50k,7769.0,white,0.0,no(M2 and SIP pres),0.0
50.439,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,16863.0,black,1.0,<2 mo. follow-up,1.1668997
61.02698,male,0.0,Colon Cancer,13.0,under $11k,31943.0,white,2.0,no(M2 and SIP pres),2.0
66.37097,male,0.0,CHF,12.0,$25-$50k,50099.0,white,1.0,no(M2 and SIP pres),0.4947999
54.08899,female,1.0,Lung Cancer,12.0,$11-$25k,23806.0,white,0.0,<2 mo. follow-up,0.0
75.26398,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,444915.0,white,1.0,adl>=4 (>=5 if sur),1.0
31.72099,male,0.0,MOSF w/Malig,20.0,under $11k,58405.0,white,0.0,<2 mo. follow-up,0.0
80.01099,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,50808.0,white,1.0,<2 mo. follow-up,3.0786133
83.59497,male,0.0,ARF/MOSF w/Sepsis,19.0,>$50k,81350.0,white,0.0,<2 mo. follow-up,0.0
43.64697,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,528848.0,white,1.0,adl>=4 (>=5 if sur),2.7421875
38.12198,female,0.0,Lung Cancer,12.0,under $11k,8624.0,white,1.0,<2 mo. follow-up,2.1303711
79.07495,female,0.0,CHF,7.0,under $11k,24141.0,white,1.0,no(M2 and SIP pres),0.4947999
84.91199,male,1.0,Cirrhosis,16.0,>$50k,30383.0,white,1.0,<2 mo. follow-up,1.0
74.64795,male,1.0,Coma,8.0,under $11k,34042.0,white,2.0,<2 mo. follow-up,2.0
56.271,male,0.0,Lung Cancer,16.0,under $11k,15227.0,white,1.0,no(M2 and SIP pres),2.3735352
75.23096,male,0.0,CHF,20.0,$25-$50k,29545.0,white,0.0,no(M2 and SIP pres),0.0
40.53098,female,0.0,Colon Cancer,11.0,>$50k,26039.0,hispanic,1.0,no(M2 and SIP pres),2.2045898
74.40094,male,1.0,CHF,15.0,>$50k,22733.0,white,1.0,<2 mo. follow-up,3.5600586
77.67596,female,0.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,25024.0,black,2.0,<2 mo. follow-up,2.0
68.24597,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,162892.0,asian,1.0,<2 mo. follow-up,3.1791992
38.32999,male,0.0,Cirrhosis,12.0,under $11k,6062.0,white,1.0,no(M2 and SIP pres),2.1689453
48.36697,male,0.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,74504.0,white,1.0,no(M2 and SIP pres),2.2773438
80.87598,female,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,147296.0,white,0.0,<2 mo. follow-up,0.0
63.38699,male,0.0,Lung Cancer,12.0,under $11k,7253.0,white,1.0,<2 mo. follow-up,2.3168945
60.03598,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,142731.0,white,1.0,<2 mo. follow-up,2.7958984
71.45197,female,0.0,COPD,10.0,under $11k,29501.0,white,6.0,no(M2 and SIP pres),6.0
32.95297,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,42572.0,white,1.0,<2 mo. follow-up,3.1787109
39.63898,male,0.0,Cirrhosis,13.0,under $11k,272602.0,white,0.0,SIP>=30,0.0
85.11694,male,0.0,CHF,8.0,$11-$25k,15112.0,white,3.0,<2 mo. follow-up,3.0
68.87299,female,1.0,Lung Cancer,18.0,under $11k,9982.0,white,1.0,<2 mo. follow-up,3.4711914
77.13599,male,1.0,Cirrhosis,19.0,$11-$25k,42561.0,white,1.0,<2 mo. follow-up,3.3701172
61.99597,male,0.0,CHF,12.0,under $11k,26184.0,white,1.0,no(M2 and SIP pres),1.0
50.97598,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,93205.0,white,0.0,no(M2 and SIP pres),0.0
53.45898,female,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,1057324.0,white,2.0,adl>=4 (>=5 if sur),2.0
70.93994,male,0.0,CHF,12.0,under $11k,20186.0,asian,0.0,<2 mo. follow-up,0.0
89.77399,male,0.0,CHF,8.0,under $11k,5897.0,white,1.0,<2 mo. follow-up,1.8389997
81.67596,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,125968.0,white,1.0,<2 mo. follow-up,3.7275391
59.10199,male,0.0,CHF,7.0,$25-$50k,34775.0,hispanic,2.0,<2 mo. follow-up,2.0
56.64099,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,20497.0,white,5.0,no(M2 and SIP pres),5.0
67.37,female,0.0,Cirrhosis,12.0,under $11k,50138.0,white,1.0,adl>=4 (>=5 if sur),3.855299
57.46698,male,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,150471.0,asian,1.0,<2 mo. follow-up,3.2636719
68.87897,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,65136.0,black,1.0,<2 mo. follow-up,3.7280273
35.806,female,0.0,CHF,12.0,under $11k,20092.0,white,1.0,<2 mo. follow-up,2.1542969
35.603,male,0.0,Colon Cancer,12.0,under $11k,41788.0,white,1.0,<2 mo. follow-up,2.9345703
43.47699,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,79576.0,hispanic,0.0,<2 mo. follow-up,0.0
58.68597,male,0.0,CHF,14.0,under $11k,16964.0,white,0.0,<2 mo. follow-up,0.0
44.60797,female,1.0,Cirrhosis,8.0,under $11k,214817.0,hispanic,7.0,<2 mo. follow-up,7.0
70.04797,male,0.0,Cirrhosis,14.0,$25-$50k,26738.0,white,1.0,<2 mo. follow-up,1.0
45.043,female,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,194716.0,white,4.0,<2 mo. follow-up,4.0
60.79398,female,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,141714.0,white,0.0,no(M2 and SIP pres),0.0
55.88199,female,0.0,Lung Cancer,14.0,under $11k,6593.0,black,1.0,no(M2 and SIP pres),2.2241211
65.02899,female,0.0,CHF,12.0,under $11k,3087.0,black,6.0,<2 mo. follow-up,6.0
19.17,female,0.0,CHF,12.0,under $11k,166750.0,hispanic,1.0,<2 mo. follow-up,2.340332
72.84296,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,196869.0,white,1.0,<2 mo. follow-up,2.65625
42.03699,male,1.0,Cirrhosis,20.0,>$50k,100295.0,white,0.0,<2 mo. follow-up,0.0
59.806,female,0.0,COPD,14.0,$25-$50k,75895.0,asian,0.0,<2 mo. follow-up,0.0
49.56097,male,1.0,Coma,16.0,>$50k,245849.0,black,5.0,<2 mo. follow-up,5.0
51.93997,male,0.0,MOSF w/Malig,12.0,under $11k,280893.0,white,0.0,no(M2 and SIP pres),0.0
55.24698,female,0.0,CHF,11.0,under $11k,6536.0,white,1.0,<2 mo. follow-up,1.8389997
73.75494,male,0.0,MOSF w/Malig,12.0,under $11k,29426.0,black,1.0,<2 mo. follow-up,3.8896484
47.93198,female,1.0,MOSF w/Malig,12.0,under $11k,92238.0,white,1.0,<2 mo. follow-up,3.2519531
58.69699,female,0.0,CHF,12.0,$11-$25k,6849.0,hispanic,1.0,SIP>=30,2.371582
60.73099,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,363112.0,hispanic,2.0,no(M2 and SIP pres),2.0
68.50397,male,0.0,MOSF w/Malig,16.0,>$50k,41674.0,white,1.0,no(M2 and SIP pres),1.0
41.75497,female,1.0,Coma,16.0,>$50k,69323.0,white,5.0,<2 mo. follow-up,5.0
48.14798,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,23166.0,white,1.0,<2 mo. follow-up,2.1948242
48.564,male,0.0,MOSF w/Malig,19.0,under $11k,225659.0,white,1.0,no(M2 and SIP pres),0.4947999
45.51398,male,1.0,Cirrhosis,16.0,>$50k,323371.0,asian,1.0,<2 mo. follow-up,1.0
82.66699,female,0.0,Coma,12.0,under $11k,130916.0,white,7.0,adl>=4 (>=5 if sur),7.0
42.45599,male,0.0,ARF/MOSF w/Sepsis,10.0,>$50k,63445.0,hispanic,0.0,SIP>=30,0.0
70.20898,male,0.0,Lung Cancer,16.0,>$50k,9088.0,white,1.0,no(M2 and SIP pres),0.4947999
40.39999,male,0.0,Lung Cancer,12.0,under $11k,12693.0,white,1.0,no(M2 and SIP pres),2.730957
76.08997,male,0.0,CHF,8.0,under $11k,12254.0,white,1.0,<2 mo. follow-up,4.5273972
77.85895,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,89858.0,white,1.0,<2 mo. follow-up,3.6572266
71.02295,male,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,132772.0,white,1.0,<2 mo. follow-up,2.4824219
30.35999,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,283773.0,black,0.0,adl>=4 (>=5 if sur),0.0
76.74194,male,0.0,CHF,12.0,under $11k,14066.0,white,1.0,no(M2 and SIP pres),2.9550781
76.97198,female,0.0,CHF,13.0,>$50k,11489.0,black,0.0,no(M2 and SIP pres),0.0
71.745,female,0.0,CHF,16.0,$11-$25k,9478.0,white,1.0,adl>=4 (>=5 if sur),2.5449219
65.93298,female,0.0,CHF,13.0,under $11k,10227.0,asian,3.0,no(M2 and SIP pres),3.0
69.98199,female,0.0,CHF,12.0,under $11k,65732.0,black,7.0,adl>=4 (>=5 if sur),7.0
82.14099,male,0.0,MOSF w/Malig,12.0,under $11k,113460.0,black,1.0,<2 mo. follow-up,4.4794922
41.06198,female,0.0,ARF/MOSF w/Sepsis,15.0,$11-$25k,16536.0,black,1.0,<2 mo. follow-up,2.0395508
56.34998,female,0.0,COPD,12.0,under $11k,4944.0,white,1.0,no(M2 and SIP pres),0.4947999
67.72894,male,0.0,CHF,18.0,$11-$25k,32258.0,white,1.0,<2 mo. follow-up,2.9853516
51.18698,male,0.0,Colon Cancer,12.0,under $11k,30006.0,white,1.0,<2 mo. follow-up,3.5170898
48.43799,male,1.0,MOSF w/Malig,15.0,>$50k,275297.0,white,1.0,<2 mo. follow-up,2.2446289
63.573,female,1.0,MOSF w/Malig,12.0,$25-$50k,231839.0,white,1.0,<2 mo. follow-up,3.2402344
56.74197,male,0.0,Colon Cancer,18.0,$11-$25k,41129.0,white,0.0,no(M2 and SIP pres),0.0
52.43799,male,0.0,CHF,12.0,$11-$25k,73122.0,white,0.0,no(M2 and SIP pres),0.0
73.59094,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,25024.0,white,1.0,adl>=4 (>=5 if sur),2.7763672
56.50098,male,1.0,Cirrhosis,12.0,under $11k,95243.0,white,6.0,<2 mo. follow-up,6.0
45.22699,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,213989.0,white,1.0,<2 mo. follow-up,3.4370117
54.44498,male,1.0,ARF/MOSF w/Sepsis,18.0,>$50k,61442.0,white,1.0,<2 mo. follow-up,2.5195312
85.36096,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,51486.0,white,0.0,<2 mo. follow-up,0.0
46.08099,male,0.0,CHF,14.0,under $11k,170570.0,hispanic,1.0,no(M2 and SIP pres),1.0
32.42697,female,1.0,ARF/MOSF w/Sepsis,11.0,under $11k,382471.0,white,1.0,<2 mo. follow-up,4.0322266
66.27496,male,0.0,Colon Cancer,20.0,>$50k,18606.0,white,1.0,<2 mo. follow-up,0.4947999
78.53796,female,0.0,COPD,16.0,$25-$50k,8697.0,white,0.0,no(M2 and SIP pres),0.0
50.95099,female,1.0,MOSF w/Malig,12.0,under $11k,449923.0,black,0.0,<2 mo. follow-up,0.0
39.81897,male,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,54871.0,white,1.0,<2 mo. follow-up,3.3813477
31.34299,female,1.0,Coma,12.0,under $11k,148727.0,white,1.0,<2 mo. follow-up,3.6069336
73.14697,male,0.0,CHF,4.0,>$50k,20810.0,white,4.0,no(M2 and SIP pres),4.0
73.70294,male,0.0,CHF,24.0,under $11k,14284.0,white,1.0,no(M2 and SIP pres),0.4947999
71.75397,female,0.0,COPD,9.0,under $11k,135615.0,black,1.0,no(M2 and SIP pres),2.8969727
63.59799,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,51942.0,white,1.0,<2 mo. follow-up,2.206543
72.323,male,0.0,Colon Cancer,12.0,under $11k,36244.0,white,1.0,<2 mo. follow-up,3.3491211
44.12299,female,0.0,MOSF w/Malig,12.0,under $11k,293158.0,white,0.0,<2 mo. follow-up,0.0
21.74899,male,0.0,ARF/MOSF w/Sepsis,13.0,under $11k,156314.0,white,0.0,no(M2 and SIP pres),0.0
67.85797,female,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,234034.0,white,0.0,<2 mo. follow-up,0.0
58.05099,female,0.0,Lung Cancer,12.0,under $11k,9864.0,black,1.0,no(M2 and SIP pres),2.5302734
57.84799,male,1.0,MOSF w/Malig,14.0,$25-$50k,139623.0,white,5.0,<2 mo. follow-up,5.0
72.56097,male,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,301990.0,white,1.0,<2 mo. follow-up,1.0
49.53,female,0.0,CHF,11.0,under $11k,10545.0,black,1.0,no(M2 and SIP pres),2.2373047
60.65399,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,475387.0,white,1.0,<2 mo. follow-up,3.0224609
69.41797,male,1.0,Lung Cancer,14.0,$11-$25k,7194.0,asian,6.0,<2 mo. follow-up,6.0
25.89699,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,251227.0,hispanic,5.0,adl>=4 (>=5 if sur),5.0
47.43298,male,1.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,169364.0,white,1.0,<2 mo. follow-up,3.0639648
36.29797,male,0.0,Cirrhosis,12.0,under $11k,48925.0,white,1.0,<2 mo. follow-up,0.4947999
63.07999,male,0.0,CHF,14.0,under $11k,29706.0,hispanic,3.0,no(M2 and SIP pres),3.0
61.77399,male,0.0,CHF,12.0,>$50k,21076.0,white,0.0,no(M2 and SIP pres),0.0
55.23297,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,233772.0,other,1.0,<2 mo. follow-up,2.7539062
72.42694,female,1.0,Cirrhosis,12.0,under $11k,69587.0,other,1.0,<2 mo. follow-up,3.1469727
80.38599,male,0.0,Colon Cancer,8.0,$25-$50k,11109.0,white,0.0,no(M2 and SIP pres),0.0
74.12695,male,1.0,Coma,14.0,under $11k,22541.0,white,1.0,<2 mo. follow-up,4.6728516
34.32199,female,0.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,271769.0,hispanic,6.0,adl>=4 (>=5 if sur),6.0
51.491,female,1.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,1056280.0,white,0.0,adl>=4 (>=5 if sur),0.0
64.92499,female,0.0,CHF,5.0,under $11k,22303.0,hispanic,3.0,<2 mo. follow-up,3.0
71.95599,male,0.0,CHF,12.0,under $11k,35928.0,asian,1.0,<2 mo. follow-up,2.6972656
60.59097,female,0.0,Colon Cancer,12.0,$25-$50k,35397.0,white,0.0,no(M2 and SIP pres),0.0
33.09,male,1.0,MOSF w/Malig,12.0,under $11k,216416.0,asian,1.0,<2 mo. follow-up,2.6982422
74.74896,male,0.0,CHF,12.0,under $11k,10758.0,white,1.0,<2 mo. follow-up,2.0253906
50.90198,male,0.0,CHF,14.0,$25-$50k,37558.0,white,0.0,no(M2 and SIP pres),0.0
55.866,male,0.0,CHF,16.0,$25-$50k,68122.0,white,0.0,no(M2 and SIP pres),0.0
77.396,male,0.0,CHF,14.0,$25-$50k,9246.0,white,1.0,no(M2 and SIP pres),0.4947999
63.017,male,0.0,ARF/MOSF w/Sepsis,8.0,$25-$50k,133878.0,white,1.0,<2 mo. follow-up,0.4947999
41.974,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,328134.0,white,1.0,<2 mo. follow-up,2.0996094
67.88495,male,1.0,ARF/MOSF w/Sepsis,18.0,$25-$50k,181177.0,white,1.0,<2 mo. follow-up,2.4399414
46.48297,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,95454.0,white,1.0,no(M2 and SIP pres),2.9467773
64.51697,male,0.0,CHF,9.0,under $11k,125379.0,white,1.0,SIP>=30,0.4947999
65.711,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,497053.0,white,0.0,<2 mo. follow-up,0.0
73.42896,male,0.0,CHF,12.0,>$50k,79641.0,white,1.0,<2 mo. follow-up,1.0
34.05899,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,250630.0,black,0.0,no(M2 and SIP pres),0.0
32.40198,female,1.0,MOSF w/Malig,17.0,$25-$50k,262612.0,white,0.0,<2 mo. follow-up,0.0
28.30099,male,0.0,CHF,12.0,under $11k,194198.0,white,1.0,<2 mo. follow-up,2.690918
56.323,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,151266.0,white,1.0,<2 mo. follow-up,2.5961914
47.98099,female,0.0,Lung Cancer,18.0,under $11k,25024.0,white,1.0,no(M2 and SIP pres),2.5249023
70.125,female,1.0,Coma,12.0,under $11k,96471.0,white,1.0,<2 mo. follow-up,2.3598633
35.31799,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,212409.0,black,1.0,<2 mo. follow-up,2.6660156
52.827,male,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,116166.0,white,7.0,<2 mo. follow-up,7.0
68.64899,male,0.0,CHF,18.0,$11-$25k,75142.0,white,1.0,<2 mo. follow-up,0.4947999
69.52795,male,0.0,ARF/MOSF w/Sepsis,17.0,>$50k,122312.0,white,0.0,SIP>=30,0.0
63.05798,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,600192.0,white,1.0,<2 mo. follow-up,3.199707
66.09198,male,0.0,Lung Cancer,18.0,>$50k,8272.0,asian,1.0,<2 mo. follow-up,0.4947999
70.48297,female,0.0,CHF,16.0,under $11k,19065.0,white,1.0,<2 mo. follow-up,1.0
60.98599,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,864424.0,white,1.0,<2 mo. follow-up,2.4799805
85.862,female,1.0,COPD,12.0,$11-$25k,329169.0,white,1.0,<2 mo. follow-up,3.7705078
59.81097,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,401801.0,black,6.0,adl>=4 (>=5 if sur),6.0
56.65399,female,0.0,Colon Cancer,12.0,$25-$50k,61711.0,black,1.0,no(M2 and SIP pres),2.2573242
82.086,male,0.0,CHF,12.0,$25-$50k,22899.0,other,1.0,no(M2 and SIP pres),3.9150391
33.5,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,158358.0,hispanic,0.0,SIP>=30,0.0
72.84094,male,0.0,Lung Cancer,12.0,under $11k,10314.0,white,1.0,<2 mo. follow-up,2.465332
78.43695,female,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,106126.0,white,1.0,<2 mo. follow-up,3.5576172
78.00995,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,298193.0,white,1.0,<2 mo. follow-up,2.7758789
67.92596,female,0.0,Colon Cancer,12.0,under $11k,30406.0,white,1.0,<2 mo. follow-up,2.3935547
68.55597,male,0.0,CHF,14.0,$25-$50k,11855.0,white,1.0,<2 mo. follow-up,2.421875
68.68195,male,0.0,Lung Cancer,12.0,$11-$25k,8686.0,white,1.0,<2 mo. follow-up,2.6171875
33.01297,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,77603.0,white,1.0,<2 mo. follow-up,2.7485352
55.96399,male,0.0,Cirrhosis,14.0,$25-$50k,193362.0,white,1.0,no(M2 and SIP pres),1.0
79.45496,female,0.0,CHF,16.0,>$50k,13703.0,white,1.0,no(M2 and SIP pres),1.1668997
60.37198,male,0.0,ARF/MOSF w/Sepsis,18.0,$25-$50k,234608.0,white,0.0,<2 mo. follow-up,0.0
71.65796,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,477929.0,white,1.0,<2 mo. follow-up,2.7861328
95.66095,female,0.0,CHF,10.0,under $11k,12435.0,white,4.0,<2 mo. follow-up,4.0
61.88098,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,777314.0,white,1.0,<2 mo. follow-up,3.3334961
72.35297,female,1.0,CHF,13.0,$11-$25k,25184.0,white,1.0,<2 mo. follow-up,3.7695312
57.93597,male,1.0,Cirrhosis,12.0,under $11k,29521.0,white,1.0,<2 mo. follow-up,3.8852539
47.82498,male,0.0,Cirrhosis,14.0,under $11k,29605.0,white,1.0,<2 mo. follow-up,0.4947999
70.14899,male,0.0,CHF,12.0,under $11k,12331.0,white,1.0,<2 mo. follow-up,2.0800781
50.44998,female,1.0,Coma,12.0,under $11k,28491.0,white,1.0,<2 mo. follow-up,2.6328125
72.0,female,0.0,CHF,12.0,under $11k,40390.0,black,1.0,<2 mo. follow-up,2.5849609
65.92999,female,0.0,CHF,12.0,under $11k,60355.0,white,1.0,<2 mo. follow-up,1.8389997
69.77997,male,0.0,CHF,16.0,$25-$50k,117036.0,white,1.0,no(M2 and SIP pres),2.8129883
59.211,female,1.0,Lung Cancer,14.0,>$50k,8126.0,white,6.0,<2 mo. follow-up,6.0
32.27698,female,1.0,MOSF w/Malig,16.0,>$50k,175267.0,white,1.0,<2 mo. follow-up,2.4165039
47.63898,female,0.0,Lung Cancer,13.0,under $11k,13877.0,white,1.0,<2 mo. follow-up,0.4947999
74.26398,male,0.0,CHF,14.0,>$50k,35636.0,white,0.0,<2 mo. follow-up,0.0
71.29895,male,1.0,Coma,14.0,under $11k,37330.0,white,1.0,<2 mo. follow-up,2.5908203
78.05096,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,167412.0,white,0.0,no(M2 and SIP pres),0.0
82.88599,male,0.0,CHF,14.0,$11-$25k,8568.0,white,1.0,no(M2 and SIP pres),0.4947999
55.37,male,0.0,CHF,16.0,$25-$50k,30070.0,white,4.0,no(M2 and SIP pres),4.0
63.53198,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,188077.0,other,1.0,<2 mo. follow-up,2.53125
72.32599,male,0.0,Cirrhosis,19.0,$25-$50k,21341.0,white,1.0,adl>=4 (>=5 if sur),3.8486328
50.64499,male,0.0,Cirrhosis,14.0,$11-$25k,27047.0,white,1.0,<2 mo. follow-up,1.1668997
44.37,female,1.0,Cirrhosis,11.0,$11-$25k,88231.0,white,1.0,<2 mo. follow-up,1.0
52.75598,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,25511.0,white,1.0,<2 mo. follow-up,3.9453125
63.27197,male,0.0,Lung Cancer,12.0,under $11k,11532.0,white,5.0,<2 mo. follow-up,5.0
68.20294,female,0.0,Colon Cancer,14.0,under $11k,133944.0,white,0.0,no(M2 and SIP pres),0.0
72.12598,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,127395.0,white,1.0,<2 mo. follow-up,4.0605469
71.11298,female,1.0,Lung Cancer,11.0,under $11k,9606.0,black,1.0,<2 mo. follow-up,3.7338867
63.836,female,0.0,CHF,12.0,>$50k,31055.0,white,1.0,no(M2 and SIP pres),1.1668997
52.38599,male,0.0,MOSF w/Malig,14.0,under $11k,140565.0,white,1.0,no(M2 and SIP pres),2.3676758
86.04199,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,205980.0,white,0.0,<2 mo. follow-up,0.0
80.646,female,0.0,CHF,13.0,under $11k,34235.0,white,1.0,no(M2 and SIP pres),3.2436523
70.034,male,0.0,CHF,16.0,under $11k,6528.0,white,1.0,no(M2 and SIP pres),1.8389997
65.99896,female,0.0,Cirrhosis,11.0,under $11k,53190.0,white,5.0,SIP>=30,5.0
70.59296,male,0.0,Lung Cancer,12.0,under $11k,17079.0,asian,4.0,no(M2 and SIP pres),4.0
49.99597,female,1.0,Coma,14.0,under $11k,712554.0,white,6.0,adl>=4 (>=5 if sur),6.0
62.89899,female,0.0,CHF,16.0,$11-$25k,12826.0,black,1.0,no(M2 and SIP pres),2.1884766
55.87698,female,0.0,COPD,12.0,under $11k,55987.0,white,1.0,<2 mo. follow-up,3.9853516
42.237,female,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,41885.0,white,1.0,<2 mo. follow-up,0.4947999
49.60999,female,0.0,Cirrhosis,14.0,>$50k,5215.0,white,1.0,no(M2 and SIP pres),1.0
78.43695,female,0.0,COPD,12.0,under $11k,34499.0,white,3.0,adl>=4 (>=5 if sur),3.0
55.98599,male,1.0,CHF,18.0,>$50k,90756.0,white,0.0,<2 mo. follow-up,0.0
74.46698,female,1.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,161673.0,white,0.0,<2 mo. follow-up,0.0
44.90097,female,1.0,MOSF w/Malig,14.0,>$50k,307552.0,other,0.0,<2 mo. follow-up,0.0
44.383,male,0.0,ARF/MOSF w/Sepsis,20.0,>$50k,246214.0,white,1.0,<2 mo. follow-up,2.4560547
26.51299,female,0.0,ARF/MOSF w/Sepsis,17.0,under $11k,87124.0,hispanic,0.0,no(M2 and SIP pres),0.0
70.90796,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,390845.0,white,1.0,<2 mo. follow-up,3.4643555
63.64697,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,142625.0,white,6.0,adl>=4 (>=5 if sur),6.0
72.54797,female,0.0,Colon Cancer,12.0,under $11k,10862.0,asian,1.0,<2 mo. follow-up,1.8320312
81.24298,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,172335.0,white,2.0,no(M2 and SIP pres),2.0
34.59299,male,1.0,MOSF w/Malig,17.0,under $11k,118073.0,white,7.0,<2 mo. follow-up,7.0
61.39398,male,0.0,CHF,14.0,$11-$25k,54893.0,white,2.0,<2 mo. follow-up,2.0
76.05499,male,0.0,CHF,14.0,under $11k,7626.0,white,1.0,no(M2 and SIP pres),4.5273438
49.49197,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,177889.0,white,7.0,no(M2 and SIP pres),7.0
78.03699,male,0.0,CHF,12.0,$11-$25k,35566.0,white,1.0,<2 mo. follow-up,3.8549805
54.02298,female,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,676210.0,white,0.0,<2 mo. follow-up,0.0
85.10297,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,62841.0,white,1.0,no(M2 and SIP pres),1.0
52.02197,male,0.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,593198.0,hispanic,7.0,no(M2 and SIP pres),7.0
86.62799,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,96480.0,white,0.0,<2 mo. follow-up,0.0
58.95398,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,298234.0,white,1.0,<2 mo. follow-up,3.206543
57.69699,male,0.0,Lung Cancer,16.0,>$50k,12827.0,white,1.0,no(M2 and SIP pres),0.494751
59.44397,male,1.0,Coma,24.0,>$50k,223643.0,white,0.0,<2 mo. follow-up,0.0
37.74698,male,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,577381.0,white,3.0,<2 mo. follow-up,3.0
52.99698,male,1.0,ARF/MOSF w/Sepsis,16.0,>$50k,174687.0,white,1.0,<2 mo. follow-up,3.7827148
76.28497,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,141756.0,white,1.0,adl>=4 (>=5 if sur),1.0
57.53,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,261184.0,white,7.0,adl>=4 (>=5 if sur),7.0
70.20398,male,0.0,Lung Cancer,10.0,$25-$50k,10586.0,white,0.0,SIP>=30,0.0
66.04498,male,0.0,Lung Cancer,13.0,>$50k,11532.0,white,0.0,no(M2 and SIP pres),0.0
42.69397,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,76504.0,white,1.0,<2 mo. follow-up,3.315918
44.23297,male,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,78031.0,hispanic,0.0,no(M2 and SIP pres),0.0
49.892,male,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,36044.0,white,3.0,<2 mo. follow-up,3.0
20.523,male,0.0,MOSF w/Malig,12.0,$11-$25k,784726.0,other,6.0,<2 mo. follow-up,6.0
62.5,female,0.0,Lung Cancer,9.0,under $11k,10163.0,white,1.0,no(M2 and SIP pres),3.8549805
37.47598,male,1.0,CHF,9.0,$11-$25k,270127.0,hispanic,0.0,<2 mo. follow-up,0.0
59.45499,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,976623.0,white,2.0,adl>=4 (>=5 if sur),2.0
66.26099,female,0.0,CHF,12.0,under $11k,11494.0,black,1.0,<2 mo. follow-up,4.8818359
59.03598,male,0.0,CHF,20.0,>$50k,21359.0,white,0.0,no(M2 and SIP pres),0.0
60.271,male,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,460668.0,white,3.0,<2 mo. follow-up,3.0
20.99699,male,1.0,Coma,14.0,under $11k,278242.0,asian,1.0,<2 mo. follow-up,3.309082
55.655,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,34920.0,white,5.0,adl>=4 (>=5 if sur),5.0
45.43698,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,636886.0,white,1.0,<2 mo. follow-up,2.8330078
49.92499,male,0.0,Colon Cancer,17.0,>$50k,23578.0,white,0.0,no(M2 and SIP pres),0.0
42.11899,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,1086011.0,hispanic,0.0,no(M2 and SIP pres),0.0
75.08795,male,1.0,Coma,12.0,under $11k,157000.0,white,1.0,<2 mo. follow-up,3.8095703
44.32599,male,0.0,CHF,14.0,under $11k,44950.0,black,0.0,SIP>=30,0.0
75.17896,male,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,191750.0,white,0.0,<2 mo. follow-up,0.0
51.452,female,0.0,Lung Cancer,12.0,$25-$50k,10606.0,white,0.0,no(M2 and SIP pres),0.0
62.37598,male,1.0,MOSF w/Malig,18.0,>$50k,139026.0,black,4.0,<2 mo. follow-up,4.0
54.47498,male,0.0,Lung Cancer,16.0,>$50k,94914.0,white,0.0,no(M2 and SIP pres),0.0
52.62997,male,0.0,Colon Cancer,12.0,under $11k,12265.0,white,1.0,no(M2 and SIP pres),1.857666
75.77496,female,0.0,CHF,13.0,under $11k,10782.0,white,1.0,<2 mo. follow-up,0.494751
76.961,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,88755.0,hispanic,3.0,adl>=4 (>=5 if sur),3.0
54.71597,female,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,31403.0,white,2.0,<2 mo. follow-up,2.0
79.70398,female,1.0,MOSF w/Malig,16.0,$11-$25k,56752.0,white,1.0,<2 mo. follow-up,3.6772461
53.36099,male,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,314092.0,white,0.0,<2 mo. follow-up,0.0
73.94897,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,208988.0,asian,1.0,<2 mo. follow-up,3.9243164
21.20999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,73268.0,hispanic,1.0,<2 mo. follow-up,1.0
86.35199,female,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,125804.0,white,0.0,<2 mo. follow-up,0.0
33.55197,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,26882.0,black,1.0,no(M2 and SIP pres),3.2265625
64.58295,male,0.0,Lung Cancer,12.0,$25-$50k,5751.0,white,0.0,<2 mo. follow-up,0.0
79.54596,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,30631.0,white,1.0,<2 mo. follow-up,3.5649414
67.71497,female,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,46447.0,white,1.0,no(M2 and SIP pres),1.8388672
48.73599,female,0.0,Lung Cancer,12.0,under $11k,117616.0,white,1.0,<2 mo. follow-up,3.0268555
63.79498,female,0.0,Lung Cancer,16.0,>$50k,11253.0,white,1.0,adl>=4 (>=5 if sur),3.1831055
88.422,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,111560.0,white,1.0,<2 mo. follow-up,6.2734375
54.38199,male,1.0,ARF/MOSF w/Sepsis,13.0,$11-$25k,508881.0,white,2.0,<2 mo. follow-up,2.0
63.62198,male,0.0,CHF,14.0,under $11k,36522.0,white,1.0,no(M2 and SIP pres),1.0
35.52597,female,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,190585.0,white,0.0,<2 mo. follow-up,0.0
80.46295,male,0.0,CHF,16.0,>$50k,13833.0,white,1.0,no(M2 and SIP pres),1.0
44.02499,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,35099.0,white,6.0,<2 mo. follow-up,6.0
35.26599,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,48956.0,white,6.0,SIP>=30,6.0
37.25098,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,83192.0,white,1.0,<2 mo. follow-up,3.012207
62.133,male,1.0,CHF,12.0,>$50k,153171.0,white,1.0,<2 mo. follow-up,0.494751
32.64099,female,1.0,MOSF w/Malig,12.0,$11-$25k,358494.0,white,0.0,<2 mo. follow-up,0.0
76.44098,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,23486.0,white,0.0,no(M2 and SIP pres),0.0
77.59094,male,1.0,ARF/MOSF w/Sepsis,8.0,under $11k,355655.0,white,1.0,<2 mo. follow-up,3.7192383
51.09698,male,0.0,Lung Cancer,16.0,under $11k,37350.0,white,0.0,<2 mo. follow-up,0.0
95.70697,female,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,16032.0,white,1.0,<2 mo. follow-up,6.9287109
78.18799,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,18497.0,white,1.0,<2 mo. follow-up,4.9316406
61.142,male,0.0,ARF/MOSF w/Sepsis,22.0,$25-$50k,365437.0,black,2.0,<2 mo. follow-up,2.0
84.99695,male,0.0,Coma,12.0,under $11k,19473.0,white,1.0,<2 mo. follow-up,3.3886719
84.37195,female,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,64321.0,white,3.0,<2 mo. follow-up,3.0
77.99298,male,1.0,CHF,21.0,$25-$50k,90070.0,black,1.0,<2 mo. follow-up,2.6665039
79.97797,male,1.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,121331.0,white,6.0,<2 mo. follow-up,6.0
79.06396,male,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,107076.0,white,0.0,<2 mo. follow-up,0.0
45.043,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,30354.0,white,1.0,<2 mo. follow-up,1.6142578
50.155,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,372270.0,white,0.0,adl>=4 (>=5 if sur),0.0
56.211,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,135949.0,white,5.0,adl>=4 (>=5 if sur),5.0
51.18698,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,56973.0,white,1.0,<2 mo. follow-up,2.8598633
47.95099,male,0.0,MOSF w/Malig,18.0,$11-$25k,53439.0,hispanic,0.0,adl>=4 (>=5 if sur),0.0
100.24597,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,51328.0,white,1.0,<2 mo. follow-up,4.1796875
75.95294,male,1.0,Coma,17.0,$11-$25k,13525.0,white,1.0,<2 mo. follow-up,3.0849609
36.39398,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,492853.0,black,5.0,<2 mo. follow-up,5.0
76.21399,female,0.0,COPD,14.0,under $11k,30490.0,white,3.0,no(M2 and SIP pres),3.0
87.05798,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,202508.0,white,5.0,adl>=4 (>=5 if sur),5.0
80.10095,female,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,299289.0,white,0.0,<2 mo. follow-up,0.0
62.724,female,1.0,Coma,18.0,$11-$25k,109193.0,white,1.0,<2 mo. follow-up,2.4272461
81.50897,male,0.0,CHF,12.0,under $11k,13004.0,white,4.0,adl>=4 (>=5 if sur),4.0
32.08499,male,0.0,CHF,12.0,under $11k,162263.0,hispanic,5.0,no(M2 and SIP pres),5.0
71.85498,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,95439.0,asian,0.0,<2 mo. follow-up,0.0
90.20697,female,0.0,ARF/MOSF w/Sepsis,9.0,$11-$25k,12549.0,white,1.0,<2 mo. follow-up,0.494751
67.92896,female,0.0,CHF,8.0,under $11k,82258.0,hispanic,1.0,SIP>=30,1.1667481
35.76498,female,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,94457.0,white,5.0,no(M2 and SIP pres),5.0
73.75494,female,1.0,Coma,12.0,under $11k,334890.0,hispanic,5.0,<2 mo. follow-up,5.0
54.004,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,748973.0,white,1.0,adl>=4 (>=5 if sur),1.0
52.51199,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,69096.0,white,3.0,no(M2 and SIP pres),3.0
38.168,female,0.0,ARF/MOSF w/Sepsis,20.0,$25-$50k,151909.0,hispanic,1.0,SIP>=30,2.9682617
49.02399,female,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,64403.0,white,0.0,<2 mo. follow-up,0.0
47.96198,male,0.0,COPD,14.0,under $11k,39258.0,white,1.0,<2 mo. follow-up,1.1667481
22.91299,male,0.0,ARF/MOSF w/Sepsis,13.0,under $11k,59999.0,black,7.0,adl>=4 (>=5 if sur),7.0
68.53894,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,246417.0,black,1.0,<2 mo. follow-up,2.4624023
94.80096,female,0.0,Lung Cancer,12.0,under $11k,11088.0,white,1.0,<2 mo. follow-up,4.578125
47.88498,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,165774.0,black,1.0,<2 mo. follow-up,3.1933594
52.98599,male,0.0,CHF,12.0,under $11k,24044.0,white,1.0,no(M2 and SIP pres),1.0
41.26199,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,346799.0,white,1.0,no(M2 and SIP pres),1.0
60.96899,male,0.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,156906.0,white,5.0,no(M2 and SIP pres),5.0
71.84698,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,210555.0,white,1.0,<2 mo. follow-up,2.0454102
84.31799,male,0.0,ARF/MOSF w/Sepsis,18.0,>$50k,462018.0,asian,1.0,<2 mo. follow-up,2.8022461
38.21799,female,1.0,Coma,14.0,>$50k,97521.0,white,5.0,<2 mo. follow-up,5.0
79.15698,female,1.0,Coma,15.0,$25-$50k,16231.0,white,1.0,<2 mo. follow-up,3.6679688
33.59097,male,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,81881.0,hispanic,1.0,no(M2 and SIP pres),1.8388672
73.61798,male,1.0,MOSF w/Malig,16.0,>$50k,86043.0,white,5.0,<2 mo. follow-up,5.0
98.08899,female,1.0,Coma,16.0,under $11k,16613.0,white,1.0,<2 mo. follow-up,6.3632812
65.09497,female,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,358169.0,white,0.0,adl>=4 (>=5 if sur),0.0
67.39197,female,0.0,ARF/MOSF w/Sepsis,9.0,$11-$25k,213912.0,black,0.0,<2 mo. follow-up,0.0
69.77698,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,88609.0,white,1.0,<2 mo. follow-up,2.9160156
77.20496,female,0.0,COPD,12.0,under $11k,14068.0,white,1.0,<2 mo. follow-up,3.659668
68.40796,female,0.0,COPD,12.0,under $11k,19252.0,white,1.0,<2 mo. follow-up,4.4960938
74.25098,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,205063.0,white,3.0,<2 mo. follow-up,3.0
35.92599,male,1.0,MOSF w/Malig,12.0,$25-$50k,389403.0,white,0.0,<2 mo. follow-up,0.0
61.952,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,451954.0,white,1.0,Coma or Intub,3.0234375
75.87695,male,0.0,ARF/MOSF w/Sepsis,19.0,>$50k,39709.0,white,1.0,no(M2 and SIP pres),2.2265625
50.034,female,1.0,MOSF w/Malig,12.0,under $11k,60562.0,white,1.0,<2 mo. follow-up,3.3105469
66.90796,female,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,137219.0,white,5.0,<2 mo. follow-up,5.0
38.94299,female,1.0,Cirrhosis,12.0,under $11k,283724.0,asian,0.0,<2 mo. follow-up,0.0
32.07397,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,793804.0,hispanic,0.0,Coma or Intub,0.0
57.75198,female,0.0,CHF,11.0,under $11k,10350.0,black,1.0,SIP>=30,1.0
48.435,male,0.0,Colon Cancer,12.0,under $11k,18298.0,white,1.0,<2 mo. follow-up,2.5161133
56.50897,male,1.0,Coma,12.0,$11-$25k,25303.0,white,1.0,<2 mo. follow-up,2.1625977
48.47098,female,0.0,Lung Cancer,17.0,under $11k,41422.0,white,0.0,<2 mo. follow-up,0.0
23.24199,female,1.0,MOSF w/Malig,16.0,under $11k,636743.0,white,1.0,<2 mo. follow-up,2.65625
84.91394,male,0.0,CHF,16.0,under $11k,42792.0,white,2.0,<2 mo. follow-up,2.0
57.28998,male,1.0,MOSF w/Malig,14.0,>$50k,433153.0,white,0.0,<2 mo. follow-up,0.0
62.741,male,0.0,Cirrhosis,12.0,$11-$25k,17289.0,hispanic,1.0,no(M2 and SIP pres),1.1667481
73.91595,female,0.0,Colon Cancer,12.0,under $11k,37120.0,white,5.0,<2 mo. follow-up,5.0
62.34598,male,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,54050.0,white,0.0,<2 mo. follow-up,0.0
19.765,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,25024.0,hispanic,1.0,<2 mo. follow-up,2.1357422
62.965,male,0.0,CHF,12.0,under $11k,32473.0,white,1.0,<2 mo. follow-up,3.5175781
51.98398,male,0.0,Colon Cancer,14.0,>$50k,30678.0,white,0.0,<2 mo. follow-up,0.0
78.62,female,0.0,Lung Cancer,12.0,under $11k,20276.0,white,1.0,<2 mo. follow-up,1.1667481
46.51898,female,1.0,Coma,12.0,under $11k,79492.0,black,1.0,<2 mo. follow-up,3.140625
60.16699,male,1.0,MOSF w/Malig,12.0,under $11k,142620.0,white,2.0,<2 mo. follow-up,2.0
33.01297,female,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,25024.0,white,1.0,<2 mo. follow-up,3.2822266
53.71899,male,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,651870.0,white,0.0,adl>=4 (>=5 if sur),0.0
38.87698,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,282625.0,white,1.0,SIP>=30,3.0825195
61.689,male,0.0,Colon Cancer,12.0,under $11k,16468.0,white,1.0,<2 mo. follow-up,2.4331055
69.125,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,64500.0,white,2.0,no(M2 and SIP pres),2.0
30.98399,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,175051.0,white,1.0,<2 mo. follow-up,2.6137695
62.75998,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,985215.0,white,0.0,<2 mo. follow-up,0.0
62.28897,male,0.0,Colon Cancer,12.0,under $11k,34721.0,white,0.0,<2 mo. follow-up,0.0
38.94299,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,147307.0,white,5.0,adl>=4 (>=5 if sur),5.0
53.314,female,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,517087.0,asian,1.0,SIP>=30,3.1201172
67.63898,male,0.0,Lung Cancer,12.0,under $11k,21057.0,white,0.0,SIP>=30,0.0
57.34698,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,139549.0,hispanic,6.0,no(M2 and SIP pres),6.0
40.14798,male,0.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,172266.0,white,0.0,no(M2 and SIP pres),0.0
60.37,female,0.0,Colon Cancer,12.0,>$50k,8439.0,white,0.0,no(M2 and SIP pres),0.0
22.741,male,0.0,Coma,17.0,$25-$50k,150904.0,hispanic,0.0,no(M2 and SIP pres),0.0
33.67798,female,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,758539.0,black,0.0,<2 mo. follow-up,0.0
71.29095,male,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,117388.0,black,1.0,<2 mo. follow-up,2.4750977
59.452,female,0.0,Colon Cancer,12.0,under $11k,27070.0,white,2.0,no(M2 and SIP pres),2.0
74.97894,female,1.0,MOSF w/Malig,18.0,$25-$50k,60987.0,white,2.0,<2 mo. follow-up,2.0
75.67999,male,1.0,MOSF w/Malig,16.0,$25-$50k,122270.0,white,0.0,<2 mo. follow-up,0.0
65.26196,female,0.0,Lung Cancer,12.0,>$50k,35260.0,white,1.0,no(M2 and SIP pres),1.0
65.74896,female,0.0,CHF,12.0,$11-$25k,34253.0,white,1.0,<2 mo. follow-up,3.8549805
75.97296,male,0.0,CHF,16.0,$25-$50k,51180.0,white,3.0,<2 mo. follow-up,3.0
72.33899,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,146792.0,white,1.0,<2 mo. follow-up,1.0
70.62299,male,0.0,Lung Cancer,12.0,$25-$50k,48292.0,white,0.0,<2 mo. follow-up,0.0
61.80698,female,0.0,COPD,20.0,>$50k,17086.0,white,0.0,<2 mo. follow-up,0.0
68.758,female,0.0,Colon Cancer,16.0,under $11k,24338.0,white,0.0,<2 mo. follow-up,0.0
32.616,female,0.0,CHF,12.0,$11-$25k,8228.0,white,0.0,no(M2 and SIP pres),0.0
78.48596,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,168174.0,white,1.0,<2 mo. follow-up,3.2768555
41.64798,female,0.0,Colon Cancer,14.0,>$50k,16011.0,white,0.0,<2 mo. follow-up,0.0
55.58398,female,0.0,MOSF w/Malig,11.0,$11-$25k,25024.0,white,1.0,SIP>=30,2.9018555
64.32898,male,0.0,Lung Cancer,12.0,under $11k,7735.0,white,1.0,<2 mo. follow-up,2.3125
77.77698,female,1.0,Coma,16.0,under $11k,63572.0,white,1.0,<2 mo. follow-up,1.0
82.98999,male,0.0,CHF,8.0,$11-$25k,51711.0,white,0.0,no(M2 and SIP pres),0.0
72.77496,female,0.0,CHF,12.0,under $11k,28137.0,black,4.0,adl>=4 (>=5 if sur),4.0
70.04498,female,0.0,COPD,9.0,under $11k,119685.0,black,5.0,adl>=4 (>=5 if sur),5.0
43.93198,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,57142.0,white,1.0,no(M2 and SIP pres),1.0
70.61694,female,0.0,Coma,14.0,$25-$50k,75372.0,white,7.0,<2 mo. follow-up,7.0
38.07797,female,0.0,MOSF w/Malig,16.0,$11-$25k,51241.0,white,1.0,<2 mo. follow-up,2.4296875
38.90997,female,0.0,Cirrhosis,11.0,under $11k,19379.0,white,0.0,SIP>=30,0.0
27.29099,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,50203.0,white,1.0,<2 mo. follow-up,3.1616211
20.85399,male,0.0,CHF,15.0,>$50k,20579.0,hispanic,0.0,no(M2 and SIP pres),0.0
55.767,male,0.0,Lung Cancer,12.0,under $11k,30453.0,white,1.0,<2 mo. follow-up,3.7163086
42.09399,female,0.0,Lung Cancer,12.0,under $11k,43422.0,black,3.0,<2 mo. follow-up,3.0
78.81995,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,436904.0,white,6.0,<2 mo. follow-up,6.0
65.74695,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,130357.0,white,1.0,<2 mo. follow-up,3.0336914
50.01199,male,0.0,Lung Cancer,16.0,>$50k,9518.0,black,1.0,<2 mo. follow-up,3.8549805
23.24699,male,1.0,MOSF w/Malig,12.0,>$50k,419195.0,white,0.0,<2 mo. follow-up,0.0
38.418,male,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,257291.0,white,1.0,<2 mo. follow-up,2.7998047
91.25299,female,0.0,CHF,14.0,under $11k,23547.0,white,0.0,<2 mo. follow-up,0.0
45.31097,male,0.0,Colon Cancer,12.0,$11-$25k,32838.0,white,1.0,<2 mo. follow-up,1.0
49.16898,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,59761.0,white,3.0,<2 mo. follow-up,3.0
27.058,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,194402.0,white,0.0,<2 mo. follow-up,0.0
65.99896,male,0.0,Colon Cancer,18.0,$25-$50k,3792.0,black,1.0,<2 mo. follow-up,0.494751
70.03699,female,0.0,Lung Cancer,14.0,under $11k,14609.0,black,5.0,<2 mo. follow-up,5.0
60.504,male,1.0,Cirrhosis,13.0,under $11k,49985.0,white,1.0,<2 mo. follow-up,3.0488281
29.53299,male,0.0,MOSF w/Malig,17.0,under $11k,102427.0,black,1.0,<2 mo. follow-up,0.494751
53.07599,female,0.0,CHF,16.0,>$50k,29187.0,hispanic,4.0,adl>=4 (>=5 if sur),4.0
67.784,female,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,411846.0,white,2.0,<2 mo. follow-up,2.0
53.26199,female,1.0,ARF/MOSF w/Sepsis,12.0,>$50k,203408.0,white,5.0,<2 mo. follow-up,5.0
59.17599,female,1.0,Coma,15.0,$25-$50k,31803.0,white,0.0,<2 mo. follow-up,0.0
47.21997,male,0.0,CHF,14.0,under $11k,14827.0,white,3.0,adl>=4 (>=5 if sur),3.0
54.021,male,0.0,Lung Cancer,12.0,under $11k,6533.0,white,1.0,<2 mo. follow-up,2.4956055
81.25397,female,0.0,Lung Cancer,12.0,$11-$25k,15945.0,white,4.0,adl>=4 (>=5 if sur),4.0
91.43896,female,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,68103.0,white,6.0,adl>=4 (>=5 if sur),6.0
65.31696,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,80470.0,white,2.0,<2 mo. follow-up,2.0
48.94998,female,0.0,CHF,12.0,under $11k,12684.0,hispanic,1.0,no(M2 and SIP pres),0.494751
54.853,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,272366.0,white,1.0,<2 mo. follow-up,3.4838867
75.16797,female,0.0,MOSF w/Malig,14.0,$25-$50k,31213.0,asian,4.0,<2 mo. follow-up,4.0
70.16296,male,0.0,CHF,16.0,$25-$50k,159568.0,white,0.0,no(M2 and SIP pres),0.0
91.08795,female,0.0,ARF/MOSF w/Sepsis,20.0,>$50k,34662.0,white,0.0,<2 mo. follow-up,0.0
50.76797,male,1.0,ARF/MOSF w/Sepsis,19.0,>$50k,312860.0,white,0.0,<2 mo. follow-up,0.0
29.77399,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,333521.0,white,0.0,no(M2 and SIP pres),0.0
63.37,male,1.0,ARF/MOSF w/Sepsis,11.0,under $11k,65661.0,hispanic,7.0,<2 mo. follow-up,7.0
38.80399,female,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,407955.0,hispanic,5.0,<2 mo. follow-up,5.0
77.50598,female,0.0,COPD,12.0,under $11k,32303.0,white,1.0,<2 mo. follow-up,4.3789062
65.90796,female,0.0,Colon Cancer,17.0,>$50k,9327.0,white,1.0,no(M2 and SIP pres),1.984375
23.84399,female,0.0,MOSF w/Malig,15.0,$11-$25k,215913.0,hispanic,0.0,no(M2 and SIP pres),0.0
58.724,male,1.0,ARF/MOSF w/Sepsis,20.0,>$50k,461154.0,white,0.0,<2 mo. follow-up,0.0
79.71497,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,241269.0,white,0.0,no(M2 and SIP pres),0.0
48.81897,male,1.0,Lung Cancer,16.0,under $11k,14258.0,black,4.0,<2 mo. follow-up,4.0
41.98798,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,501348.0,white,0.0,SIP>=30,0.0
79.04199,male,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,274616.0,white,0.0,<2 mo. follow-up,0.0
44.616,male,0.0,CHF,16.0,under $11k,71501.0,white,5.0,<2 mo. follow-up,5.0
24.21899,male,1.0,MOSF w/Malig,13.0,under $11k,106744.0,black,0.0,<2 mo. follow-up,0.0
66.146,male,1.0,CHF,17.0,$25-$50k,44384.0,white,0.0,<2 mo. follow-up,0.0
58.53,female,0.0,CHF,12.0,under $11k,8325.0,asian,1.0,<2 mo. follow-up,1.0
41.54999,male,0.0,CHF,21.0,under $11k,31741.0,white,1.0,no(M2 and SIP pres),0.494751
75.146,female,0.0,Colon Cancer,12.0,under $11k,22930.0,white,1.0,<2 mo. follow-up,2.5004883
21.922,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,407547.0,hispanic,1.0,no(M2 and SIP pres),2.0605469
58.09998,female,1.0,MOSF w/Malig,12.0,under $11k,197978.0,white,1.0,<2 mo. follow-up,2.9145508
89.77997,male,1.0,Coma,12.0,under $11k,19078.0,white,1.0,<2 mo. follow-up,5.6455078
60.61298,male,0.0,CHF,12.0,$11-$25k,42604.0,hispanic,0.0,no(M2 and SIP pres),0.0
52.87097,male,0.0,ARF/MOSF w/Sepsis,11.0,$25-$50k,509887.0,white,2.0,adl>=4 (>=5 if sur),2.0
94.55194,male,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,40533.0,white,0.0,<2 mo. follow-up,0.0
29.53,female,0.0,ARF/MOSF w/Sepsis,15.0,$11-$25k,89501.0,asian,0.0,SIP>=30,0.0
75.10999,male,0.0,Lung Cancer,14.0,$25-$50k,8323.0,asian,1.0,<2 mo. follow-up,1.8388672
83.13495,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,47079.0,hispanic,1.0,<2 mo. follow-up,3.7661133
38.93799,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,1045982.0,hispanic,6.0,<2 mo. follow-up,6.0
61.70599,female,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,60681.0,white,5.0,<2 mo. follow-up,5.0
49.32199,female,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,193938.0,white,0.0,no(M2 and SIP pres),0.0
72.26794,male,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,77088.0,white,1.0,no(M2 and SIP pres),1.0
59.81897,female,0.0,CHF,11.0,$25-$50k,12972.0,black,0.0,<2 mo. follow-up,0.0
79.98895,male,0.0,COPD,13.0,$25-$50k,17986.0,black,1.0,SIP>=30,0.494751
67.35699,male,0.0,CHF,20.0,>$50k,36549.0,white,1.0,no(M2 and SIP pres),3.1831055
70.29199,female,0.0,CHF,13.0,under $11k,22123.0,black,0.0,SIP>=30,0.0
77.42096,female,1.0,Coma,12.0,under $11k,93782.0,white,1.0,<2 mo. follow-up,3.1269531
82.29395,male,0.0,Coma,12.0,under $11k,39770.0,white,1.0,<2 mo. follow-up,2.8618164
56.02698,male,0.0,CHF,14.0,$11-$25k,32470.0,white,1.0,SIP>=30,1.1667481
64.88397,male,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,221993.0,white,5.0,<2 mo. follow-up,5.0
33.60699,male,0.0,Coma,16.0,>$50k,53325.0,asian,0.0,no(M2 and SIP pres),0.0
88.91199,female,0.0,Coma,17.0,$25-$50k,43891.0,black,5.0,adl>=4 (>=5 if sur),5.0
54.81198,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,653743.0,black,0.0,no(M2 and SIP pres),0.0
66.49396,male,0.0,Colon Cancer,12.0,under $11k,28819.0,white,1.0,<2 mo. follow-up,2.890625
52.22198,male,0.0,MOSF w/Malig,14.0,under $11k,73669.0,asian,1.0,adl>=4 (>=5 if sur),1.0
72.07397,male,0.0,CHF,13.0,$11-$25k,22723.0,white,3.0,no(M2 and SIP pres),3.0
41.95499,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,495977.0,white,3.0,no(M2 and SIP pres),3.0
46.78699,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,494827.0,hispanic,6.0,no(M2 and SIP pres),6.0
74.46399,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,44037.0,white,1.0,<2 mo. follow-up,1.0
60.06799,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,838218.0,asian,1.0,<2 mo. follow-up,3.109375
63.37,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,140411.0,hispanic,0.0,Coma or Intub,0.0
66.77594,male,0.0,CHF,12.0,under $11k,13271.0,white,1.0,<2 mo. follow-up,3.9477539
27.12099,female,0.0,ARF/MOSF w/Sepsis,20.0,$25-$50k,69535.0,hispanic,2.0,<2 mo. follow-up,2.0
77.40497,female,0.0,Colon Cancer,18.0,>$50k,39468.0,white,0.0,no(M2 and SIP pres),0.0
78.55695,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,487176.0,asian,0.0,adl>=4 (>=5 if sur),0.0
40.84598,male,0.0,Cirrhosis,13.0,$11-$25k,33793.0,white,1.0,<2 mo. follow-up,1.1667481
66.27496,male,0.0,MOSF w/Malig,14.0,under $11k,69356.0,black,1.0,<2 mo. follow-up,1.0
61.59598,male,0.0,CHF,15.0,>$50k,32311.0,white,0.0,<2 mo. follow-up,0.0
88.18298,female,0.0,CHF,12.0,under $11k,25625.0,white,1.0,<2 mo. follow-up,4.9394531
59.48499,male,0.0,CHF,12.0,$25-$50k,52138.0,white,0.0,no(M2 and SIP pres),0.0
50.66898,male,0.0,Colon Cancer,12.0,under $11k,76684.0,white,1.0,<2 mo. follow-up,2.7949219
29.02399,female,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,25024.0,hispanic,0.0,adl>=4 (>=5 if sur),0.0
76.80194,female,1.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,1226766.0,white,0.0,Coma or Intub,0.0
83.93994,male,0.0,CHF,14.0,>$50k,79139.0,white,0.0,no(M2 and SIP pres),0.0
91.61896,male,0.0,Coma,12.0,under $11k,10709.0,white,7.0,adl>=4 (>=5 if sur),7.0
29.76299,female,0.0,ARF/MOSF w/Sepsis,13.0,under $11k,296857.0,white,0.0,adl>=4 (>=5 if sur),0.0
58.60599,female,0.0,ARF/MOSF w/Sepsis,15.0,>$50k,538323.0,asian,0.0,no(M2 and SIP pres),0.0
40.78,male,0.0,ARF/MOSF w/Sepsis,18.0,$11-$25k,105330.0,white,0.0,no(M2 and SIP pres),0.0
92.64294,male,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,26196.0,white,0.0,<2 mo. follow-up,0.0
45.80197,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,215484.0,hispanic,1.0,no(M2 and SIP pres),2.2841797
54.52399,female,1.0,MOSF w/Malig,12.0,$25-$50k,263308.0,white,0.0,<2 mo. follow-up,0.0
77.85895,male,0.0,CHF,12.0,under $11k,13403.0,white,1.0,<2 mo. follow-up,3.0351562
30.53799,male,0.0,Lung Cancer,20.0,>$50k,17851.0,white,1.0,<2 mo. follow-up,0.494751
66.05597,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,283022.0,white,1.0,<2 mo. follow-up,3.1586914
49.42398,female,0.0,ARF/MOSF w/Sepsis,18.0,$25-$50k,809561.0,white,0.0,adl>=4 (>=5 if sur),0.0
47.93399,female,0.0,MOSF w/Malig,16.0,$25-$50k,64713.0,asian,0.0,no(M2 and SIP pres),0.0
77.28998,male,0.0,CHF,12.0,$11-$25k,4408.0,white,1.0,no(M2 and SIP pres),0.494751
58.14398,male,0.0,CHF,12.0,under $11k,32904.0,hispanic,1.0,no(M2 and SIP pres),0.494751
58.09399,male,0.0,MOSF w/Malig,14.0,under $11k,75939.0,white,0.0,<2 mo. follow-up,0.0
69.79895,female,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,99643.0,white,0.0,<2 mo. follow-up,0.0
24.98299,female,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,37548.0,white,0.0,<2 mo. follow-up,0.0
67.98395,male,0.0,Lung Cancer,16.0,>$50k,31422.0,white,1.0,<2 mo. follow-up,1.8388672
31.94299,female,0.0,CHF,12.0,$11-$25k,27706.0,white,2.0,<2 mo. follow-up,2.0
54.461,male,1.0,ARF/MOSF w/Sepsis,16.0,>$50k,256932.0,white,3.0,<2 mo. follow-up,3.0
63.91199,female,0.0,CHF,18.0,>$50k,3241.0,white,1.0,<2 mo. follow-up,3.1831055
58.15698,male,0.0,CHF,12.0,under $11k,8082.0,white,1.0,no(M2 and SIP pres),2.4472656
48.05698,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,22509.0,black,1.0,<2 mo. follow-up,3.4160156
76.23798,male,0.0,CHF,16.0,$11-$25k,22612.0,white,0.0,<2 mo. follow-up,0.0
50.29999,female,0.0,ARF/MOSF w/Sepsis,6.0,under $11k,589642.0,hispanic,1.0,SIP>=30,3.1318359
32.25699,male,0.0,Colon Cancer,12.0,under $11k,15115.0,white,1.0,<2 mo. follow-up,2.4589844
80.87299,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,47516.0,white,7.0,<2 mo. follow-up,7.0
35.50198,female,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,86275.0,black,1.0,no(M2 and SIP pres),3.8613281
65.32495,male,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,51732.0,white,1.0,<2 mo. follow-up,3.1479492
67.72296,male,0.0,CHF,12.0,under $11k,10358.0,white,1.0,no(M2 and SIP pres),1.1667481
65.02899,female,0.0,Coma,12.0,under $11k,64130.0,white,0.0,adl>=4 (>=5 if sur),0.0
84.25995,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,26395.0,white,6.0,<2 mo. follow-up,6.0
34.47198,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,19858.0,white,1.0,<2 mo. follow-up,2.8930664
42.24197,male,0.0,CHF,13.0,under $11k,22158.0,white,0.0,<2 mo. follow-up,0.0
44.00299,male,0.0,Lung Cancer,12.0,$11-$25k,9377.0,hispanic,1.0,SIP>=30,1.1667481
87.48798,male,0.0,CHF,12.0,under $11k,102946.0,white,1.0,<2 mo. follow-up,4.2802734
82.33496,female,1.0,Coma,14.0,$25-$50k,29987.0,white,1.0,<2 mo. follow-up,5.5546875
56.58298,female,0.0,CHF,11.0,under $11k,150141.0,white,1.0,no(M2 and SIP pres),1.0
18.11899,male,1.0,MOSF w/Malig,12.0,under $11k,262520.0,white,0.0,<2 mo. follow-up,0.0
67.61395,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,212194.0,white,1.0,SIP>=30,1.0
39.53699,female,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,50949.0,white,0.0,no(M2 and SIP pres),0.0
34.103,female,0.0,CHF,12.0,under $11k,401408.0,hispanic,0.0,no(M2 and SIP pres),0.0
85.53595,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,49143.0,white,1.0,<2 mo. follow-up,5.8476562
73.26996,female,0.0,COPD,4.0,under $11k,16373.0,white,2.0,<2 mo. follow-up,2.0
48.42697,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,49165.0,white,1.0,<2 mo. follow-up,3.7768555
61.37698,male,0.0,Cirrhosis,12.0,$25-$50k,341731.0,white,1.0,SIP>=30,3.8950195
41.487,male,0.0,Colon Cancer,12.0,under $11k,37940.0,black,1.0,<2 mo. follow-up,2.1621094
66.91595,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,178495.0,white,1.0,<2 mo. follow-up,3.0839844
31.20299,male,0.0,ARF/MOSF w/Sepsis,17.0,$25-$50k,209845.0,other,0.0,<2 mo. follow-up,0.0
73.00195,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,50658.0,white,1.0,no(M2 and SIP pres),1.0
27.187,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,110216.0,hispanic,1.0,no(M2 and SIP pres),1.0
50.064,male,0.0,CHF,12.0,under $11k,13088.0,white,1.0,<2 mo. follow-up,2.3662109
41.42599,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,275961.0,white,2.0,no(M2 and SIP pres),2.0
69.25397,female,1.0,Coma,16.0,$11-$25k,52100.0,white,0.0,<2 mo. follow-up,0.0
64.54498,male,0.0,CHF,9.0,under $11k,36225.0,white,1.0,<2 mo. follow-up,3.2719727
47.30499,male,1.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,570603.0,white,1.0,<2 mo. follow-up,4.6552734
72.82697,male,0.0,CHF,12.0,$11-$25k,7619.0,black,0.0,SIP>=30,0.0
78.90497,male,0.0,CHF,10.0,under $11k,19787.0,white,0.0,<2 mo. follow-up,0.0
53.45697,female,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,148758.0,black,0.0,no(M2 and SIP pres),0.0
34.439,female,0.0,MOSF w/Malig,12.0,under $11k,53540.0,black,0.0,<2 mo. follow-up,0.0
52.36099,male,0.0,CHF,14.0,under $11k,18956.0,white,0.0,no(M2 and SIP pres),0.0
44.13699,female,0.0,Lung Cancer,17.0,$25-$50k,84983.0,white,1.0,<2 mo. follow-up,3.5
77.53595,male,0.0,COPD,12.0,under $11k,100611.0,white,1.0,<2 mo. follow-up,4.2373047
54.61697,male,0.0,Lung Cancer,14.0,$25-$50k,20575.0,white,2.0,no(M2 and SIP pres),2.0
63.767,male,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,177499.0,white,1.0,<2 mo. follow-up,4.4824219
49.21799,female,0.0,MOSF w/Malig,16.0,>$50k,21363.0,white,1.0,<2 mo. follow-up,2.2861328
86.83099,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,83218.0,white,5.0,<2 mo. follow-up,5.0
46.56799,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,95981.0,white,1.0,<2 mo. follow-up,3.2910156
58.431,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,97332.0,white,0.0,no(M2 and SIP pres),0.0
74.49396,female,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,56321.0,white,1.0,<2 mo. follow-up,3.8999023
47.17599,female,1.0,MOSF w/Malig,14.0,>$50k,915302.0,white,0.0,<2 mo. follow-up,0.0
71.42499,female,1.0,Cirrhosis,12.0,under $11k,60990.0,white,1.0,<2 mo. follow-up,4.2353516
52.84097,female,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,283898.0,white,7.0,<2 mo. follow-up,7.0
65.81,male,0.0,Lung Cancer,18.0,$25-$50k,14638.0,white,0.0,<2 mo. follow-up,0.0
20.991,male,0.0,ARF/MOSF w/Sepsis,13.0,>$50k,69111.0,white,0.0,<2 mo. follow-up,0.0
79.56696,female,1.0,Coma,12.0,under $11k,54981.0,white,1.0,<2 mo. follow-up,3.2192383
42.36798,male,0.0,CHF,12.0,$25-$50k,26673.0,white,0.0,<2 mo. follow-up,0.0
72.06299,female,0.0,CHF,9.0,under $11k,6761.0,hispanic,1.0,<2 mo. follow-up,1.0
84.04895,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,63995.0,white,1.0,<2 mo. follow-up,4.2011719
41.33899,male,0.0,CHF,12.0,under $11k,27099.0,white,1.0,<2 mo. follow-up,2.9267578
66.22595,male,1.0,ARF/MOSF w/Sepsis,18.0,$25-$50k,837022.0,white,2.0,<2 mo. follow-up,2.0
67.52899,male,0.0,CHF,12.0,under $11k,9941.0,other,7.0,<2 mo. follow-up,7.0
43.06097,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,727548.0,hispanic,1.0,adl>=4 (>=5 if sur),2.9472656
23.17,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,26594.0,black,0.0,<2 mo. follow-up,0.0
84.99896,male,0.0,MOSF w/Malig,18.0,under $11k,18968.0,white,1.0,<2 mo. follow-up,0.494751
52.88397,male,0.0,ARF/MOSF w/Sepsis,19.0,>$50k,34829.0,white,2.0,no(M2 and SIP pres),2.0
56.57498,male,0.0,CHF,16.0,$11-$25k,120213.0,asian,0.0,no(M2 and SIP pres),0.0
59.02499,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,84586.0,white,7.0,<2 mo. follow-up,7.0
35.379,female,0.0,Colon Cancer,18.0,>$50k,30835.0,white,0.0,<2 mo. follow-up,0.0
50.59799,male,0.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,178970.0,white,1.0,adl>=4 (>=5 if sur),2.9150391
39.52399,male,0.0,CHF,11.0,under $11k,8793.0,black,1.0,<2 mo. follow-up,2.2358398
51.702,female,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,203761.0,white,1.0,<2 mo. follow-up,1.0
74.74896,female,1.0,ARF/MOSF w/Sepsis,8.0,under $11k,71884.0,hispanic,0.0,<2 mo. follow-up,0.0
68.43799,male,0.0,MOSF w/Malig,15.0,>$50k,22713.0,white,0.0,<2 mo. follow-up,0.0
26.754,female,0.0,Coma,12.0,under $11k,97238.0,other,1.0,<2 mo. follow-up,1.9611816
68.60797,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,98679.0,white,0.0,<2 mo. follow-up,0.0
54.61697,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,144291.0,white,1.0,<2 mo. follow-up,3.8549805
91.12695,female,0.0,CHF,17.0,$11-$25k,13810.0,white,0.0,no(M2 and SIP pres),0.0
75.047,female,1.0,Cirrhosis,12.0,under $11k,32043.0,white,6.0,<2 mo. follow-up,6.0
65.29999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,267914.0,white,1.0,<2 mo. follow-up,1.0
61.49197,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,270064.0,black,1.0,<2 mo. follow-up,2.1645508
73.15796,male,0.0,Lung Cancer,12.0,under $11k,30093.0,white,1.0,<2 mo. follow-up,4.3505859
57.36099,female,0.0,Lung Cancer,14.0,$11-$25k,7234.0,other,5.0,<2 mo. follow-up,5.0
49.72998,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,225448.0,white,6.0,adl>=4 (>=5 if sur),6.0
70.12994,male,0.0,CHF,16.0,>$50k,24386.0,white,1.0,no(M2 and SIP pres),1.0
61.79898,male,0.0,CHF,12.0,under $11k,286496.0,white,1.0,no(M2 and SIP pres),3.3452148
47.896,female,1.0,ARF/MOSF w/Sepsis,18.0,>$50k,25024.0,white,0.0,<2 mo. follow-up,0.0
52.129,male,0.0,CHF,13.0,$11-$25k,36250.0,white,1.0,<2 mo. follow-up,0.494751
51.461,female,1.0,Lung Cancer,12.0,under $11k,38782.0,white,1.0,<2 mo. follow-up,3.2802734
59.95297,male,0.0,Cirrhosis,12.0,$11-$25k,37026.0,white,2.0,adl>=4 (>=5 if sur),2.0
77.29999,female,0.0,Colon Cancer,12.0,>$50k,23099.0,white,1.0,<2 mo. follow-up,0.494751
77.52496,male,1.0,Coma,10.0,$11-$25k,229171.0,white,1.0,<2 mo. follow-up,1.0
50.09399,male,0.0,CHF,13.0,$25-$50k,172027.0,white,1.0,no(M2 and SIP pres),0.494751
43.53998,female,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,313131.0,white,0.0,<2 mo. follow-up,0.0
65.01794,male,0.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,346376.0,white,1.0,<2 mo. follow-up,1.0
75.55597,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,128893.0,white,0.0,Coma or Intub,0.0
61.76599,female,0.0,ARF/MOSF w/Sepsis,13.0,under $11k,33585.0,black,0.0,<2 mo. follow-up,0.0
35.47198,male,1.0,MOSF w/Malig,16.0,$25-$50k,687411.0,white,1.0,<2 mo. follow-up,2.5102539
56.36697,male,1.0,ARF/MOSF w/Sepsis,6.0,under $11k,299542.0,hispanic,0.0,<2 mo. follow-up,0.0
74.69995,female,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,76763.0,black,1.0,<2 mo. follow-up,1.0
46.09198,female,0.0,MOSF w/Malig,12.0,under $11k,545065.0,white,1.0,<2 mo. follow-up,3.6855469
53.27899,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,96262.0,white,1.0,<2 mo. follow-up,3.3676758
53.06198,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,471833.0,asian,1.0,<2 mo. follow-up,2.6240234
69.133,male,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,57562.0,asian,3.0,<2 mo. follow-up,3.0
54.46997,male,1.0,ARF/MOSF w/Sepsis,18.0,>$50k,658861.0,hispanic,1.0,<2 mo. follow-up,3.0800781
45.96298,female,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,402858.0,white,3.0,<2 mo. follow-up,3.0
38.83099,female,1.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,449656.0,white,0.0,<2 mo. follow-up,0.0
48.43799,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,126356.0,white,0.0,<2 mo. follow-up,0.0
74.88794,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,367797.0,white,1.0,adl>=4 (>=5 if sur),1.0
68.08795,male,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,543761.0,white,0.0,adl>=4 (>=5 if sur),0.0
27.30199,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,147320.0,hispanic,1.0,<2 mo. follow-up,3.5473633
64.66296,female,0.0,CHF,15.0,$11-$25k,82891.0,white,1.0,<2 mo. follow-up,0.494751
74.47998,male,0.0,CHF,12.0,under $11k,43115.0,hispanic,0.0,no(M2 and SIP pres),0.0
56.96597,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,743890.0,white,1.0,<2 mo. follow-up,2.800293
68.32599,male,0.0,ARF/MOSF w/Sepsis,19.0,>$50k,19224.0,white,1.0,no(M2 and SIP pres),0.494751
64.02997,male,1.0,CHF,12.0,>$50k,193563.0,white,0.0,<2 mo. follow-up,0.0
56.01898,male,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,25024.0,hispanic,7.0,<2 mo. follow-up,7.0
56.42697,female,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,25024.0,white,0.0,<2 mo. follow-up,0.0
74.97296,female,0.0,CHF,9.0,under $11k,5306.0,black,1.0,<2 mo. follow-up,4.5273438
66.64197,female,0.0,Lung Cancer,10.0,under $11k,55841.0,white,1.0,<2 mo. follow-up,0.494751
37.25699,male,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,188152.0,hispanic,0.0,<2 mo. follow-up,0.0
59.70697,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,770591.0,white,4.0,<2 mo. follow-up,4.0
57.91397,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,376476.0,white,2.0,adl>=4 (>=5 if sur),2.0
79.81396,male,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,181788.0,white,0.0,adl>=4 (>=5 if sur),0.0
80.49298,male,0.0,CHF,15.0,$25-$50k,27792.0,white,1.0,<2 mo. follow-up,2.3549805
63.56198,female,0.0,COPD,12.0,under $11k,56383.0,black,0.0,<2 mo. follow-up,0.0
89.92499,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,215263.0,asian,1.0,<2 mo. follow-up,3.8125
75.64996,female,0.0,Lung Cancer,12.0,under $11k,9252.0,white,1.0,<2 mo. follow-up,2.3491211
52.33398,female,0.0,CHF,14.0,under $11k,44858.0,white,1.0,<2 mo. follow-up,0.494751
41.21298,female,0.0,Lung Cancer,14.0,$25-$50k,17155.0,white,3.0,adl>=4 (>=5 if sur),3.0
62.60898,female,0.0,Lung Cancer,12.0,$11-$25k,36914.0,white,1.0,no(M2 and SIP pres),3.484375
71.47198,male,0.0,CHF,18.0,>$50k,22851.0,white,2.0,<2 mo. follow-up,2.0
43.129,female,0.0,Lung Cancer,12.0,under $11k,32776.0,white,1.0,<2 mo. follow-up,2.9306641
45.16098,male,1.0,Coma,12.0,under $11k,47000.0,white,0.0,<2 mo. follow-up,0.0
55.76498,female,0.0,MOSF w/Malig,20.0,$25-$50k,84742.0,white,1.0,<2 mo. follow-up,2.9794922
70.12695,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,93405.0,white,2.0,<2 mo. follow-up,2.0
70.20697,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,480909.0,white,4.0,Coma or Intub,4.0
65.87299,female,1.0,ARF/MOSF w/Sepsis,9.0,under $11k,349615.0,white,1.0,<2 mo. follow-up,1.0
37.77399,female,0.0,Lung Cancer,14.0,>$50k,124501.0,white,0.0,<2 mo. follow-up,0.0
27.866,female,0.0,CHF,18.0,$25-$50k,34964.0,white,2.0,<2 mo. follow-up,2.0
46.51898,male,0.0,CHF,14.0,under $11k,466224.0,hispanic,0.0,<2 mo. follow-up,0.0
75.461,female,0.0,CHF,12.0,under $11k,22979.0,black,1.0,<2 mo. follow-up,3.3642578
66.50494,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,983206.0,white,1.0,Coma or Intub,2.8105469
49.89697,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,550783.0,black,0.0,adl>=4 (>=5 if sur),0.0
45.08698,male,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,385690.0,asian,1.0,<2 mo. follow-up,3.7890625
71.849,male,0.0,CHF,12.0,under $11k,64436.0,white,1.0,<2 mo. follow-up,2.8486328
56.88199,female,1.0,MOSF w/Malig,12.0,under $11k,25415.0,white,1.0,<2 mo. follow-up,2.9951172
39.02298,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,288218.0,black,2.0,<2 mo. follow-up,2.0
56.10999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,419661.0,white,1.0,<2 mo. follow-up,2.902832
66.26398,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,210275.0,asian,1.0,<2 mo. follow-up,2.4750977
67.92596,female,1.0,MOSF w/Malig,12.0,under $11k,320408.0,white,1.0,<2 mo. follow-up,2.7646484
82.02594,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,122708.0,white,1.0,Coma or Intub,3.4726562
55.13797,male,0.0,Lung Cancer,14.0,under $11k,29367.0,white,0.0,<2 mo. follow-up,0.0
38.771,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,27652.0,white,1.0,no(M2 and SIP pres),2.1386719
23.76999,female,0.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,54663.0,hispanic,0.0,<2 mo. follow-up,0.0
36.67398,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,288912.0,black,1.0,<2 mo. follow-up,2.5756836
89.82599,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,22772.0,white,1.0,<2 mo. follow-up,3.5668945
71.06396,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,88606.0,white,1.0,<2 mo. follow-up,1.0
84.46796,female,1.0,Coma,10.0,under $11k,9740.0,black,1.0,<2 mo. follow-up,5.7636719
93.46997,female,0.0,CHF,12.0,>$50k,13705.0,white,0.0,SIP>=30,0.0
57.48898,male,1.0,Cirrhosis,12.0,under $11k,49892.0,white,1.0,<2 mo. follow-up,3.3417969
73.99896,female,0.0,COPD,12.0,under $11k,15322.0,white,1.0,no(M2 and SIP pres),3.0947266
57.43997,female,0.0,Colon Cancer,12.0,$25-$50k,50645.0,white,0.0,adl>=4 (>=5 if sur),0.0
70.45599,female,1.0,Coma,11.0,>$50k,52477.0,black,0.0,<2 mo. follow-up,0.0
63.88199,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,178201.0,white,1.0,<2 mo. follow-up,3.230957
46.00699,male,1.0,MOSF w/Malig,14.0,$25-$50k,135769.0,white,1.0,<2 mo. follow-up,3.2695312
63.07999,female,0.0,CHF,12.0,under $11k,11751.0,white,1.0,<2 mo. follow-up,2.2646484
64.34796,male,0.0,Cirrhosis,14.0,under $11k,7934.0,hispanic,1.0,<2 mo. follow-up,1.8388672
52.02698,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,287368.0,white,0.0,no(M2 and SIP pres),0.0
59.75598,male,0.0,Cirrhosis,14.0,>$50k,29213.0,white,1.0,no(M2 and SIP pres),2.7348633
72.80194,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,226908.0,white,1.0,<2 mo. follow-up,2.4453125
73.68695,male,0.0,Lung Cancer,12.0,under $11k,14124.0,white,1.0,<2 mo. follow-up,3.9892578
70.508,female,0.0,MOSF w/Malig,12.0,under $11k,42089.0,white,1.0,<2 mo. follow-up,1.9824219
55.50198,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,338671.0,white,0.0,no(M2 and SIP pres),0.0
63.94299,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,252684.0,hispanic,1.0,<2 mo. follow-up,1.1667481
47.47998,female,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,339838.0,white,1.0,<2 mo. follow-up,0.494751
50.51099,female,0.0,ARF/MOSF w/Sepsis,15.0,$25-$50k,131648.0,white,1.0,<2 mo. follow-up,0.494751
66.771,female,0.0,Colon Cancer,12.0,under $11k,18716.0,white,1.0,<2 mo. follow-up,0.494751
51.85199,male,0.0,MOSF w/Malig,14.0,$25-$50k,54700.0,white,0.0,<2 mo. follow-up,0.0
58.63397,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,145518.0,hispanic,0.0,<2 mo. follow-up,0.0
74.41797,female,0.0,ARF/MOSF w/Sepsis,15.0,>$50k,243036.0,white,1.0,<2 mo. follow-up,2.7583008
60.01398,male,0.0,Colon Cancer,16.0,>$50k,54862.0,white,1.0,no(M2 and SIP pres),2.5766602
34.53799,female,1.0,Cirrhosis,12.0,>$50k,318788.0,hispanic,6.0,<2 mo. follow-up,6.0
79.25494,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,194939.0,white,1.0,<2 mo. follow-up,4.1640625
59.409,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,618719.0,white,1.0,<2 mo. follow-up,2.7148438
46.31598,female,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,123254.0,black,1.0,<2 mo. follow-up,2.4165039
73.10895,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,258088.0,asian,1.0,<2 mo. follow-up,3.5952148
72.28699,male,1.0,ARF/MOSF w/Sepsis,11.0,under $11k,235312.0,white,0.0,<2 mo. follow-up,0.0
51.72897,female,0.0,CHF,12.0,under $11k,11742.0,white,1.0,no(M2 and SIP pres),0.494751
52.89499,female,0.0,ARF/MOSF w/Sepsis,18.0,>$50k,110588.0,white,0.0,no(M2 and SIP pres),0.0
44.31799,male,0.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,500747.0,white,2.0,adl>=4 (>=5 if sur),2.0
75.87695,male,0.0,COPD,12.0,under $11k,247610.0,white,1.0,<2 mo. follow-up,2.9624023
69.46198,male,0.0,ARF/MOSF w/Sepsis,15.0,$25-$50k,156624.0,white,1.0,no(M2 and SIP pres),2.7578125
42.44998,female,0.0,Lung Cancer,17.0,>$50k,10409.0,white,1.0,<2 mo. follow-up,2.4477539
66.98999,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,501448.0,white,1.0,<2 mo. follow-up,2.8271484
63.36798,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,294992.0,white,0.0,no(M2 and SIP pres),0.0
61.741,male,1.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,337918.0,white,1.0,<2 mo. follow-up,3.7597656
68.23297,male,0.0,MOSF w/Malig,16.0,>$50k,110698.0,white,2.0,adl>=4 (>=5 if sur),2.0
70.04199,male,0.0,Colon Cancer,12.0,$11-$25k,22080.0,white,0.0,no(M2 and SIP pres),0.0
71.36798,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,86494.0,white,1.0,<2 mo. follow-up,2.8989258
43.25497,male,0.0,ARF/MOSF w/Sepsis,15.0,$25-$50k,186516.0,white,1.0,no(M2 and SIP pres),1.1667481
73.90594,male,0.0,Colon Cancer,12.0,under $11k,12433.0,white,1.0,<2 mo. follow-up,2.9345703
59.19498,male,0.0,CHF,12.0,$11-$25k,31431.0,white,4.0,adl>=4 (>=5 if sur),4.0
70.81195,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,213777.0,white,2.0,<2 mo. follow-up,2.0
73.98499,female,0.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,140801.0,black,0.0,adl>=4 (>=5 if sur),0.0
70.41797,female,0.0,Colon Cancer,14.0,under $11k,22418.0,hispanic,1.0,no(M2 and SIP pres),1.1667481
79.93195,female,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,207417.0,white,6.0,<2 mo. follow-up,6.0
66.62299,female,0.0,ARF/MOSF w/Sepsis,13.0,>$50k,53890.0,white,0.0,<2 mo. follow-up,0.0
58.69998,female,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,208373.0,white,1.0,<2 mo. follow-up,1.0
29.26999,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,272792.0,hispanic,1.0,<2 mo. follow-up,3.0727539
36.26797,female,0.0,ARF/MOSF w/Sepsis,21.0,>$50k,262040.0,white,0.0,no(M2 and SIP pres),0.0
97.23999,male,0.0,CHF,12.0,under $11k,19291.0,white,6.0,<2 mo. follow-up,6.0
44.37198,male,0.0,MOSF w/Malig,14.0,>$50k,174634.0,white,0.0,no(M2 and SIP pres),0.0
62.06198,male,0.0,Coma,16.0,>$50k,105947.0,white,1.0,no(M2 and SIP pres),1.8569336
57.97699,male,1.0,MOSF w/Malig,12.0,under $11k,70163.0,white,1.0,<2 mo. follow-up,3.3110352
75.96698,male,0.0,COPD,0.0,$11-$25k,21141.0,white,1.0,<2 mo. follow-up,1.8388672
71.99695,female,0.0,Coma,12.0,under $11k,155313.0,white,1.0,<2 mo. follow-up,2.0209961
31.403,female,0.0,ARF/MOSF w/Sepsis,21.0,>$50k,84726.0,white,1.0,<2 mo. follow-up,2.734375
59.87097,male,0.0,Colon Cancer,12.0,under $11k,20640.0,white,1.0,no(M2 and SIP pres),2.0478516
71.12897,female,0.0,COPD,13.0,$11-$25k,57493.0,white,1.0,Coma or Intub,3.3452148
69.19397,male,0.0,CHF,12.0,under $11k,23046.0,white,4.0,<2 mo. follow-up,4.0
64.02197,male,0.0,Colon Cancer,12.0,under $11k,50669.0,white,1.0,<2 mo. follow-up,3.3325195
71.49097,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,136072.0,black,1.0,<2 mo. follow-up,3.0576172
45.19598,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,481895.0,white,1.0,<2 mo. follow-up,2.9648438
28.627,male,0.0,CHF,10.0,under $11k,30279.0,hispanic,0.0,<2 mo. follow-up,0.0
54.14099,male,0.0,Cirrhosis,12.0,under $11k,13221.0,white,1.0,<2 mo. follow-up,3.0756836
46.04199,female,0.0,Colon Cancer,12.0,under $11k,15981.0,white,1.0,<2 mo. follow-up,1.9838867
71.19495,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,141913.0,white,0.0,no(M2 and SIP pres),0.0
60.25998,female,0.0,Lung Cancer,12.0,under $11k,23886.0,white,1.0,<2 mo. follow-up,3.3417969
68.68695,male,0.0,CHF,12.0,>$50k,7975.0,white,1.0,no(M2 and SIP pres),0.494751
58.741,male,0.0,CHF,8.0,under $11k,33382.0,white,4.0,<2 mo. follow-up,4.0
71.89294,male,0.0,CHF,31.0,>$50k,4750.0,white,1.0,no(M2 and SIP pres),2.1518555
62.34399,male,0.0,CHF,14.0,$25-$50k,145561.0,white,0.0,no(M2 and SIP pres),0.0
60.66299,female,1.0,MOSF w/Malig,12.0,under $11k,233830.0,white,1.0,<2 mo. follow-up,2.8022461
50.40097,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,81871.0,other,1.0,<2 mo. follow-up,1.8530273
51.52399,female,0.0,Lung Cancer,14.0,under $11k,21235.0,white,1.0,<2 mo. follow-up,3.5327148
52.71698,male,1.0,Coma,20.0,>$50k,75660.0,black,0.0,<2 mo. follow-up,0.0
64.64899,female,0.0,Lung Cancer,12.0,$11-$25k,29507.0,white,1.0,no(M2 and SIP pres),2.8950195
73.51996,female,0.0,Colon Cancer,12.0,under $11k,13121.0,white,1.0,<2 mo. follow-up,2.8608398
63.685,female,1.0,Coma,11.0,$11-$25k,207959.0,white,3.0,<2 mo. follow-up,3.0
66.33295,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,933220.0,white,0.0,adl>=4 (>=5 if sur),0.0
38.76498,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,143626.0,white,0.0,<2 mo. follow-up,0.0
65.55798,male,0.0,Cirrhosis,21.0,$11-$25k,9123.0,white,1.0,no(M2 and SIP pres),0.494751
46.56,female,1.0,ARF/MOSF w/Sepsis,12.0,>$50k,149633.0,white,2.0,<2 mo. follow-up,2.0
67.89294,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,269491.0,white,0.0,no(M2 and SIP pres),0.0
58.24197,male,0.0,Colon Cancer,12.0,$11-$25k,11848.0,white,1.0,adl>=4 (>=5 if sur),2.4750977
68.65997,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,71707.0,white,0.0,<2 mo. follow-up,0.0
53.49197,female,0.0,ARF/MOSF w/Sepsis,4.0,under $11k,199060.0,hispanic,5.0,<2 mo. follow-up,5.0
70.71295,female,0.0,Colon Cancer,12.0,under $11k,35262.0,white,1.0,<2 mo. follow-up,2.4257812
68.73895,male,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,58336.0,white,1.0,<2 mo. follow-up,2.9160156
60.87097,male,0.0,Colon Cancer,12.0,under $11k,11670.0,white,1.0,<2 mo. follow-up,3.1943359
77.14398,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,328863.0,white,0.0,adl>=4 (>=5 if sur),0.0
61.92999,male,0.0,Cirrhosis,8.0,under $11k,7500.0,hispanic,1.0,no(M2 and SIP pres),0.494751
43.05798,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,94436.0,white,1.0,no(M2 and SIP pres),2.9926758
54.47998,male,0.0,MOSF w/Malig,12.0,under $11k,19860.0,white,1.0,<2 mo. follow-up,0.494751
80.323,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,51079.0,white,1.0,<2 mo. follow-up,6.4658203
32.28198,male,1.0,MOSF w/Malig,13.0,under $11k,226262.0,hispanic,0.0,<2 mo. follow-up,0.0
44.73099,male,1.0,ARF/MOSF w/Sepsis,18.0,under $11k,800959.0,white,0.0,<2 mo. follow-up,0.0
49.44598,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,53642.0,hispanic,1.0,<2 mo. follow-up,4.1162109
68.07098,male,0.0,ARF/MOSF w/Sepsis,6.0,$11-$25k,96931.0,white,1.0,<2 mo. follow-up,2.5209961
61.71899,male,0.0,CHF,12.0,under $11k,205874.0,white,1.0,<2 mo. follow-up,1.1667481
63.15097,male,1.0,CHF,10.0,$11-$25k,276936.0,white,1.0,<2 mo. follow-up,1.0
58.68597,female,0.0,Lung Cancer,12.0,$11-$25k,18292.0,black,0.0,no(M2 and SIP pres),0.0
65.19598,male,1.0,ARF/MOSF w/Sepsis,18.0,>$50k,25024.0,white,1.0,<2 mo. follow-up,1.0
62.81998,male,0.0,CHF,12.0,$11-$25k,62304.0,white,0.0,<2 mo. follow-up,0.0
90.35699,male,0.0,CHF,5.0,$11-$25k,9994.0,white,1.0,<2 mo. follow-up,0.494751
58.98199,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,267221.0,asian,1.0,no(M2 and SIP pres),1.0
79.896,male,1.0,Coma,12.0,under $11k,73135.0,white,1.0,<2 mo. follow-up,5.7919922
77.74396,female,1.0,CHF,18.0,under $11k,34096.0,white,5.0,<2 mo. follow-up,5.0
72.05194,male,0.0,CHF,12.0,under $11k,27158.0,hispanic,1.0,no(M2 and SIP pres),3.253418
61.49799,female,0.0,Lung Cancer,12.0,under $11k,6507.0,white,0.0,<2 mo. follow-up,0.0
53.26797,female,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,309174.0,white,1.0,<2 mo. follow-up,0.494751
67.16998,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,326479.0,white,1.0,<2 mo. follow-up,2.9189453
86.41998,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,88769.0,white,1.0,<2 mo. follow-up,4.0419922
48.76898,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,318152.0,white,0.0,no(M2 and SIP pres),0.0
41.12799,female,0.0,Coma,14.0,$25-$50k,141917.0,white,7.0,<2 mo. follow-up,7.0
52.31998,male,0.0,CHF,16.0,>$50k,14200.0,white,1.0,no(M2 and SIP pres),2.1513672
71.75397,male,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,198019.0,white,5.0,<2 mo. follow-up,5.0
64.41595,female,1.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,81959.0,hispanic,7.0,<2 mo. follow-up,7.0
56.66299,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,184814.0,white,1.0,<2 mo. follow-up,2.5776367
20.73099,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,25024.0,hispanic,1.0,no(M2 and SIP pres),2.8066406
77.31097,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,318057.0,black,0.0,no(M2 and SIP pres),0.0
56.03299,male,1.0,ARF/MOSF w/Sepsis,18.0,$11-$25k,52414.0,white,0.0,<2 mo. follow-up,0.0
76.42999,male,0.0,Lung Cancer,12.0,>$50k,29862.0,white,0.0,adl>=4 (>=5 if sur),0.0
69.58795,male,0.0,Lung Cancer,16.0,under $11k,9532.0,other,1.0,<2 mo. follow-up,2.340332
70.32996,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,65043.0,white,1.0,<2 mo. follow-up,1.0
68.34497,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,118074.0,white,1.0,<2 mo. follow-up,2.8154297
76.76099,male,0.0,CHF,16.0,$25-$50k,82924.0,white,2.0,<2 mo. follow-up,2.0
58.823,female,0.0,CHF,14.0,$11-$25k,58144.0,white,1.0,<2 mo. follow-up,3.0629883
31.79999,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,285267.0,black,2.0,<2 mo. follow-up,2.0
55.32898,male,0.0,CHF,14.0,>$50k,39435.0,white,0.0,<2 mo. follow-up,0.0
55.35098,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,559190.0,white,1.0,<2 mo. follow-up,3.6201172
40.05197,female,0.0,Colon Cancer,14.0,under $11k,26709.0,asian,1.0,no(M2 and SIP pres),0.494751
33.043,male,0.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,584811.0,hispanic,1.0,no(M2 and SIP pres),3.3510742
75.20898,female,0.0,CHF,14.0,under $11k,16236.0,hispanic,0.0,no(M2 and SIP pres),0.0
59.55099,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,49137.0,white,1.0,<2 mo. follow-up,3.3422852
65.30298,male,1.0,Coma,16.0,under $11k,114803.0,white,1.0,<2 mo. follow-up,1.0
34.31299,male,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,109897.0,white,1.0,<2 mo. follow-up,1.0
68.51495,female,0.0,Coma,16.0,under $11k,269996.0,white,0.0,Coma or Intub,0.0
70.56494,female,0.0,Lung Cancer,20.0,under $11k,13976.0,white,1.0,no(M2 and SIP pres),2.3232422
59.31,female,0.0,Cirrhosis,12.0,under $11k,45458.0,white,1.0,<2 mo. follow-up,4.1611328
35.17297,male,1.0,MOSF w/Malig,12.0,$11-$25k,194955.0,hispanic,0.0,<2 mo. follow-up,0.0
60.39999,male,0.0,MOSF w/Malig,10.0,under $11k,81201.0,white,0.0,adl>=4 (>=5 if sur),0.0
37.96298,male,1.0,ARF/MOSF w/Sepsis,13.0,$11-$25k,569861.0,white,0.0,<2 mo. follow-up,0.0
56.56097,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,690753.0,white,1.0,<2 mo. follow-up,2.6245117
65.29999,female,0.0,Lung Cancer,12.0,under $11k,14436.0,white,1.0,<2 mo. follow-up,3.4487305
84.08496,male,0.0,CHF,16.0,>$50k,29939.0,white,0.0,no(M2 and SIP pres),0.0
71.05798,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,178983.0,white,0.0,no(M2 and SIP pres),0.0
36.33099,male,1.0,Coma,12.0,under $11k,191073.0,white,1.0,<2 mo. follow-up,2.7856445
78.26996,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,155711.0,white,2.0,Coma or Intub,2.0
83.49597,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,174489.0,white,1.0,<2 mo. follow-up,4.5117188
48.58298,male,0.0,CHF,12.0,under $11k,222936.0,white,1.0,<2 mo. follow-up,3.1904297
63.33499,male,0.0,Colon Cancer,16.0,>$50k,43200.0,white,1.0,<2 mo. follow-up,1.0
34.53497,female,1.0,MOSF w/Malig,12.0,under $11k,437598.0,hispanic,1.0,<2 mo. follow-up,4.1826172
53.69699,male,0.0,CHF,12.0,$25-$50k,155191.0,white,0.0,<2 mo. follow-up,0.0
46.89099,female,0.0,CHF,12.0,$11-$25k,108058.0,white,0.0,<2 mo. follow-up,0.0
66.89099,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,223592.0,white,1.0,<2 mo. follow-up,3.0917969
31.17599,female,1.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,558904.0,hispanic,7.0,<2 mo. follow-up,7.0
77.55499,female,0.0,Coma,12.0,under $11k,168806.0,white,3.0,<2 mo. follow-up,3.0
36.70099,female,1.0,Coma,14.0,$11-$25k,139607.0,white,1.0,<2 mo. follow-up,3.4394531
52.24899,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,154101.0,white,0.0,<2 mo. follow-up,0.0
80.23499,female,1.0,MOSF w/Malig,12.0,under $11k,22474.0,other,1.0,<2 mo. follow-up,3.253418
47.49298,male,0.0,Colon Cancer,12.0,>$50k,32899.0,white,0.0,no(M2 and SIP pres),0.0
64.75,male,0.0,ARF/MOSF w/Sepsis,17.0,>$50k,161773.0,white,1.0,<2 mo. follow-up,3.2602539
39.78098,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,87541.0,white,1.0,<2 mo. follow-up,0.494751
79.70398,female,0.0,CHF,14.0,$11-$25k,28450.0,white,0.0,no(M2 and SIP pres),0.0
64.25696,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,52715.0,white,0.0,no(M2 and SIP pres),0.0
48.375,female,0.0,Lung Cancer,19.0,>$50k,19535.0,white,1.0,<2 mo. follow-up,0.494751
52.293,male,0.0,Colon Cancer,18.0,>$50k,24621.0,white,0.0,<2 mo. follow-up,0.0
69.91595,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,269095.0,white,1.0,<2 mo. follow-up,3.4599609
60.20499,female,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,189109.0,asian,0.0,no(M2 and SIP pres),0.0
60.91699,female,0.0,Lung Cancer,16.0,under $11k,13116.0,white,1.0,no(M2 and SIP pres),2.2416992
53.75198,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,345497.0,white,1.0,<2 mo. follow-up,2.5043945
30.53799,male,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,130205.0,white,1.0,<2 mo. follow-up,1.0
73.84796,female,1.0,ARF/MOSF w/Sepsis,18.0,$11-$25k,77209.0,hispanic,1.0,<2 mo. follow-up,4.2841797
63.93399,female,1.0,Colon Cancer,14.0,under $11k,39476.0,white,6.0,<2 mo. follow-up,6.0
71.69299,female,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,164001.0,white,5.0,<2 mo. follow-up,5.0
69.56897,male,0.0,COPD,8.0,under $11k,35691.0,black,5.0,<2 mo. follow-up,5.0
71.12396,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,227604.0,black,1.0,<2 mo. follow-up,3.0898438
65.52997,female,0.0,CHF,8.0,under $11k,32728.0,black,0.0,<2 mo. follow-up,0.0
60.65997,female,0.0,Coma,12.0,under $11k,59110.0,hispanic,1.0,<2 mo. follow-up,2.8994141
75.16199,male,0.0,CHF,20.0,>$50k,43004.0,white,0.0,no(M2 and SIP pres),0.0
60.72299,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,165860.0,white,1.0,<2 mo. follow-up,3.6044922
54.67499,male,0.0,Colon Cancer,16.0,>$50k,32539.0,white,1.0,<2 mo. follow-up,2.9594727
56.00299,male,0.0,CHF,10.0,under $11k,130715.0,white,0.0,<2 mo. follow-up,0.0
58.54599,female,0.0,CHF,12.0,under $11k,11516.0,white,1.0,<2 mo. follow-up,3.3901367
78.27496,female,1.0,Coma,12.0,under $11k,63413.0,asian,1.0,<2 mo. follow-up,2.3945312
79.07495,female,0.0,CHF,12.0,under $11k,14921.0,white,3.0,no(M2 and SIP pres),3.0
71.146,male,0.0,CHF,19.0,>$50k,8208.0,white,1.0,no(M2 and SIP pres),2.4311523
47.20898,male,0.0,CHF,12.0,$25-$50k,120554.0,white,0.0,<2 mo. follow-up,0.0
52.97198,male,0.0,CHF,9.0,$25-$50k,109462.0,white,3.0,SIP>=30,3.0
59.28299,female,1.0,MOSF w/Malig,12.0,$11-$25k,263478.0,black,5.0,<2 mo. follow-up,5.0
66.92096,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,259419.0,hispanic,0.0,<2 mo. follow-up,0.0
44.89297,female,0.0,Colon Cancer,12.0,>$50k,25024.0,white,1.0,<2 mo. follow-up,0.494751
52.323,male,0.0,CHF,14.0,$11-$25k,108450.0,white,1.0,no(M2 and SIP pres),3.3037109
41.60699,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,590617.0,hispanic,1.0,<2 mo. follow-up,2.734375
53.50299,male,0.0,CHF,14.0,>$50k,150298.0,white,0.0,<2 mo. follow-up,0.0
73.24799,male,0.0,Cirrhosis,18.0,under $11k,12039.0,white,1.0,<2 mo. follow-up,2.6772461
74.17395,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,322777.0,white,1.0,<2 mo. follow-up,2.5429688
57.49799,male,1.0,ARF/MOSF w/Sepsis,17.0,>$50k,347324.0,white,0.0,<2 mo. follow-up,0.0
72.20294,male,0.0,Lung Cancer,18.0,$11-$25k,38812.0,white,1.0,no(M2 and SIP pres),3.4951172
57.98199,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,461451.0,asian,1.0,<2 mo. follow-up,2.9321289
54.88599,male,0.0,CHF,14.0,under $11k,39274.0,black,0.0,no(M2 and SIP pres),0.0
31.84099,female,0.0,Colon Cancer,12.0,under $11k,34588.0,white,1.0,<2 mo. follow-up,0.494751
55.43298,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,35245.0,white,6.0,SIP>=30,6.0
86.55396,male,0.0,Coma,7.0,under $11k,139613.0,white,0.0,<2 mo. follow-up,0.0
36.89297,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,556242.0,black,5.0,<2 mo. follow-up,5.0
68.51196,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,265912.0,black,5.0,SIP>=30,5.0
34.23999,female,0.0,CHF,12.0,$11-$25k,120821.0,white,1.0,no(M2 and SIP pres),0.494751
75.28296,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,542002.0,white,1.0,<2 mo. follow-up,2.8818359
77.54999,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,382453.0,white,1.0,<2 mo. follow-up,2.7924805
30.97899,male,0.0,Coma,12.0,under $11k,229100.0,hispanic,0.0,no(M2 and SIP pres),0.0
63.63898,female,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,902281.0,hispanic,1.0,<2 mo. follow-up,3.065918
46.935,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,160986.0,white,1.0,<2 mo. follow-up,4.4863281
45.27597,female,0.0,CHF,12.0,under $11k,76227.0,black,1.0,<2 mo. follow-up,3.1689453
39.86899,male,1.0,MOSF w/Malig,12.0,under $11k,497787.0,white,1.0,<2 mo. follow-up,2.5600586
65.73596,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,195264.0,white,1.0,no(M2 and SIP pres),3.4580078
49.34198,female,1.0,Coma,22.0,$25-$50k,201340.0,hispanic,5.0,<2 mo. follow-up,5.0
59.35397,female,0.0,Colon Cancer,18.0,under $11k,30984.0,white,0.0,no(M2 and SIP pres),0.0
73.52795,female,0.0,COPD,12.0,under $11k,5988.0,white,1.0,<2 mo. follow-up,2.5693359
71.18695,male,1.0,ARF/MOSF w/Sepsis,20.0,>$50k,201762.0,asian,1.0,<2 mo. follow-up,1.0
60.22198,male,0.0,CHF,12.0,under $11k,53341.0,black,1.0,<2 mo. follow-up,3.3642578
75.29895,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,361878.0,white,0.0,adl>=4 (>=5 if sur),0.0
66.53497,male,0.0,CHF,12.0,under $11k,22157.0,asian,1.0,<2 mo. follow-up,2.8154297
20.29599,female,1.0,MOSF w/Malig,12.0,under $11k,355578.0,hispanic,1.0,<2 mo. follow-up,1.0
68.82098,female,0.0,COPD,12.0,under $11k,21750.0,white,6.0,<2 mo. follow-up,6.0
60.29797,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,51183.0,white,1.0,<2 mo. follow-up,2.7836914
87.35394,female,0.0,CHF,12.0,under $11k,11602.0,white,1.0,no(M2 and SIP pres),5.25
58.32999,female,0.0,MOSF w/Malig,8.0,under $11k,57209.0,white,6.0,adl>=4 (>=5 if sur),6.0
79.12897,female,0.0,COPD,13.0,under $11k,25770.0,white,1.0,<2 mo. follow-up,1.8388672
41.09799,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,43026.0,hispanic,0.0,<2 mo. follow-up,0.0
72.13995,male,1.0,Lung Cancer,12.0,$11-$25k,30670.0,black,1.0,<2 mo. follow-up,1.0
40.74698,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,310749.0,white,0.0,adl>=4 (>=5 if sur),0.0
66.67798,male,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,192030.0,hispanic,1.0,<2 mo. follow-up,1.0
32.008,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,348165.0,hispanic,1.0,<2 mo. follow-up,3.8959961
62.32397,female,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,916502.0,white,3.0,adl>=4 (>=5 if sur),3.0
54.96799,male,0.0,MOSF w/Malig,14.0,under $11k,347848.0,white,1.0,SIP>=30,1.0
40.82098,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,58518.0,white,0.0,no(M2 and SIP pres),0.0
69.48096,female,0.0,Colon Cancer,11.0,under $11k,30978.0,hispanic,0.0,<2 mo. follow-up,0.0
58.793,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,234692.0,white,1.0,<2 mo. follow-up,1.9633789
52.22699,female,0.0,Coma,7.0,under $11k,192402.0,white,1.0,no(M2 and SIP pres),2.2666016
94.54895,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,88695.0,black,6.0,<2 mo. follow-up,6.0
49.70599,male,0.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,910119.0,hispanic,0.0,no(M2 and SIP pres),0.0
77.06494,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,26899.0,white,1.0,<2 mo. follow-up,5.4121094
65.95996,male,1.0,MOSF w/Malig,12.0,under $11k,68139.0,white,6.0,<2 mo. follow-up,6.0
42.82797,male,0.0,ARF/MOSF w/Sepsis,20.0,>$50k,85800.0,white,0.0,no(M2 and SIP pres),0.0
86.71594,female,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,25502.0,white,0.0,no(M2 and SIP pres),0.0
68.07397,male,0.0,COPD,8.0,$11-$25k,66904.0,white,6.0,<2 mo. follow-up,6.0
50.56299,male,0.0,Coma,16.0,>$50k,232891.0,white,1.0,<2 mo. follow-up,2.1708984
60.54498,male,1.0,MOSF w/Malig,16.0,>$50k,239928.0,white,4.0,<2 mo. follow-up,4.0
45.81497,female,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,1161504.0,hispanic,0.0,no(M2 and SIP pres),0.0
81.57397,male,0.0,CHF,16.0,$25-$50k,19878.0,white,1.0,adl>=4 (>=5 if sur),1.8388672
83.35895,female,1.0,Coma,12.0,$25-$50k,22522.0,white,7.0,<2 mo. follow-up,7.0
79.65796,male,0.0,Lung Cancer,11.0,under $11k,10991.0,black,5.0,adl>=4 (>=5 if sur),5.0
18.502,female,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,327791.0,hispanic,1.0,SIP>=30,2.4863281
62.52197,male,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,279274.0,hispanic,7.0,<2 mo. follow-up,7.0
66.15198,male,0.0,CHF,12.0,$11-$25k,80163.0,black,4.0,adl>=4 (>=5 if sur),4.0
86.37097,male,0.0,CHF,12.0,under $11k,9019.0,white,1.0,<2 mo. follow-up,5.9873047
59.31,female,0.0,MOSF w/Malig,14.0,>$50k,63881.0,white,5.0,SIP>=30,5.0
68.34198,male,1.0,COPD,8.0,under $11k,25024.0,white,1.0,<2 mo. follow-up,1.0
26.14099,male,1.0,MOSF w/Malig,14.0,under $11k,87952.0,hispanic,0.0,<2 mo. follow-up,0.0
51.26099,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,230224.0,white,1.0,<2 mo. follow-up,5.6826172
67.09399,female,0.0,COPD,14.0,under $11k,433012.0,white,4.0,<2 mo. follow-up,4.0
60.26599,female,0.0,CHF,12.0,$25-$50k,13646.0,black,1.0,<2 mo. follow-up,0.494751
72.375,female,0.0,COPD,18.0,>$50k,53913.0,white,1.0,<2 mo. follow-up,5.0234375
47.60599,female,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,174923.0,white,0.0,<2 mo. follow-up,0.0
65.25397,female,0.0,Coma,18.0,$25-$50k,149859.0,white,0.0,adl>=4 (>=5 if sur),0.0
54.103,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,467237.0,white,0.0,<2 mo. follow-up,0.0
65.71698,female,1.0,ARF/MOSF w/Sepsis,18.0,>$50k,460259.0,asian,1.0,<2 mo. follow-up,1.0
83.06598,female,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,118843.0,black,1.0,<2 mo. follow-up,1.0
85.45099,male,1.0,ARF/MOSF w/Sepsis,20.0,under $11k,65216.0,white,1.0,<2 mo. follow-up,4.5664062
74.37396,male,0.0,CHF,6.0,$11-$25k,23855.0,white,0.0,no(M2 and SIP pres),0.0
67.81696,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,56904.0,white,7.0,<2 mo. follow-up,7.0
76.099,female,0.0,COPD,19.0,$11-$25k,53633.0,white,0.0,no(M2 and SIP pres),0.0
63.978,female,0.0,Colon Cancer,13.0,$11-$25k,21967.0,white,1.0,<2 mo. follow-up,1.1667481
80.50397,male,1.0,Coma,12.0,under $11k,23637.0,white,1.0,<2 mo. follow-up,4.5996094
60.69299,male,0.0,CHF,15.0,under $11k,8561.0,white,0.0,no(M2 and SIP pres),0.0
72.01898,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,136226.0,white,0.0,<2 mo. follow-up,0.0
54.73798,male,0.0,CHF,12.0,under $11k,156205.0,white,1.0,no(M2 and SIP pres),1.0
45.85898,female,0.0,Coma,12.0,under $11k,502025.0,white,0.0,adl>=4 (>=5 if sur),0.0
63.53998,male,1.0,ARF/MOSF w/Sepsis,10.0,$25-$50k,647638.0,hispanic,0.0,<2 mo. follow-up,0.0
84.70599,female,1.0,ARF/MOSF w/Sepsis,19.0,>$50k,26000.0,white,1.0,<2 mo. follow-up,5.8369141
63.017,male,0.0,Lung Cancer,27.0,>$50k,26494.0,white,1.0,<2 mo. follow-up,0.494751
30.741,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,364515.0,black,0.0,no(M2 and SIP pres),0.0
29.10899,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,44220.0,white,1.0,<2 mo. follow-up,3.0449219
59.31,male,0.0,Colon Cancer,15.0,>$50k,25024.0,white,1.0,no(M2 and SIP pres),1.8730469
49.76898,female,1.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,25024.0,white,1.0,adl>=4 (>=5 if sur),3.3203125
47.978,male,0.0,CHF,12.0,under $11k,23716.0,white,1.0,<2 mo. follow-up,2.3818359
65.17999,male,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,218454.0,white,1.0,<2 mo. follow-up,1.0
69.92694,male,0.0,ARF/MOSF w/Sepsis,13.0,under $11k,94568.0,white,1.0,SIP>=30,3.5058594
66.57599,male,1.0,Colon Cancer,12.0,$25-$50k,4971.0,white,0.0,<2 mo. follow-up,0.0
42.23999,male,1.0,Cirrhosis,12.0,under $11k,16101.0,white,0.0,<2 mo. follow-up,0.0
61.13599,male,0.0,Colon Cancer,12.0,under $11k,7688.0,white,1.0,<2 mo. follow-up,1.0
71.18994,male,0.0,COPD,8.0,under $11k,3214.0,black,1.0,SIP>=30,2.578125
59.59799,male,0.0,Lung Cancer,15.0,under $11k,7063.0,white,1.0,<2 mo. follow-up,3.402832
65.81,male,0.0,CHF,15.0,under $11k,7104.0,black,0.0,no(M2 and SIP pres),0.0
67.88495,female,0.0,CHF,7.0,under $11k,7143.0,white,1.0,<2 mo. follow-up,1.1668997
42.70499,male,0.0,Lung Cancer,14.0,$11-$25k,6662.0,white,6.0,<2 mo. follow-up,6.0
79.35095,male,0.0,CHF,7.0,under $11k,10774.0,white,1.0,<2 mo. follow-up,1.0
34.14398,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,44464.0,white,1.0,<2 mo. follow-up,4.1367188
85.12799,female,0.0,COPD,10.0,under $11k,11331.0,hispanic,1.0,<2 mo. follow-up,1.8389997
80.33398,male,0.0,CHF,12.0,under $11k,15306.0,white,1.0,<2 mo. follow-up,2.8393555
62.84497,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,79451.0,white,1.0,<2 mo. follow-up,2.3706055
56.91199,male,0.0,Lung Cancer,15.0,$25-$50k,13620.0,white,2.0,<2 mo. follow-up,2.0
44.47897,female,0.0,Lung Cancer,13.0,$25-$50k,25121.0,white,1.0,adl>=4 (>=5 if sur),3.9077148
29.13599,male,0.0,MOSF w/Malig,18.0,under $11k,20860.0,white,0.0,<2 mo. follow-up,0.0
82.06396,male,0.0,CHF,12.0,under $11k,3265.0,white,0.0,no(M2 and SIP pres),0.0
54.63699,male,0.0,CHF,12.0,under $11k,10749.0,white,1.0,<2 mo. follow-up,2.4262695
90.89099,female,0.0,Colon Cancer,11.0,under $11k,13201.0,other,2.0,<2 mo. follow-up,2.0
70.80396,female,0.0,Lung Cancer,12.0,under $11k,13253.0,white,1.0,<2 mo. follow-up,1.0
82.11896,female,0.0,CHF,14.0,under $11k,3189.0,white,1.0,no(M2 and SIP pres),3.9838867
30.03999,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,17692.0,black,1.0,adl>=4 (>=5 if sur),2.2026367
83.65796,female,0.0,CHF,16.0,under $11k,6931.0,white,3.0,no(M2 and SIP pres),3.0
77.66699,male,1.0,CHF,15.0,under $11k,16398.0,white,1.0,<2 mo. follow-up,2.9882812
93.75494,female,0.0,CHF,12.0,under $11k,10622.0,white,7.0,adl>=4 (>=5 if sur),7.0
63.48499,female,0.0,Lung Cancer,12.0,$11-$25k,22166.0,black,1.0,<2 mo. follow-up,1.0
58.63898,male,0.0,CHF,12.0,$25-$50k,17714.0,white,0.0,no(M2 and SIP pres),0.0
84.10095,female,0.0,ARF/MOSF w/Sepsis,8.0,under $11k,42058.0,white,6.0,no(M2 and SIP pres),6.0
51.52399,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,9931.0,white,1.0,<2 mo. follow-up,2.4150391
95.56494,female,0.0,CHF,8.0,under $11k,4417.0,white,2.0,adl>=4 (>=5 if sur),2.0
55.42499,female,0.0,Lung Cancer,13.0,under $11k,10085.0,white,1.0,no(M2 and SIP pres),3.2207031
53.42099,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,14593.0,white,1.0,<2 mo. follow-up,0.4947999
84.33099,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,17909.0,white,1.0,no(M2 and SIP pres),0.4947999
57.23199,female,0.0,Lung Cancer,9.0,$11-$25k,4652.0,asian,0.0,no(M2 and SIP pres),0.0
46.74597,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,94302.0,white,0.0,adl>=4 (>=5 if sur),0.0
87.20099,female,0.0,CHF,12.0,under $11k,21775.0,white,0.0,<2 mo. follow-up,0.0
80.29596,female,1.0,COPD,10.0,under $11k,11442.0,white,2.0,<2 mo. follow-up,2.0
78.26099,male,0.0,COPD,12.0,under $11k,13574.0,white,1.0,no(M2 and SIP pres),1.8389997
75.99695,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,81626.0,white,1.0,adl>=4 (>=5 if sur),1.1668997
60.86798,male,0.0,ARF/MOSF w/Sepsis,4.0,under $11k,259334.0,white,2.0,<2 mo. follow-up,2.0
57.11697,male,0.0,Lung Cancer,12.0,>$50k,8150.0,white,2.0,<2 mo. follow-up,2.0
67.38898,male,0.0,COPD,12.0,under $11k,6146.0,white,1.0,<2 mo. follow-up,4.5273972
71.90094,male,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,27244.0,white,0.0,no(M2 and SIP pres),0.0
21.20999,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,6719.0,white,0.0,no(M2 and SIP pres),0.0
53.67297,male,1.0,Coma,17.0,$11-$25k,6521.0,black,1.0,<2 mo. follow-up,2.2983398
71.45197,female,0.0,CHF,10.0,under $11k,4995.0,black,1.0,no(M2 and SIP pres),1.8389997
76.15094,male,1.0,Lung Cancer,12.0,under $11k,16484.0,white,4.0,<2 mo. follow-up,4.0
64.99396,male,0.0,CHF,17.0,$11-$25k,7826.0,white,0.0,SIP>=30,0.0
37.81,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,57170.0,white,0.0,<2 mo. follow-up,0.0
42.01498,male,0.0,ARF/MOSF w/Sepsis,17.0,under $11k,9923.0,white,1.0,no(M2 and SIP pres),0.4947999
62.84698,male,1.0,MOSF w/Malig,14.0,under $11k,46029.0,white,1.0,<2 mo. follow-up,0.4947999
74.77899,male,0.0,CHF,9.0,under $11k,10348.0,white,0.0,no(M2 and SIP pres),0.0
79.67694,female,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,27784.0,white,5.0,<2 mo. follow-up,5.0
24.78,female,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,20322.0,black,4.0,<2 mo. follow-up,4.0
72.95294,male,0.0,Lung Cancer,14.0,$11-$25k,13340.0,white,2.0,<2 mo. follow-up,2.0
31.56699,male,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,46374.0,white,1.0,<2 mo. follow-up,1.0
56.961,male,0.0,Cirrhosis,16.0,$25-$50k,19128.0,white,1.0,no(M2 and SIP pres),0.4947999
85.31995,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,10257.0,white,4.0,<2 mo. follow-up,4.0
65.70599,female,1.0,Colon Cancer,12.0,under $11k,2924.0,white,0.0,<2 mo. follow-up,0.0
87.19196,female,1.0,ARF/MOSF w/Sepsis,9.0,under $11k,15135.0,white,6.0,<2 mo. follow-up,6.0
73.35199,male,0.0,Cirrhosis,12.0,under $11k,16690.0,white,1.0,no(M2 and SIP pres),1.0
88.89795,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,15777.0,white,6.0,<2 mo. follow-up,6.0
68.26294,male,0.0,Lung Cancer,12.0,under $11k,5599.0,white,1.0,<2 mo. follow-up,2.5110989
72.47595,male,0.0,CHF,8.0,under $11k,55572.0,white,0.0,<2 mo. follow-up,0.0
64.54999,female,0.0,Lung Cancer,15.0,$11-$25k,10349.0,white,1.0,<2 mo. follow-up,3.1831989
77.32495,male,0.0,MOSF w/Malig,16.0,>$50k,12638.0,white,1.0,<2 mo. follow-up,0.4947999
73.91095,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,46732.0,white,1.0,<2 mo. follow-up,2.5981445
61.43997,female,0.0,Cirrhosis,11.0,under $11k,9601.0,black,3.0,no(M2 and SIP pres),3.0
74.33795,male,0.0,COPD,12.0,under $11k,6024.0,white,1.0,adl>=4 (>=5 if sur),3.0766602
51.461,female,0.0,Cirrhosis,8.0,under $11k,30321.0,white,1.0,SIP>=30,3.5332031
61.98499,male,0.0,Colon Cancer,20.0,$11-$25k,3503.0,white,2.0,no(M2 and SIP pres),2.0
89.36597,male,0.0,CHF,12.0,under $11k,4119.0,white,1.0,adl>=4 (>=5 if sur),4.5273972
85.85596,male,0.0,COPD,12.0,under $11k,10144.0,white,3.0,adl>=4 (>=5 if sur),3.0
83.69299,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,8571.0,white,1.0,adl>=4 (>=5 if sur),4.7822266
50.36798,male,0.0,Lung Cancer,20.0,>$50k,10558.0,white,0.0,no(M2 and SIP pres),0.0
69.435,male,0.0,CHF,12.0,>$50k,2722.0,white,1.0,no(M2 and SIP pres),1.9543457
81.57196,female,1.0,CHF,12.0,under $11k,42506.0,white,1.0,<2 mo. follow-up,3.2646484
75.16498,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,19845.0,white,1.0,<2 mo. follow-up,3.3955078
28.411,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,15781.0,white,1.0,no(M2 and SIP pres),2.3706055
75.80298,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,20469.0,white,1.0,adl>=4 (>=5 if sur),3.3759766
40.77798,male,0.0,ARF/MOSF w/Sepsis,17.0,$11-$25k,15497.0,white,0.0,<2 mo. follow-up,0.0
63.10699,male,0.0,CHF,12.0,under $11k,40364.0,white,1.0,no(M2 and SIP pres),1.8389997
81.40997,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,15727.0,white,1.0,adl>=4 (>=5 if sur),2.9394531
83.51495,female,1.0,Coma,12.0,under $11k,21857.0,white,1.0,<2 mo. follow-up,1.0
46.27798,male,0.0,Lung Cancer,16.0,$25-$50k,6112.0,white,0.0,no(M2 and SIP pres),0.0
65.06494,male,0.0,Lung Cancer,12.0,$11-$25k,9324.0,white,1.0,no(M2 and SIP pres),0.4947999
71.84399,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,247553.0,white,5.0,adl>=4 (>=5 if sur),5.0
57.85599,female,0.0,Lung Cancer,11.0,$11-$25k,6191.0,black,1.0,no(M2 and SIP pres),1.9558106
91.35394,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,9472.0,black,1.0,adl>=4 (>=5 if sur),6.2675781
84.32599,male,0.0,CHF,12.0,under $11k,8797.0,white,0.0,no(M2 and SIP pres),0.0
69.74097,male,0.0,Colon Cancer,12.0,$11-$25k,6911.0,white,0.0,<2 mo. follow-up,0.0
77.75995,male,1.0,CHF,12.0,under $11k,35881.0,white,3.0,<2 mo. follow-up,3.0
50.59,male,0.0,ARF/MOSF w/Sepsis,17.0,>$50k,49205.0,white,0.0,SIP>=30,0.0
73.336,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,50127.0,white,4.0,adl>=4 (>=5 if sur),4.0
82.60394,female,0.0,ARF/MOSF w/Sepsis,8.0,under $11k,38687.0,white,0.0,no(M2 and SIP pres),0.0
52.49597,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,12827.0,white,0.0,no(M2 and SIP pres),0.0
82.34094,male,1.0,Cirrhosis,4.0,under $11k,4338.0,white,1.0,<2 mo. follow-up,2.7255859
39.896,male,0.0,Cirrhosis,12.0,under $11k,5221.0,white,1.0,<2 mo. follow-up,1.8635254
70.83899,male,0.0,COPD,8.0,under $11k,15529.0,white,1.0,SIP>=30,0.4947999
66.61694,male,0.0,Colon Cancer,12.0,under $11k,21410.0,white,1.0,<2 mo. follow-up,1.0
45.06998,female,0.0,Lung Cancer,16.0,$25-$50k,11897.0,white,2.0,no(M2 and SIP pres),2.0
54.28299,female,0.0,ARF/MOSF w/Sepsis,10.0,$25-$50k,15118.0,white,2.0,<2 mo. follow-up,2.0
68.44897,male,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,357428.0,white,1.0,adl>=4 (>=5 if sur),1.0
87.09698,female,0.0,CHF,12.0,under $11k,42836.0,white,2.0,no(M2 and SIP pres),2.0
90.81195,female,0.0,CHF,12.0,under $11k,40846.0,white,0.0,adl>=4 (>=5 if sur),0.0
46.72699,female,0.0,Cirrhosis,9.0,under $11k,2666.0,white,1.0,no(M2 and SIP pres),1.1668997
65.20197,male,1.0,Cirrhosis,14.0,under $11k,14254.0,white,4.0,<2 mo. follow-up,4.0
48.94998,male,0.0,CHF,12.0,$25-$50k,34640.0,white,0.0,no(M2 and SIP pres),0.0
80.70599,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,9764.0,white,5.0,<2 mo. follow-up,5.0
60.31497,female,0.0,CHF,10.0,under $11k,26095.0,black,0.0,<2 mo. follow-up,0.0
80.64099,female,0.0,COPD,12.0,under $11k,8667.0,white,1.0,<2 mo. follow-up,4.3330078
67.47998,female,0.0,Colon Cancer,11.0,under $11k,7020.0,white,1.0,no(M2 and SIP pres),1.0
77.758,male,1.0,ARF/MOSF w/Sepsis,16.0,$11-$25k,17610.0,white,5.0,<2 mo. follow-up,5.0
36.27698,female,0.0,ARF/MOSF w/Sepsis,11.0,under $11k,20110.0,white,0.0,no(M2 and SIP pres),0.0
80.75,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,25860.0,white,2.0,no(M2 and SIP pres),2.0
68.323,female,0.0,COPD,12.0,under $11k,33471.0,white,1.0,no(M2 and SIP pres),1.0
71.63599,female,0.0,COPD,7.0,under $11k,10530.0,white,4.0,no(M2 and SIP pres),4.0
70.76495,male,0.0,COPD,11.0,$11-$25k,8711.0,white,0.0,no(M2 and SIP pres),0.0
89.487,female,0.0,COPD,12.0,under $11k,3584.0,white,0.0,no(M2 and SIP pres),0.0
55.80298,female,0.0,COPD,12.0,under $11k,3057.0,white,6.0,adl>=4 (>=5 if sur),6.0
72.59698,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,17419.0,white,4.0,adl>=4 (>=5 if sur),4.0
79.62994,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,11895.0,white,3.0,no(M2 and SIP pres),3.0
71.54297,female,1.0,MOSF w/Malig,12.0,under $11k,31316.0,white,5.0,<2 mo. follow-up,5.0
42.78998,female,1.0,MOSF w/Malig,12.0,under $11k,19185.0,white,1.0,<2 mo. follow-up,2.5180664
73.91895,female,0.0,CHF,7.0,under $11k,4780.0,white,5.0,<2 mo. follow-up,5.0
67.37598,male,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,21696.0,white,0.0,no(M2 and SIP pres),0.0
77.06995,female,0.0,CHF,10.0,under $11k,3634.0,white,1.0,<2 mo. follow-up,1.0
72.10095,male,0.0,CHF,12.0,under $11k,24014.0,white,1.0,no(M2 and SIP pres),1.0
96.422,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,17637.0,white,1.0,<2 mo. follow-up,4.890625
70.034,female,0.0,CHF,8.0,$11-$25k,69542.0,white,1.0,no(M2 and SIP pres),1.0
65.51697,male,0.0,Lung Cancer,12.0,under $11k,8659.0,white,0.0,no(M2 and SIP pres),0.0
91.67694,male,1.0,ARF/MOSF w/Sepsis,14.0,under $11k,14107.0,white,0.0,<2 mo. follow-up,0.0
36.53699,male,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,117256.0,white,1.0,adl>=4 (>=5 if sur),1.0
81.284,female,0.0,CHF,12.0,>$50k,5025.0,white,0.0,no(M2 and SIP pres),0.0
71.16498,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,17918.0,white,0.0,no(M2 and SIP pres),0.0
62.64499,female,0.0,Colon Cancer,12.0,under $11k,9016.0,white,7.0,<2 mo. follow-up,7.0
39.31299,female,0.0,MOSF w/Malig,12.0,under $11k,24390.0,white,0.0,no(M2 and SIP pres),0.0
77.24799,female,1.0,Lung Cancer,12.0,under $11k,41185.0,white,0.0,<2 mo. follow-up,0.0
41.02698,male,1.0,Cirrhosis,18.0,>$50k,57856.0,white,1.0,<2 mo. follow-up,1.1668997
77.96594,female,0.0,COPD,15.0,$11-$25k,14553.0,white,3.0,SIP>=30,3.0
62.63898,male,0.0,Lung Cancer,16.0,$11-$25k,26939.0,black,0.0,adl>=4 (>=5 if sur),0.0
68.27698,male,0.0,Colon Cancer,16.0,under $11k,5046.0,white,2.0,no(M2 and SIP pres),2.0
68.64099,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,50918.0,white,0.0,no(M2 and SIP pres),0.0
64.43298,male,1.0,COPD,20.0,under $11k,5135.0,white,0.0,<2 mo. follow-up,0.0
86.65295,male,0.0,CHF,12.0,under $11k,4723.0,white,0.0,no(M2 and SIP pres),0.0
67.409,male,0.0,CHF,12.0,under $11k,9601.0,white,1.0,<2 mo. follow-up,2.5053711
71.79999,male,0.0,ARF/MOSF w/Sepsis,21.0,under $11k,31459.0,white,0.0,no(M2 and SIP pres),0.0
84.85999,male,0.0,COPD,10.0,under $11k,8570.0,black,1.0,no(M2 and SIP pres),2.5110989
76.06,male,1.0,COPD,14.0,under $11k,35239.0,white,0.0,<2 mo. follow-up,0.0
78.672,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,10477.0,white,5.0,adl>=4 (>=5 if sur),5.0
30.55199,male,0.0,Cirrhosis,12.0,under $11k,76135.0,black,0.0,no(M2 and SIP pres),0.0
50.396,female,0.0,COPD,5.0,under $11k,4530.0,black,1.0,no(M2 and SIP pres),1.0
56.00299,female,0.0,Lung Cancer,12.0,>$50k,10614.0,white,1.0,no(M2 and SIP pres),0.4947999
76.33698,female,0.0,COPD,8.0,under $11k,9457.0,white,1.0,no(M2 and SIP pres),3.0761719
59.21399,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,33298.0,black,1.0,<2 mo. follow-up,1.0
66.34595,female,0.0,COPD,11.0,under $11k,4751.0,white,3.0,no(M2 and SIP pres),3.0
61.48099,female,0.0,CHF,4.0,$11-$25k,21507.0,white,5.0,no(M2 and SIP pres),5.0
63.27399,male,0.0,CHF,10.0,$11-$25k,7418.0,white,5.0,no(M2 and SIP pres),5.0
79.64996,male,0.0,COPD,15.0,under $11k,4776.0,white,4.0,no(M2 and SIP pres),4.0
62.51599,female,0.0,COPD,12.0,under $11k,134421.0,black,0.0,adl>=4 (>=5 if sur),0.0
57.60999,male,0.0,Lung Cancer,12.0,$25-$50k,14797.0,white,0.0,no(M2 and SIP pres),0.0
85.50598,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,24531.0,white,0.0,<2 mo. follow-up,0.0
68.29297,male,0.0,CHF,15.0,$11-$25k,4825.0,white,0.0,<2 mo. follow-up,0.0
88.28699,female,0.0,COPD,10.0,under $11k,7485.0,white,6.0,SIP>=30,6.0
80.32898,female,0.0,Colon Cancer,10.0,under $11k,6066.0,white,0.0,adl>=4 (>=5 if sur),0.0
25.92999,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,31526.0,white,1.0,no(M2 and SIP pres),0.4947999
85.15796,female,0.0,CHF,12.0,under $11k,5272.0,white,1.0,<2 mo. follow-up,3.1811523
40.375,male,0.0,COPD,10.0,under $11k,3558.0,hispanic,1.0,SIP>=30,1.0
65.53595,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,38225.0,white,3.0,SIP>=30,3.0
59.35098,female,0.0,Lung Cancer,16.0,>$50k,14557.0,white,1.0,<2 mo. follow-up,3.0551758
69.95996,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,33506.0,white,0.0,no(M2 and SIP pres),0.0
83.35394,male,0.0,CHF,16.0,under $11k,6006.0,white,3.0,no(M2 and SIP pres),3.0
62.17697,female,0.0,CHF,6.0,under $11k,5648.0,black,1.0,no(M2 and SIP pres),4.5273972
64.63196,female,0.0,CHF,12.0,under $11k,14478.0,white,1.0,<2 mo. follow-up,1.0
77.98798,female,1.0,COPD,12.0,under $11k,28654.0,white,0.0,<2 mo. follow-up,0.0
25.782,male,0.0,ARF/MOSF w/Sepsis,18.0,$25-$50k,9020.0,other,1.0,no(M2 and SIP pres),1.0
92.95599,female,1.0,COPD,8.0,under $11k,16444.0,white,2.0,<2 mo. follow-up,2.0
81.56897,female,0.0,CHF,12.0,$25-$50k,6537.0,white,0.0,no(M2 and SIP pres),0.0
65.06195,female,0.0,Lung Cancer,12.0,under $11k,3867.0,white,1.0,no(M2 and SIP pres),2.2426758
72.047,female,0.0,Colon Cancer,16.0,$25-$50k,7914.0,black,0.0,no(M2 and SIP pres),0.0
77.97894,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,8999.0,white,1.0,no(M2 and SIP pres),1.0
70.44995,male,1.0,Coma,20.0,under $11k,25671.0,white,0.0,<2 mo. follow-up,0.0
67.95099,female,1.0,Colon Cancer,12.0,under $11k,33734.0,white,1.0,<2 mo. follow-up,1.1668997
75.33197,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,180272.0,white,1.0,<2 mo. follow-up,1.0
76.646,female,0.0,COPD,16.0,>$50k,12745.0,white,7.0,<2 mo. follow-up,7.0
81.28699,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,12674.0,white,1.0,<2 mo. follow-up,5.4804688
93.91394,female,1.0,COPD,12.0,under $11k,13570.0,white,4.0,<2 mo. follow-up,4.0
80.72296,female,0.0,COPD,12.0,under $11k,7633.0,white,4.0,adl>=4 (>=5 if sur),4.0
60.35599,male,1.0,Colon Cancer,12.0,under $11k,13863.0,white,1.0,<2 mo. follow-up,2.2954102
60.34497,male,1.0,ARF/MOSF w/Sepsis,11.0,$11-$25k,86807.0,white,4.0,<2 mo. follow-up,4.0
93.77399,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,15581.0,white,1.0,<2 mo. follow-up,5.1074219
70.82794,female,0.0,MOSF w/Malig,12.0,under $11k,14896.0,white,1.0,<2 mo. follow-up,2.4926758
69.76898,female,1.0,Lung Cancer,12.0,under $11k,9542.0,white,0.0,<2 mo. follow-up,0.0
46.349,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,100904.0,white,1.0,<2 mo. follow-up,2.762207
61.14697,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,23298.0,white,1.0,<2 mo. follow-up,2.2729492
51.13998,male,0.0,ARF/MOSF w/Sepsis,6.0,under $11k,7438.0,white,0.0,adl>=4 (>=5 if sur),0.0
59.69598,male,0.0,Colon Cancer,12.0,under $11k,40846.0,white,1.0,<2 mo. follow-up,2.3588867
73.31995,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,28079.0,white,1.0,<2 mo. follow-up,2.4248047
35.76199,male,0.0,ARF/MOSF w/Sepsis,15.0,$11-$25k,14027.0,white,1.0,no(M2 and SIP pres),1.8389997
77.35797,female,0.0,COPD,12.0,under $11k,28820.0,white,1.0,no(M2 and SIP pres),3.2709961
83.57794,male,1.0,ARF/MOSF w/Sepsis,0.0,under $11k,65318.0,white,1.0,<2 mo. follow-up,1.0
82.80096,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,35464.0,white,1.0,<2 mo. follow-up,0.4947999
58.82498,male,0.0,Lung Cancer,12.0,under $11k,5670.0,black,1.0,no(M2 and SIP pres),0.4947999
77.56097,female,0.0,CHF,12.0,under $11k,5333.0,hispanic,1.0,no(M2 and SIP pres),0.4947999
53.70297,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,91986.0,white,1.0,SIP>=30,1.0
78.43695,female,1.0,MOSF w/Malig,14.0,$25-$50k,17635.0,white,0.0,<2 mo. follow-up,0.0
52.68997,male,0.0,COPD,12.0,$25-$50k,11201.0,white,1.0,no(M2 and SIP pres),1.0
44.30399,female,1.0,Cirrhosis,12.0,under $11k,56112.0,black,0.0,<2 mo. follow-up,0.0
82.09399,male,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,15079.0,white,0.0,<2 mo. follow-up,0.0
44.48199,female,0.0,CHF,12.0,$25-$50k,13559.0,white,1.0,no(M2 and SIP pres),1.0
75.086,male,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,38936.0,white,0.0,<2 mo. follow-up,0.0
63.93399,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,39951.0,white,1.0,<2 mo. follow-up,0.4947999
73.336,male,1.0,Lung Cancer,8.0,under $11k,6528.0,white,0.0,<2 mo. follow-up,0.0
57.21799,male,0.0,Lung Cancer,7.0,under $11k,6209.0,white,0.0,no(M2 and SIP pres),0.0
64.58899,male,0.0,CHF,12.0,under $11k,20287.0,white,1.0,<2 mo. follow-up,2.5820312
73.73297,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,35954.0,white,0.0,no(M2 and SIP pres),0.0
61.01599,male,0.0,MOSF w/Malig,14.0,$11-$25k,43814.0,white,0.0,no(M2 and SIP pres),0.0
43.26898,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,11032.0,white,1.0,<2 mo. follow-up,2.1391602
61.63397,male,0.0,CHF,8.0,under $11k,13547.0,white,0.0,no(M2 and SIP pres),0.0
83.30194,male,0.0,CHF,12.0,under $11k,3822.0,white,1.0,no(M2 and SIP pres),0.4947999
83.01996,female,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,21266.0,white,0.0,no(M2 and SIP pres),0.0
49.28699,female,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,106935.0,black,2.0,SIP>=30,2.0
65.46198,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,68682.0,white,1.0,<2 mo. follow-up,1.0
75.63898,male,0.0,CHF,7.0,$25-$50k,5284.0,white,1.0,no(M2 and SIP pres),0.4947999
54.43698,male,0.0,CHF,14.0,$25-$50k,12503.0,white,1.0,no(M2 and SIP pres),0.4947999
49.61499,female,1.0,MOSF w/Malig,12.0,under $11k,42791.0,white,1.0,<2 mo. follow-up,2.5019531
40.68698,female,1.0,Lung Cancer,14.0,>$50k,26951.0,asian,0.0,<2 mo. follow-up,0.0
41.448,male,0.0,Cirrhosis,16.0,>$50k,15982.0,white,0.0,no(M2 and SIP pres),0.0
75.34296,male,0.0,CHF,12.0,$11-$25k,5532.0,black,1.0,no(M2 and SIP pres),1.0
69.35797,female,0.0,COPD,14.0,under $11k,4764.0,white,4.0,SIP>=30,4.0
54.43399,male,0.0,Lung Cancer,12.0,under $11k,4818.0,black,1.0,<2 mo. follow-up,2.2055664
75.07996,female,0.0,COPD,5.0,under $11k,39957.0,white,1.0,<2 mo. follow-up,1.0
54.66397,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,96588.0,white,1.0,<2 mo. follow-up,1.9960938
72.40497,male,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,48378.0,white,0.0,no(M2 and SIP pres),0.0
75.12695,female,0.0,COPD,9.0,under $11k,53401.0,white,7.0,SIP>=30,7.0
65.05096,male,0.0,Lung Cancer,16.0,$25-$50k,6174.0,white,0.0,SIP>=30,0.0
62.35498,male,1.0,ARF/MOSF w/Sepsis,20.0,under $11k,45424.0,white,1.0,<2 mo. follow-up,1.0
51.767,female,1.0,Colon Cancer,12.0,under $11k,6608.0,white,0.0,<2 mo. follow-up,0.0
72.64099,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,30733.0,white,1.0,<2 mo. follow-up,1.0
87.70996,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,46354.0,white,3.0,adl>=4 (>=5 if sur),3.0
80.159,male,0.0,ARF/MOSF w/Sepsis,11.0,$25-$50k,131511.0,white,1.0,adl>=4 (>=5 if sur),1.0
57.51999,female,0.0,Lung Cancer,12.0,$11-$25k,6630.0,white,3.0,no(M2 and SIP pres),3.0
74.51599,male,1.0,Lung Cancer,14.0,under $11k,3122.0,white,3.0,<2 mo. follow-up,3.0
67.034,male,0.0,COPD,12.0,$11-$25k,25793.0,white,0.0,no(M2 and SIP pres),0.0
65.53894,male,0.0,CHF,19.0,>$50k,10474.0,white,0.0,<2 mo. follow-up,0.0
76.44397,female,0.0,CHF,12.0,under $11k,5718.0,white,1.0,no(M2 and SIP pres),1.0
75.27698,male,0.0,CHF,12.0,under $11k,6045.0,white,0.0,<2 mo. follow-up,0.0
84.41595,male,0.0,COPD,4.0,under $11k,11238.0,white,3.0,no(M2 and SIP pres),3.0
82.09399,male,1.0,COPD,12.0,under $11k,13125.0,white,1.0,<2 mo. follow-up,5.2265625
78.25598,female,1.0,Coma,12.0,under $11k,7774.0,white,1.0,<2 mo. follow-up,1.7348633
81.56299,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,15296.0,white,0.0,no(M2 and SIP pres),0.0
61.306,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,74086.0,white,1.0,<2 mo. follow-up,2.1899414
70.68896,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,49259.0,white,2.0,<2 mo. follow-up,2.0
89.31396,male,1.0,COPD,12.0,under $11k,26630.0,white,0.0,<2 mo. follow-up,0.0
63.58099,male,0.0,Colon Cancer,12.0,under $11k,5187.0,white,1.0,no(M2 and SIP pres),3.1831989
92.29797,female,0.0,CHF,12.0,under $11k,19765.0,white,1.0,<2 mo. follow-up,3.9008789
74.409,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,26899.0,white,0.0,no(M2 and SIP pres),0.0
88.172,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,6992.0,white,1.0,<2 mo. follow-up,1.8625488
82.32697,male,1.0,COPD,12.0,under $11k,15828.0,white,6.0,<2 mo. follow-up,6.0
95.41394,female,0.0,ARF/MOSF w/Sepsis,8.0,under $11k,21600.0,white,4.0,adl>=4 (>=5 if sur),4.0
76.12598,male,0.0,COPD,12.0,$25-$50k,4546.0,white,0.0,no(M2 and SIP pres),0.0
86.49097,male,0.0,ARF/MOSF w/Sepsis,19.0,under $11k,110134.0,white,7.0,adl>=4 (>=5 if sur),7.0
70.21796,male,1.0,ARF/MOSF w/Sepsis,14.0,$11-$25k,27165.0,white,0.0,<2 mo. follow-up,0.0
69.84796,female,0.0,COPD,12.0,under $11k,27437.0,hispanic,2.0,no(M2 and SIP pres),2.0
48.909,male,0.0,COPD,6.0,under $11k,162243.0,white,0.0,no(M2 and SIP pres),0.0
70.65295,male,0.0,Colon Cancer,5.0,$25-$50k,8013.0,white,2.0,no(M2 and SIP pres),2.0
39.12698,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,19532.0,white,0.0,no(M2 and SIP pres),0.0
69.21295,female,1.0,COPD,12.0,under $11k,19470.0,white,1.0,<2 mo. follow-up,1.0
19.75099,male,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,8945.0,black,1.0,no(M2 and SIP pres),1.6252441
65.87799,female,1.0,ARF/MOSF w/Sepsis,14.0,>$50k,10435.0,white,1.0,<2 mo. follow-up,2.1923828
85.89996,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,9867.0,white,7.0,adl>=4 (>=5 if sur),7.0
77.73895,male,1.0,ARF/MOSF w/Sepsis,20.0,$25-$50k,298360.0,white,0.0,adl>=4 (>=5 if sur),0.0
88.03595,female,0.0,ARF/MOSF w/Sepsis,10.0,under $11k,15815.0,white,1.0,no(M2 and SIP pres),1.0
71.66595,female,0.0,COPD,14.0,>$50k,7804.0,white,0.0,<2 mo. follow-up,0.0
70.31897,female,0.0,Lung Cancer,12.0,$25-$50k,4416.0,white,1.0,<2 mo. follow-up,1.9909668
69.14398,male,0.0,COPD,12.0,under $11k,10137.0,white,1.0,no(M2 and SIP pres),1.0
80.87097,female,0.0,COPD,12.0,under $11k,10512.0,white,0.0,no(M2 and SIP pres),0.0
72.67596,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,11472.0,white,1.0,<2 mo. follow-up,1.0
90.11597,female,0.0,COPD,5.0,under $11k,10945.0,white,1.0,<2 mo. follow-up,3.855299
91.88995,female,0.0,CHF,12.0,>$50k,5870.0,white,3.0,no(M2 and SIP pres),3.0
85.29498,male,1.0,ARF/MOSF w/Sepsis,6.0,under $11k,22704.0,black,0.0,<2 mo. follow-up,0.0
78.06195,male,0.0,CHF,6.0,under $11k,12894.0,white,5.0,<2 mo. follow-up,5.0
77.36896,male,1.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,159774.0,white,3.0,no(M2 and SIP pres),3.0
57.47598,female,0.0,MOSF w/Malig,12.0,under $11k,27525.0,hispanic,1.0,adl>=4 (>=5 if sur),0.4947999
75.12097,female,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,171895.0,white,5.0,SIP>=30,5.0
36.16397,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,90237.0,white,0.0,adl>=4 (>=5 if sur),0.0
76.10999,male,0.0,ARF/MOSF w/Sepsis,0.0,under $11k,21743.0,white,1.0,adl>=4 (>=5 if sur),5.4404297
87.13995,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,19842.0,white,1.0,<2 mo. follow-up,3.121582
76.80194,female,0.0,COPD,12.0,under $11k,32927.0,white,1.0,no(M2 and SIP pres),1.0
85.62097,female,0.0,CHF,12.0,$25-$50k,13883.0,white,0.0,SIP>=30,0.0
82.83099,female,0.0,COPD,12.0,$25-$50k,7412.0,white,1.0,adl>=4 (>=5 if sur),4.5273972
67.26099,female,0.0,COPD,14.0,$11-$25k,9286.0,black,1.0,<2 mo. follow-up,1.0
78.07794,female,0.0,COPD,15.0,$25-$50k,13959.0,white,1.0,no(M2 and SIP pres),0.4947999
48.05698,female,1.0,MOSF w/Malig,19.0,>$50k,9250.0,white,0.0,<2 mo. follow-up,0.0
70.75195,female,0.0,Lung Cancer,12.0,under $11k,19308.0,white,1.0,<2 mo. follow-up,2.953125
85.06494,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,15635.0,white,0.0,no(M2 and SIP pres),0.0
43.21399,female,0.0,Cirrhosis,21.0,>$50k,22535.0,white,3.0,<2 mo. follow-up,3.0
61.862,female,0.0,CHF,12.0,under $11k,139856.0,black,2.0,SIP>=30,2.0
55.64099,male,0.0,Lung Cancer,14.0,under $11k,12424.0,white,0.0,<2 mo. follow-up,0.0
57.35199,male,0.0,Lung Cancer,12.0,$25-$50k,5977.0,white,1.0,no(M2 and SIP pres),2.2036133
55.66098,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,30821.0,white,0.0,<2 mo. follow-up,0.0
27.228,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,95692.0,white,1.0,<2 mo. follow-up,2.6665039
64.76898,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,67778.0,white,0.0,SIP>=30,0.0
89.05695,female,1.0,ARF/MOSF w/Sepsis,20.0,under $11k,21707.0,white,7.0,<2 mo. follow-up,7.0
75.625,male,0.0,COPD,12.0,under $11k,33324.0,black,1.0,<2 mo. follow-up,5.1994972
51.56998,female,0.0,COPD,14.0,$25-$50k,7933.0,white,1.0,no(M2 and SIP pres),0.4947999
76.18896,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,58865.0,white,0.0,no(M2 and SIP pres),0.0
64.66498,female,0.0,Lung Cancer,15.0,under $11k,3253.0,white,0.0,no(M2 and SIP pres),0.0
89.62598,female,0.0,COPD,16.0,>$50k,6769.0,white,5.0,SIP>=30,5.0
71.77295,male,0.0,Colon Cancer,12.0,$25-$50k,6365.0,white,5.0,<2 mo. follow-up,5.0
77.72998,female,0.0,COPD,16.0,under $11k,2752.0,white,1.0,<2 mo. follow-up,2.2114258
52.961,male,1.0,Lung Cancer,12.0,under $11k,8388.0,black,1.0,<2 mo. follow-up,1.0
62.25098,female,0.0,COPD,12.0,under $11k,5801.0,white,0.0,no(M2 and SIP pres),0.0
63.54797,female,0.0,COPD,12.0,under $11k,35637.0,white,1.0,<2 mo. follow-up,1.0
71.30695,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,35785.0,white,5.0,SIP>=30,5.0
70.15497,male,0.0,Lung Cancer,14.0,$11-$25k,4469.0,white,0.0,<2 mo. follow-up,0.0
61.98798,male,0.0,MOSF w/Malig,14.0,$11-$25k,20414.0,white,0.0,SIP>=30,0.0
75.737,female,0.0,CHF,12.0,under $11k,11378.0,white,2.0,no(M2 and SIP pres),2.0
57.09198,male,0.0,ARF/MOSF w/Sepsis,7.0,under $11k,40735.0,white,0.0,no(M2 and SIP pres),0.0
83.55896,male,0.0,COPD,12.0,under $11k,9225.0,white,1.0,no(M2 and SIP pres),1.0
53.54999,male,0.0,CHF,16.0,>$50k,47802.0,white,0.0,no(M2 and SIP pres),0.0
66.58698,male,0.0,Lung Cancer,13.0,>$50k,7248.0,white,0.0,no(M2 and SIP pres),0.0
89.16095,male,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,74657.0,white,1.0,adl>=4 (>=5 if sur),1.0
85.45697,male,0.0,ARF/MOSF w/Sepsis,8.0,under $11k,31884.0,white,4.0,<2 mo. follow-up,4.0
66.53296,male,0.0,ARF/MOSF w/Sepsis,9.0,$11-$25k,14115.0,white,0.0,no(M2 and SIP pres),0.0
64.34998,female,1.0,Colon Cancer,12.0,under $11k,4814.0,white,1.0,<2 mo. follow-up,2.1054688
91.23895,female,1.0,ARF/MOSF w/Sepsis,16.0,under $11k,49254.0,white,1.0,<2 mo. follow-up,3.5141602
52.43799,male,0.0,Lung Cancer,12.0,under $11k,3754.0,white,1.0,<2 mo. follow-up,2.921875
69.68695,female,0.0,Lung Cancer,16.0,>$50k,7594.0,white,0.0,no(M2 and SIP pres),0.0
68.01099,female,0.0,ARF/MOSF w/Sepsis,13.0,$25-$50k,65515.0,white,0.0,<2 mo. follow-up,0.0
78.00995,male,1.0,COPD,12.0,under $11k,55591.0,white,1.0,<2 mo. follow-up,2.7246094
66.57599,male,0.0,Lung Cancer,10.0,$11-$25k,28609.0,hispanic,1.0,<2 mo. follow-up,2.8164062
71.55096,male,0.0,Lung Cancer,13.0,under $11k,4155.0,white,0.0,<2 mo. follow-up,0.0
93.63196,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,20328.0,white,6.0,<2 mo. follow-up,6.0
55.51498,male,0.0,Lung Cancer,8.0,$11-$25k,4136.0,white,1.0,SIP>=30,1.0
84.80499,female,0.0,CHF,14.0,$25-$50k,13374.0,white,7.0,<2 mo. follow-up,7.0
46.08398,female,0.0,Lung Cancer,12.0,under $11k,9901.0,black,0.0,no(M2 and SIP pres),0.0
53.99597,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,14066.0,black,1.0,<2 mo. follow-up,2.565918
44.89499,female,0.0,ARF/MOSF w/Sepsis,15.0,$25-$50k,176328.0,white,0.0,adl>=4 (>=5 if sur),0.0
67.75098,male,1.0,MOSF w/Malig,8.0,under $11k,46516.0,white,1.0,<2 mo. follow-up,1.0
75.159,female,1.0,COPD,12.0,$25-$50k,24431.0,white,0.0,<2 mo. follow-up,0.0
69.59094,male,0.0,CHF,11.0,under $11k,5894.0,white,0.0,SIP>=30,0.0
31.76999,male,0.0,Lung Cancer,12.0,under $11k,33867.0,white,2.0,adl>=4 (>=5 if sur),2.0
74.83398,female,1.0,CHF,12.0,under $11k,10763.0,white,4.0,<2 mo. follow-up,4.0
74.66699,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,46033.0,white,1.0,no(M2 and SIP pres),1.0
69.68097,female,0.0,Lung Cancer,20.0,>$50k,6840.0,white,0.0,<2 mo. follow-up,0.0
75.66895,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,20399.0,white,1.0,no(M2 and SIP pres),1.0
70.09698,male,0.0,COPD,14.0,$11-$25k,6388.0,white,1.0,no(M2 and SIP pres),1.0
79.05499,female,0.0,COPD,12.0,under $11k,9388.0,white,5.0,adl>=4 (>=5 if sur),5.0
69.06195,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,12943.0,white,0.0,no(M2 and SIP pres),0.0
83.29596,female,0.0,CHF,13.0,under $11k,47413.0,white,0.0,no(M2 and SIP pres),0.0
61.30298,male,0.0,ARF/MOSF w/Sepsis,15.0,under $11k,37775.0,other,0.0,no(M2 and SIP pres),0.0
90.073,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,9664.0,white,2.0,no(M2 and SIP pres),2.0
72.59698,male,1.0,ARF/MOSF w/Sepsis,17.0,$11-$25k,65724.0,white,0.0,<2 mo. follow-up,0.0
89.28094,male,0.0,MOSF w/Malig,8.0,under $11k,15407.0,white,1.0,no(M2 and SIP pres),1.0
78.39795,male,0.0,COPD,12.0,under $11k,7293.0,hispanic,1.0,no(M2 and SIP pres),1.0
63.44098,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,13301.0,white,4.0,no(M2 and SIP pres),4.0
70.90997,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,14078.0,white,1.0,no(M2 and SIP pres),1.0
48.48499,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,9580.0,white,0.0,no(M2 and SIP pres),0.0
75.75897,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,101328.0,black,0.0,SIP>=30,0.0
84.57495,male,0.0,CHF,12.0,under $11k,19696.0,white,1.0,<2 mo. follow-up,3.3823242
88.50696,male,1.0,CHF,12.0,under $11k,8194.0,white,6.0,<2 mo. follow-up,6.0
71.82495,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,52016.0,white,3.0,<2 mo. follow-up,3.0
61.19098,male,0.0,COPD,12.0,under $11k,27367.0,white,1.0,no(M2 and SIP pres),3.9931641
89.04297,male,1.0,ARF/MOSF w/Sepsis,12.0,>$50k,58008.0,hispanic,2.0,<2 mo. follow-up,2.0
58.50198,male,0.0,Cirrhosis,14.0,$25-$50k,18372.0,white,1.0,no(M2 and SIP pres),2.262207
81.02698,female,0.0,COPD,9.0,>$50k,11976.0,white,3.0,no(M2 and SIP pres),3.0
76.10699,female,0.0,COPD,12.0,$25-$50k,27917.0,white,0.0,no(M2 and SIP pres),0.0
71.91498,female,0.0,COPD,18.0,$11-$25k,21983.0,white,1.0,adl>=4 (>=5 if sur),1.0
75.41394,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,45105.0,white,1.0,<2 mo. follow-up,1.0
90.08398,female,0.0,COPD,12.0,under $11k,18263.0,white,5.0,adl>=4 (>=5 if sur),5.0
78.96796,female,0.0,ARF/MOSF w/Sepsis,0.0,$11-$25k,16741.0,white,7.0,no(M2 and SIP pres),7.0
69.66199,female,0.0,Lung Cancer,12.0,under $11k,41995.0,white,1.0,<2 mo. follow-up,3.0629883
47.866,male,0.0,CHF,9.0,>$50k,9214.0,white,0.0,no(M2 and SIP pres),0.0
70.20099,male,0.0,ARF/MOSF w/Sepsis,14.0,$25-$50k,9812.0,white,0.0,no(M2 and SIP pres),0.0
64.30396,male,0.0,Coma,16.0,>$50k,15716.0,white,1.0,<2 mo. follow-up,2.2578125
78.95099,female,0.0,COPD,12.0,under $11k,19168.0,black,1.0,no(M2 and SIP pres),1.0
62.56,male,0.0,Coma,18.0,>$50k,44236.0,black,0.0,no(M2 and SIP pres),0.0
73.25397,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,54799.0,white,0.0,no(M2 and SIP pres),0.0
71.32898,female,1.0,Coma,12.0,under $11k,75051.0,white,1.0,<2 mo. follow-up,2.871582
55.431,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,19018.0,white,1.0,<2 mo. follow-up,2.7421875
47.26898,male,0.0,Cirrhosis,12.0,under $11k,4884.0,white,1.0,<2 mo. follow-up,1.1668997
64.77795,male,0.0,Lung Cancer,10.0,under $11k,25747.0,white,5.0,adl>=4 (>=5 if sur),5.0
75.72894,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,168004.0,white,1.0,<2 mo. follow-up,2.6513672
83.61896,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,23847.0,white,2.0,<2 mo. follow-up,2.0
83.59796,male,1.0,Coma,12.0,under $11k,8071.0,white,1.0,<2 mo. follow-up,2.5795898
82.46399,female,0.0,CHF,12.0,under $11k,7544.0,white,1.0,<2 mo. follow-up,3.9868164
73.62097,male,0.0,Colon Cancer,12.0,under $11k,5234.0,white,5.0,<2 mo. follow-up,5.0
47.35098,female,0.0,CHF,12.0,$25-$50k,7408.0,white,1.0,no(M2 and SIP pres),1.0
79.06598,male,1.0,ARF/MOSF w/Sepsis,9.0,under $11k,46932.0,white,3.0,<2 mo. follow-up,3.0
77.21594,male,0.0,ARF/MOSF w/Sepsis,16.0,>$50k,46000.0,white,0.0,no(M2 and SIP pres),0.0
46.06198,male,0.0,Cirrhosis,19.0,>$50k,10061.0,white,1.0,no(M2 and SIP pres),1.0
75.92297,female,0.0,COPD,12.0,$11-$25k,8348.0,white,2.0,no(M2 and SIP pres),2.0
77.93298,male,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,18693.0,white,0.0,no(M2 and SIP pres),0.0
81.07898,female,0.0,COPD,12.0,under $11k,55945.0,white,4.0,<2 mo. follow-up,4.0
28.25699,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,22529.0,white,1.0,<2 mo. follow-up,1.1668997
77.30597,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,11137.0,white,6.0,adl>=4 (>=5 if sur),6.0
83.51294,male,0.0,CHF,12.0,$11-$25k,4691.0,white,5.0,adl>=4 (>=5 if sur),5.0
68.24097,female,0.0,CHF,15.0,under $11k,5608.0,white,3.0,<2 mo. follow-up,3.0
78.245,female,1.0,COPD,12.0,under $11k,69147.0,white,2.0,<2 mo. follow-up,2.0
60.77197,male,0.0,CHF,12.0,under $11k,8159.0,white,1.0,no(M2 and SIP pres),0.4947999
67.96997,male,0.0,MOSF w/Malig,12.0,under $11k,27302.0,black,0.0,no(M2 and SIP pres),0.0
75.38098,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,25486.0,white,2.0,no(M2 and SIP pres),2.0
61.56299,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,7588.0,white,0.0,no(M2 and SIP pres),0.0
69.23199,female,0.0,Colon Cancer,12.0,under $11k,37893.0,black,0.0,adl>=4 (>=5 if sur),0.0
89.32794,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,86069.0,white,1.0,<2 mo. follow-up,3.0795898
84.35297,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,19014.0,white,1.0,<2 mo. follow-up,3.1708984
73.63397,male,1.0,ARF/MOSF w/Sepsis,10.0,$11-$25k,21516.0,white,0.0,<2 mo. follow-up,0.0
87.41699,female,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,25572.0,white,2.0,no(M2 and SIP pres),2.0
75.34296,female,0.0,COPD,12.0,under $11k,81770.0,white,1.0,<2 mo. follow-up,3.2998047
78.53497,female,0.0,COPD,12.0,under $11k,10645.0,white,7.0,<2 mo. follow-up,7.0
67.06396,female,0.0,COPD,12.0,under $11k,15291.0,hispanic,3.0,adl>=4 (>=5 if sur),3.0
76.28497,male,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,12633.0,white,3.0,adl>=4 (>=5 if sur),3.0
95.58099,male,1.0,ARF/MOSF w/Sepsis,4.0,under $11k,27548.0,black,5.0,<2 mo. follow-up,5.0
60.79398,male,0.0,CHF,12.0,under $11k,26174.0,black,1.0,no(M2 and SIP pres),0.4947999
52.28497,male,0.0,COPD,12.0,under $11k,10612.0,white,1.0,no(M2 and SIP pres),0.4947999
58.32199,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,75398.0,white,1.0,<2 mo. follow-up,0.4947999
83.46899,female,0.0,COPD,14.0,$11-$25k,7015.0,white,0.0,adl>=4 (>=5 if sur),0.0
65.46997,female,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,216883.0,white,0.0,adl>=4 (>=5 if sur),0.0
77.008,male,0.0,CHF,9.0,under $11k,11872.0,white,0.0,no(M2 and SIP pres),0.0
85.37195,male,1.0,Coma,16.0,$25-$50k,18329.0,white,1.0,<2 mo. follow-up,4.3955078
83.16199,male,0.0,Lung Cancer,15.0,under $11k,18052.0,white,1.0,<2 mo. follow-up,1.1668997
65.91595,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,14437.0,white,1.0,<2 mo. follow-up,2.0917969
79.22498,male,0.0,ARF/MOSF w/Sepsis,13.0,$11-$25k,12608.0,white,0.0,no(M2 and SIP pres),0.0
78.09998,male,0.0,COPD,14.0,under $11k,14896.0,white,2.0,no(M2 and SIP pres),2.0
59.88797,female,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,18408.0,white,1.0,SIP>=30,1.0
59.27197,female,0.0,CHF,12.0,$25-$50k,9120.0,white,1.0,SIP>=30,1.0
63.25299,male,0.0,Colon Cancer,12.0,$25-$50k,4324.0,white,1.0,<2 mo. follow-up,0.4947999
69.125,female,0.0,CHF,12.0,$11-$25k,6270.0,white,0.0,adl>=4 (>=5 if sur),0.0
71.461,female,0.0,Lung Cancer,23.0,$25-$50k,9665.0,white,0.0,no(M2 and SIP pres),0.0
87.24194,male,1.0,ARF/MOSF w/Sepsis,6.0,under $11k,18381.0,white,7.0,<2 mo. follow-up,7.0
57.79898,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,129188.0,white,1.0,no(M2 and SIP pres),2.171875
72.62695,male,0.0,COPD,12.0,under $11k,15794.0,white,0.0,SIP>=30,0.0
69.21594,male,0.0,CHF,12.0,under $11k,5314.0,white,1.0,no(M2 and SIP pres),0.4947999
49.87299,female,1.0,MOSF w/Malig,14.0,under $11k,35115.0,white,1.0,<2 mo. follow-up,2.5141602
81.19098,male,0.0,ARF/MOSF w/Sepsis,7.0,$25-$50k,68286.0,white,1.0,SIP>=30,1.1668997
50.19598,female,0.0,Cirrhosis,2.0,>$50k,31479.0,white,1.0,no(M2 and SIP pres),1.1668997
69.12299,male,1.0,ARF/MOSF w/Sepsis,10.0,under $11k,53798.0,white,4.0,<2 mo. follow-up,4.0
82.35699,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,209565.0,black,1.0,<2 mo. follow-up,3.0576172
52.57797,female,0.0,Cirrhosis,11.0,under $11k,7638.0,white,1.0,<2 mo. follow-up,1.1668997
71.79498,male,0.0,COPD,18.0,$11-$25k,46839.0,white,4.0,adl>=4 (>=5 if sur),4.0
38.66699,female,0.0,Cirrhosis,9.0,under $11k,46790.0,black,0.0,<2 mo. follow-up,0.0
77.85394,female,0.0,COPD,17.0,under $11k,8190.0,white,1.0,<2 mo. follow-up,2.0913086
70.45898,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,21065.0,white,0.0,no(M2 and SIP pres),0.0
77.435,male,1.0,COPD,12.0,under $11k,5085.0,white,1.0,<2 mo. follow-up,5.7724609
83.30194,female,0.0,ARF/MOSF w/Sepsis,14.0,under $11k,25474.0,white,0.0,<2 mo. follow-up,0.0
77.42896,male,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,93900.0,white,5.0,<2 mo. follow-up,5.0
90.57599,female,1.0,CHF,12.0,under $11k,9106.0,white,1.0,<2 mo. follow-up,3.7075195
54.237,female,0.0,Cirrhosis,10.0,under $11k,3979.0,white,0.0,no(M2 and SIP pres),0.0
83.10199,male,0.0,CHF,14.0,under $11k,3464.0,white,1.0,no(M2 and SIP pres),0.4947999
66.92096,female,0.0,COPD,16.0,>$50k,13139.0,white,0.0,no(M2 and SIP pres),0.0
73.487,female,0.0,Colon Cancer,12.0,under $11k,8837.0,black,2.0,<2 mo. follow-up,2.0
66.52399,female,0.0,MOSF w/Malig,12.0,$25-$50k,26499.0,black,1.0,no(M2 and SIP pres),2.737793
41.12299,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,78089.0,black,1.0,no(M2 and SIP pres),1.0
64.81299,male,0.0,CHF,10.0,under $11k,12726.0,white,1.0,<2 mo. follow-up,1.8389997
82.15698,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,40355.0,white,6.0,adl>=4 (>=5 if sur),6.0
83.16199,male,1.0,ARF/MOSF w/Sepsis,19.0,under $11k,13316.0,white,1.0,<2 mo. follow-up,2.8325195
68.19995,female,0.0,ARF/MOSF w/Sepsis,14.0,>$50k,83351.0,white,1.0,adl>=4 (>=5 if sur),2.0317383
47.58899,male,0.0,Cirrhosis,10.0,$25-$50k,6175.0,white,0.0,no(M2 and SIP pres),0.0
74.05896,female,0.0,Colon Cancer,12.0,$25-$50k,9658.0,white,0.0,no(M2 and SIP pres),0.0
64.83496,female,1.0,Coma,18.0,$11-$25k,14380.0,asian,1.0,<2 mo. follow-up,1.0
34.51297,male,0.0,Coma,12.0,under $11k,123827.0,white,6.0,adl>=4 (>=5 if sur),6.0
85.54999,male,0.0,CHF,12.0,under $11k,11059.0,white,1.0,no(M2 and SIP pres),4.5273438
75.10999,male,0.0,Colon Cancer,16.0,>$50k,17967.0,white,0.0,no(M2 and SIP pres),0.0
70.25098,male,0.0,COPD,12.0,under $11k,21914.0,white,0.0,no(M2 and SIP pres),0.0
80.35895,female,0.0,CHF,12.0,$11-$25k,6528.0,white,0.0,no(M2 and SIP pres),0.0
52.10397,male,1.0,MOSF w/Malig,12.0,$25-$50k,18313.0,white,0.0,<2 mo. follow-up,0.0
83.461,male,1.0,ARF/MOSF w/Sepsis,20.0,$25-$50k,177467.0,white,0.0,adl>=4 (>=5 if sur),0.0
75.33197,female,1.0,ARF/MOSF w/Sepsis,9.0,$11-$25k,88774.0,white,0.0,<2 mo. follow-up,0.0
84.47894,male,0.0,COPD,12.0,under $11k,12504.0,white,1.0,no(M2 and SIP pres),4.2509766
85.48096,female,0.0,COPD,12.0,under $11k,5872.0,white,1.0,<2 mo. follow-up,2.5110989
64.06,female,0.0,Lung Cancer,14.0,$11-$25k,4562.0,white,0.0,no(M2 and SIP pres),0.0
55.896,female,1.0,Colon Cancer,14.0,under $11k,39582.0,white,5.0,<2 mo. follow-up,5.0
65.29797,male,0.0,Colon Cancer,14.0,$25-$50k,13669.0,white,2.0,<2 mo. follow-up,2.0
80.77496,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,82763.0,white,6.0,<2 mo. follow-up,6.0
74.46698,female,1.0,MOSF w/Malig,12.0,under $11k,46365.0,white,1.0,<2 mo. follow-up,3.8374023
74.875,female,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,18145.0,black,5.0,adl>=4 (>=5 if sur),5.0
46.448,male,0.0,Coma,12.0,under $11k,102951.0,white,1.0,<2 mo. follow-up,1.6599121
36.36099,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,49378.0,white,3.0,no(M2 and SIP pres),3.0
84.758,female,0.0,COPD,12.0,under $11k,55554.0,white,1.0,<2 mo. follow-up,3.980957
73.09497,male,0.0,COPD,12.0,under $11k,3231.0,white,1.0,<2 mo. follow-up,4.6621094
87.836,female,1.0,ARF/MOSF w/Sepsis,8.0,under $11k,7485.0,white,4.0,<2 mo. follow-up,4.0
65.21796,male,1.0,Cirrhosis,12.0,$25-$50k,56488.0,white,0.0,<2 mo. follow-up,0.0
39.159,male,1.0,Lung Cancer,14.0,$11-$25k,8814.0,white,3.0,<2 mo. follow-up,3.0
61.23999,female,1.0,Cirrhosis,8.0,under $11k,104725.0,black,0.0,<2 mo. follow-up,0.0
85.05396,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,143520.0,white,4.0,adl>=4 (>=5 if sur),4.0
80.54999,female,0.0,ARF/MOSF w/Sepsis,9.0,under $11k,51714.0,white,4.0,<2 mo. follow-up,4.0
73.30298,male,1.0,COPD,12.0,under $11k,73250.0,white,1.0,<2 mo. follow-up,2.6767578
66.89899,female,1.0,ARF/MOSF w/Sepsis,9.0,under $11k,87649.0,white,0.0,<2 mo. follow-up,0.0
62.04498,male,0.0,CHF,12.0,under $11k,102951.0,white,0.0,no(M2 and SIP pres),0.0
91.00098,female,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,25116.0,white,3.0,<2 mo. follow-up,3.0
70.86694,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,20128.0,white,1.0,<2 mo. follow-up,0.4947999
80.80798,male,1.0,MOSF w/Malig,12.0,under $11k,21600.0,white,0.0,<2 mo. follow-up,0.0
39.01398,male,0.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,143863.0,white,0.0,<2 mo. follow-up,0.0
96.29297,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,23315.0,white,1.0,no(M2 and SIP pres),0.4947999
60.96399,female,0.0,CHF,12.0,under $11k,7831.0,white,1.0,SIP>=30,3.1831989
57.892,male,0.0,Lung Cancer,12.0,under $11k,3803.0,black,0.0,adl>=4 (>=5 if sur),0.0
79.43097,female,0.0,Colon Cancer,19.0,$11-$25k,41940.0,white,5.0,<2 mo. follow-up,5.0
84.25494,male,0.0,CHF,12.0,under $11k,4931.0,white,1.0,no(M2 and SIP pres),1.0
62.97897,male,0.0,COPD,12.0,under $11k,42691.0,black,1.0,no(M2 and SIP pres),0.4947999
75.34296,male,0.0,Colon Cancer,12.0,under $11k,15764.0,white,1.0,<2 mo. follow-up,1.0
65.20697,female,0.0,MOSF w/Malig,13.0,$25-$50k,27314.0,white,2.0,<2 mo. follow-up,2.0
75.45197,male,1.0,CHF,12.0,$25-$50k,27479.0,white,2.0,<2 mo. follow-up,2.0
74.17096,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,24406.0,white,0.0,no(M2 and SIP pres),0.0
55.31799,female,1.0,ARF/MOSF w/Sepsis,12.0,under $11k,91472.0,white,1.0,<2 mo. follow-up,1.0
61.06998,female,0.0,COPD,12.0,>$50k,37517.0,white,1.0,<2 mo. follow-up,0.4947999
76.57996,male,0.0,ARF/MOSF w/Sepsis,16.0,under $11k,46322.0,white,0.0,<2 mo. follow-up,0.0
91.47198,female,0.0,MOSF w/Malig,17.0,>$50k,58579.0,white,4.0,adl>=4 (>=5 if sur),4.0
22.31099,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,69109.0,white,1.0,<2 mo. follow-up,1.0
60.40799,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,26252.0,white,0.0,no(M2 and SIP pres),0.0
77.15497,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,84411.0,white,1.0,<2 mo. follow-up,1.0
72.95599,male,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,16094.0,white,0.0,no(M2 and SIP pres),0.0
30.021,female,1.0,ARF/MOSF w/Sepsis,13.0,under $11k,257474.0,white,0.0,<2 mo. follow-up,0.0
66.72699,female,0.0,ARF/MOSF w/Sepsis,8.0,under $11k,57971.0,white,1.0,no(M2 and SIP pres),1.0
72.45996,female,1.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,21265.0,white,7.0,<2 mo. follow-up,7.0
59.737,male,0.0,Lung Cancer,14.0,$25-$50k,8897.0,white,0.0,<2 mo. follow-up,0.0
75.28497,female,1.0,ARF/MOSF w/Sepsis,16.0,$25-$50k,63906.0,white,1.0,<2 mo. follow-up,1.0
60.46799,male,1.0,MOSF w/Malig,16.0,>$50k,110493.0,white,1.0,<2 mo. follow-up,2.0361328
86.17096,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,215811.0,white,1.0,<2 mo. follow-up,3.4326172
79.98395,male,1.0,COPD,14.0,>$50k,18895.0,white,0.0,<2 mo. follow-up,0.0
53.65598,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,16865.0,hispanic,0.0,no(M2 and SIP pres),0.0
67.51794,female,0.0,ARF/MOSF w/Sepsis,12.0,$11-$25k,23680.0,white,1.0,no(M2 and SIP pres),1.0
83.50696,female,0.0,Colon Cancer,12.0,under $11k,8183.0,white,0.0,no(M2 and SIP pres),0.0
68.22198,male,0.0,CHF,14.0,$11-$25k,4646.0,white,1.0,no(M2 and SIP pres),0.4947999
64.72296,female,0.0,COPD,12.0,$11-$25k,20184.0,white,0.0,no(M2 and SIP pres),0.0
87.04199,female,0.0,ARF/MOSF w/Sepsis,12.0,$25-$50k,17585.0,white,5.0,adl>=4 (>=5 if sur),5.0
81.85895,female,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,25693.0,white,2.0,no(M2 and SIP pres),2.0
74.61694,female,1.0,COPD,12.0,under $11k,19026.0,white,1.0,<2 mo. follow-up,5.2617188
53.59299,female,0.0,Lung Cancer,15.0,under $11k,7058.0,white,1.0,no(M2 and SIP pres),1.0
57.84497,male,0.0,CHF,16.0,under $11k,29955.0,white,0.0,no(M2 and SIP pres),0.0
78.60596,male,0.0,ARF/MOSF w/Sepsis,18.0,under $11k,18683.0,white,5.0,no(M2 and SIP pres),5.0
43.38898,male,0.0,ARF/MOSF w/Sepsis,12.0,under $11k,25196.0,black,0.0,<2 mo. follow-up,0.0
59.34799,male,0.0,ARF/MOSF w/Sepsis,12.0,>$50k,29852.0,white,1.0,no(M2 and SIP pres),1.0
